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ABSTRACT 
 
Amanda Keatley Golembesky 
 
Peroxisome Proliferator-Activated Receptor-Alpha Gene, Obesity And Breast 
Cancer Incidence And Survival: A LIBCSP Ancillary Study  
(Under the direction of Dr. Marilie Gammon) 
 
Peroxisome proliferator-activated receptor-alpha (PPARA) has been shown to increase fatty 
acid oxidation and decrease cytokine levels, and has been implicated in insulin production. 
Genetic variants of PPARA have been associated with cardiovascular disease, obesity and 
type II diabetes mellitus. Although no research to date has investigated the possible link 
between PPARA and breast cancer incidence and survival, the function of this gene 
suggests that it could play a role in breast cancer development and prognosis. Six PPARA 
polymorphisms were evaluated in association with incident breast cancer (n=1073 cases, 
n=1112 controls) and survival (n=1073 cases) in the Long Island Breast Cancer Study 
Project, a population-based case-control study. The National Death Index was used to 
determine vital status through December 31, 2002. The case-control study analyses used 
unconditional logistic and multilevel regression, and haplotype-based analyses while the 
survival analyses employed Kaplan-Meier curves, Cox regression and haplotype-based 
analyses for all-cause and breast cancer-specific mortality (n = 132 (12.3%) and 88 (8.2%), 
respectively). The odds of breast cancer were doubled among women with PPARA 
polymorphism rs4253760 (OR=1.97 for rare vs. common homozygote alleles; 95% CI: 1.14, 
3.43). This association remained constant with the inclusion of all interrogated 
polymorphisms studied in hierarchical models. rs4253760 was also associated 
 v
with over a two-fold increase in all-cause mortality at time of disease diagnosis with inclusion 
of a continuous time interaction (HR=2.25 for rare vs. common homozyote alleles; 95% CI: 
1.00, 5.08). This beta coefficient for this time interaction is negative, implying that survival is 
improving over time, so that the HR is equal to 0.69 (95% CI: 0.36, 1.29) following five years 
of follow-up. Thus, caution is necessary when interpreting the results for this polymorphism. 
Haplotype analyses did not reveal any differences between cases and controls or survival. 
Our results are the first to evaluate the relationship between PPARA and breast cancer 
incidence and survival and suggest that replication in an independent cohort is warranted. 
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 CHAPTER 1 BODY SIZE/OBESITY 
1.1 INTRODUCTION 
Obesity has now reached epidemic proportions in the United States, but much 
remains unknown about its effects. In fact, even body size measures remain rudimentary 
and the most biologically relevant definition of body size has not been clearly established. 
This section outlines different ways of measuring and defining body size, potential critical 
windows for disease development with specific application to breast cancer, trends in 
obesity prevalence and its metabolic consequences.  
1.2 MEASURES OF BODY SIZE 
According to the American Heritage dictionary [1], obesity can be defined as “the 
condition of being obese; increased body weight caused by excessive accumulation of fat”. 
This excess fat is deposited subcutaneously, primarily in the hips, thighs and gluteus in 
women and abdominally in men [2]. To approximate excess body fat, several different 
measures of obesity have been developed, including body mass index (BMI), waist to hip 
circumference ratio (WHR), and waist circumference (WC). With the exception of BMI, these 
measures aim to capture not only excess fat but also the distribution pattern of this fat. 
Weight change (∆W), specifically weight gain, is related to obesity, and can describe excess 
fat when baseline weight is taken into consideration.
Fat tissue consists of active endocrine cells that produce and release a broad range 
of factors, including cytokines, insulin, progesterone and insulin-like growth factor (IGF)-1 
(see Figure 1.1) [3]. In particular, adult weight gain has been linked to central adiposity, 
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which is associated with high levels of free fatty acids [4], cortisol and androgen receptors 
[5]. As will be discussed later, central adiposity is also associated with a variety of adverse 
health outcomes, such as heart disease, Type II diabetes mellitus and cancer. Thus, 
abdominal adipose tissue accumulation has implications on endocrine levels and disease 
risk, illustrating the potential importance of capturing fat distribution in obesity measurement. 
 
FIGURE 1.1. Adipose tissue involvement in the release of many peptides and cytokines (adapted 
from Bray [6]) 
 
 
Obesity can be defined multiple ways and it is not clear which method may be most 
appropriate for breast cancer. Body mass index (BMI) is the most commonly used and is 
calculated by taking the ratio of weight in kilograms and height in meters squared. While this 
measure is extremely easy to calculate and implement using self-report or medical records, 
BMI has been criticized for inaccurately representing individuals who exercise extensively 
and lift weights [7]. For most individuals, however, it will be highly correlated with percent 
body fat [4]. In the Long Island Breast Cancer Study Project (LIBCSP), BMI will accurately 
measure body fat since most women are in middle age or older and unlikely to have 
extreme muscle mass.  
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WHR has been used to better measure body fat distribution (rather than general 
obesity), although waist circumference alone has been suggested to be as accurate at 
measuring central adiposity as the WHR and is easier to determine [4].  
As an alternative to obesity, weight change over time is also gaining popularity 
because it allows investigation of potential critical windows for disease development and 
may reflect changes in hormone levels over time. Case-control studies typically measure 
self-reported BMI and weight change prior to diagnosis because disease status may 
influence waist circumference if measured after diagnosis and women are unlikely to know 
their waist circumference throughout their lives. In addition, participants can generally recall 
weight accurately even over long periods of time [4]. Lastly, weight cycling, or the repeated 
loss and regain of body weight [8], has emerged as an important health concern that should 
be considered in epidemiologic investigations of body size. Like weight change, weight 
cycling may help identify critical windows for disease development and help elucidate 
disease pathogenesis. LIBCSP data did not indicate that cycling was important for breast 
cancer development in this population [9].  
In addition to these anthropometric measures of body size, several technological 
devices have been used to measure body fat percent in the clinical setting. For example, 
ultrasound, computer tomography and magnetic resonance imaging have all been assessed 
as more direct measures of body fat [10]. Unfortunately, these techniques all require 
invasive and expensive procedures, which have prevented them from being applied at the 
population level. For this reason, these methods will not be discussed in further sections. 
1.3 DEFINITION OF BODY SIZE 
Based on these different anthropometric measures, obesity has been defined several 
different ways (see Table 1.1). For BMI, the World Health Organization (WHO) defines 
overweight as 25.0-29.9 kg/m2, obesity as 30.0-39.9 kg/m2, and morbid obesity as greater 
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than 39.9 kg/m2 [5]. While BMI cut-off values have been well-established, the classification 
system for WHR, WC and body fat % are much less clear. For example, although the 
International Agency for Research on Cancer (IARC) endorsed the critical values developed 
by Han et al. [11] for WHR in their 2002 publication [4], researchers have criticized this scale 
because of its reliance on BMI thresholds for determining WC cut-off values. As an 
alternative, Zhu et al. used data from National Health and Nutrition Examination Survey 
(NHANES) III to derive WC risk thresholds without referral to BMI, recommending that 83 cm 
and 93 cm define the overweight and obese border respectively for women [12]. Lastly, the 
National Heart Lung and Blood Institute (NHLBI) has developed guidelines to combine BMI 
and WC for cardiovascular disease (CVD). They suggest that women with a WC greater 
than 0.88 cm and have a BMI between 25 and 30 are at high risk of disease; women with 
the same WC but have a BMI over 30 are considered at “very high risk” for CVD [13]. 
 
TABLE 1.1.Obesity classifications based on 4 different measures of body composition 
 Underweight Normal Weight Overweight Obese 
BMI (kg/m2)* < 18.50 18.50-24.99 25.00-29.99 ≥ 30.00 
WHR† -- ≤ 0.85 > 0.85 -- 
WC (cm)‡ -- < 80  80-87 ≥ 88 
Body fat (%)§ < 23 23-33 34-39 ≥ 40 
*BMI=body mass index, based on values cited by the World Health Organization [5] 
†WHR = Waist to hip ratio, based on values provided by Han et al. [11] and cited by 
WHO [5] for women 
‡Waist circumference values developed by Lean et al. [14] and recommended by IARC 
[4] for women 
§Numbers based on women ages 40-59, developed by Gallagher et al. [15] and 
recommended by IARC [4] 
 
1.4 DETERMINANTS OF OBESITY 
Obesity is the direct result of excess energy intake relative to energy expenditure 
although the distal causes of this imbalance are more intangible. Decreased physical activity 
and diets high in saturated fat are typically blamed although genetics and macro-level 
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factors, such as proximity to grocery stores and median neighborhood household income, 
have also been implicated [4, 16]. Other risk factors for obesity include age, which will be 
discussed in the following section, ethnicity, educational level, and alcohol consumption [4]. 
Heredity is estimated to explain approximately 25-40% of obesity based on twin, adoption 
and family studies [4]. Several genes such as leptin, PPAR-gamma and alpha, have been 
suggested to play a role in obesity development.  
1.5 TIMING OF WEIGHT CHANGE 
In women, three life events have been suggested to be of particular importance in 
the development of obesity: menarche, pregnancy and menopause. These events mark 
critical time windows of hormonal fluctuation that may play an important role in disease 
development (see Figure 1.2). Gradual gains in weight are typically found in women ages 
25-40, which have been attributed to pregnancy and a more sedentary lifestyle [4]. 
Menopause also represents a critical time period for obesity as metabolism typically slows 
and physical activity levels decrease [17]. Post-menopausal weight gain has also been 
linked to abdominal adiposity in women (more so than pre-menopausal weight gain), 
suggesting this time window might be particularly important in breast cancer development 
[17, 18].  
1.5.1 Menarche and obesity 
The menstrual cycle can be divided into two phases, the follicular phase and the 
luteal phase, both of which have implications on hormone secretion. The first stage, or 
follicular phase, is characterized by increasing estradiol and low progesterone levels as the 
uterine endometrium cells proliferate and the follicle reaches the ovarian surface [19]. In 
contrast, the second phase, or luteal stage, covers the formation and break-down of the 
corpus luteum, primarily dominated by a rise and fall in progesterone while estradiol levels 
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consistently decline [19]. Because of the difference in secreted hormones, the different 
phases also have been suggested to influence food preferences with sweet cravings 
common in the follicle stage and fat preferred during the luteal stage [17]. Obesity has been 
linked to reduced progesterone levels due to anovulation and depressed progesterone 
levels during the luteal phase of the menstrual cycle [18]. The effect of obesity on 
progesterone levels has been used as a potential explanation for the inconsistent results 
found in studies examining the relationship between obesity and risk of pre-menopausal 
breast cancer, which will be discussed in the next section.  
1.5.2 Pregnancy and obesity 
While the majority of women experience only small weight gain due to pregnancy 
(0.5-2.4 kg), approximately 10-20% of women will experience over 15 kg in postpartum 
weight gain [17]. As might be expected, pre-pregnancy weight, parity and gestational weight 
gain play large roles in influencing weight retention following pregnancy. Beyond weight 
retention, however, hormonal levels also change dramatically during pregnancy, which could 
point to another potential critical time period for breast cancer development. Once 
fertilization has occurred, estradiol and progesterone levels remain high for the duration of 
the pregnancy [19]. This hormone change coupled with possible weight retention may 
represent an understudied critical time window for disease development. 
1.5.3 Menopause and obesity 
Women are classified as post-menopausal if they experience “the absence of 
menstruation for one year” [19]. Menopause is marked by several distinct hormonal 
changes, which make women in this group more vulnerable to central adiposity. Because 
the ovaries are no longer developing follicles, estrogen levels fall dramatically. Similarly, 
since the corpus luteum no longer forms, progesterone levels fall dramatically as well. In 
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fact, after menopause, the primary source of estrogen for women becomes the 
aromatization of androgens to estrogen in fat tissue [19]. The decline in sex hormones and 
decrease in lipoprotein lipase activity in adipocytes also leads to a shift in fat accumulation 
from the periphery (buttocks and thighs) to the abdomen [17]. Thus, post-menopausal 
weight gain is most likely to result in abdominal adiposity than weight gain earlier in life. 
 
FIGURE 1.2. Hormonal factors involved in the critical windows for obesity development in 
women, adapted from Lovejoy [17] 
 
1.6 OBESITY PREVALENCE 
The prevalence of obesity in women has increased dramatically over the last decade 
in the United States (see Figure 1.3). Recent data from NHANES indicate a 7.4% increase 
in the proportion of women aged 40-59 who are obese (body mass index ≥ 30) from 
NHANES III to NHANES 1999-2000 [20]. In particular, women ages 40-49 showed an 8.5% 
increase in obesity over this time period while women ages 50-59 saw a 5.6% increase, and 
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women ages 60-69 saw a 12.7% increase [20]. More recently, Hedley et al. estimated that 
64.9% of women aged 40-59 and 68.4% of women over age 60 are overweight or obese 
[21]. These increases in obesity are occurring in the age group of women who are most at 
risk of developing breast cancer. 
Similarly, abdominal adiposity in women has increased dramatically in the last three 
decades. Using data from the National Health Examination Survey (NHES I), NHANES III 
and NHANES 1999-2000, Okosun et al. found that the mean waist circumference was 77 
cm for 1960-1962, 92 cm for 1988-1994, and 94 cm for 1999-2000 in women ages 20-79 
years [22]. Parallel increases were seen in the prevalence of women with abdominal 
obesity, defined as a waist circumference of ≥ 88cm, over these same time periods (19.4%, 
38.8% and 59.9% respectively) [22]. These increases in abdominal adiposity are troubling 
because of its strong association with many adverse health outcomes, including cancer, 
Type II diabetes mellitus and cardiovascular disease [23].  
 
FIGURE 1.3. Trends in obesity prevalence in women, using data from the National Health 
Examination Survey 1960-1962, National Health and Nutrition Examination Survey, 1971-
1974, 1976-1980, 1988-1994, 1999-2000. 
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1.7 METABOLIC CONSEQUENCES OF OBESITY 
1.7.1 Overview 
Obesity is associated with a broad range of morbidities, and excess mortality 
attributed to obesity is estimated to be second only to tobacco in the United States in the 
year 2000 (435,000 versus 385,000 deaths) [24]. Adult weight gain is associated with 
increased abdominal adiposity, which is an indicator of insulin resistance [6], and has been 
linked to Type 2 diabetes mellitus [3] and breast cancer in postmenopausal women [18]. 
Central adiposity is also associated with increased levels of small dense low density 
lipoproteins (LDL), which have been linked to coronary heart disease independently of 
cholesterol level, and lower levels of high density lipoprotein cholesterol (HDL) [3].  
1.7.2 Endocrine disturbances 
As mentioned earlier in this section, abdominal adiposity is associated with a variety 
of endocrine responses. Visceral adipose tissue has more cortisol and androgen receptors 
than subcutaneous adipose tissue, which makes it more sensitive to hormone stimulation 
and lipid metabolism [5]. This sensitivity results in several hormonal changes, highlighted in 
Table 1.2, including insulin resistance, increased insulin secretion and decreased sex 
hormone binding globulin (SHBG) for women [5]. Insulin resistance is defined as the 
impaired response of muscles and other cells to insulin [2] and can lead to elevated blood 
glucose levels with reduced utilization of glucose in the muscles [4]. Hyperinsulinemia, or 
increased insulin secretion, is the consequence of reduced glucose removal [3] and has 
been suggested to be the body’s response to obesity and insulin resistance [5]. Additionally, 
central adiposity is also associated with high triglyceride levels, low HDL levels, and 
increased levels of small, dense LDL particles, which may explain its connection to 
cardiovascular disease [3, 5]. The impact of obesity on estrogen levels will be discussed 
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more in the next section, but it is important to note that central adiposity is associated with 
increased bioavailable estrogen in post-menopausal women but not in pre-menopausal 
women [4].  
 
 
1.7.3 Obesity Associated disease 
As Table 1.3 indicates, obesity is associated with a broad range of health problems, 
including Type II diabetes, coronary heart disease and some cancers. Not surprisingly given 
the strong association between insulin resistance and obesity, Type II Diabetes Mellitus 
(DM) has been consistently linked to obesity in both males and females. In fact, in the 
Nurses’ Health Study, a risk ratio (RR) of 49.0 (95% confidence interval (CI): 34.0-71.0) was 
found for Type II DM for women with a BMI > 35 kg/m2 compared to women with a BMI < 22 
kg/m2 [25]. This relationship holds even when weight gain is examined rather than BMI as a 
measure of body size, adjusting for BMI at age 18 [25]. For cancer, the evidence is growing, 
especially for post-menopausal breast cancer and endometrial and colon cancer, although 
the RRs observed are much smaller than those found in the diabetes literature. In a recent 
meta-analysis, Bergstrom et al. found a RR of 2.52 (CI not provided) for endometrial cancer, 
a RR of 1.52 for colon cancer and a RR of 1.25 for post-menopausal breast cancer in obese 
vs. normal weight individuals [26]. While the WHO might label these associations as “slight 
TABLE 1.2. Common hormonal abnormalities associated with abdominal adiposity 
according to the World Health Organization [5] 
 
• Insulin resistance and increased insulin secretion 
• Increased free testosterone and free androstenedione levels associated with 
decreased sex hormone binding globulin (SHBG) in women 
• Decreased progesterone levels in women 
• Increased cortisol production 
• Decreased growth hormone levels 
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increases,” they are important because of the high prevalence of obesity, giving these 
associations large public health significance at the population level.  
 
TABLE 1.3. Relative risk (RR) of health problems associated with obesity according to 
the World Health Organization [5] * 
Greatly Increased Moderately increased Slightly increased 
(RR > 3.0) (RR 2.0 – 3.0) (RR 1.0 – 2.0) 
Type II Diabetes Mellitus Coronary Heart Disease Some Cancers: 
 • Metabolic Syndrome 
• Stroke 
 
• Post-menopausal breast 
cancer 
• Endometrial cancer 
• Colon Cancer 
Gallbladder disease Hypertension Reproductive hormone 
abnormalities 
Dyslipidemia Osteoarthritis (knees) Polycystic ovary syndrome 
Insulin resistance Hyperuricemia and gout Impaired fertility 
Breathlessness  Low back pain from obesity 
Sleep apnea  Fetal defects associated 
with maternal obesity 
*All RRs are approximate values 
 
1.8 CONCLUSION 
Body size is typically measured using BMI, but recent research indicates that weight 
gain may better capture the endocrine changes that result with increased central adiposity. 
The Long Island Breast Cancer Study Project is well-equipped to address obesity-related 
mechanisms because data on weight change by decade, BMI by decade, and potential 
critical windows for disease development are available for investigation. Given the epidemic 
proportion of obesity in the United States, particularly in post-menopausal women, clarifying 
the role of obesity in breast cancer development and survival has become increasingly 
important. 
 
 CHAPTER 2 BREAST CANCER INCIDENCE 
2.1 INTRODUCTION 
Much of what is known about breast cancer has evolved from its risk factor 
epidemiology. For example, it has become apparent that hormones, specifically estrogen, 
play an important role in disease development. Demographic, behavioral and dietary factors 
that influence hormone levels have been consistently associated with risk of breast cancer. 
This section outlines the trends in incidence, possible disease mechanisms and established 
and suspected risk factors for the disease.  
2.2 TRENDS IN INCIDENCE 
With 240,510 expected cases in 2007, breast cancer represents the most commonly 
diagnosed cancer in women, composing 26% of all female cancer diagnoses. It is also the 
second most common cause of cancer-related deaths in women with 40,460 estimated 
attributable deaths in 2007 comprising 15% of all female cancer-related mortalities [27]. 
Breast cancer also tends to affect older women with 94% of incident cases and 96% of 
breast cancer mortality occurring in women over the age of 40 [28]. Unlike many other 
cancers, Caucasians show a consistently higher rate of breast cancer compared to other 
races. From 2000-2004 in the United States, the annual incidence rate of breast cancer was 
132.5 per 100,000 person-years in Caucasian women compared to 118.3 per 100,000 in 
African American women [28]. 
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FIGURE 2.1. Diagram of the Breast [28] 
 
 
 
 
 
Breast cancer incidence also varies by staging with invasive cancer consistently 
occurring at higher rates than in situ breast cancer. According to the American Cancer 
Society, invasive breast cancer can be defined as cancers that have penetrated the breast 
tissue from the lobules or ducts while in situ cancers have not yet spread beyond their point 
of origin in the duct (for ductual carcinoma in situ) or in the lobules (lobular carcinoma in situ) 
(see Figure 2.1) [28]. The incidence of DCIS has been steadily increasing in the last ten 
years, possibly due to the advent of mammography, while invasive breast cancer rates have 
been more constant [28]. Women over the age of 55 years experience the highest rate of 
both breast cancer types although invasive cancer is the most common with 124,300 
estimated cases in 2007 (77.0%) compared to 37,110 expected in situ cases (23.0%) [28]. 
Across all ages, 211,240 invasive (74.2%) and 62,030 in situ (25.8%) cases were estimated 
in 2007 [28]. These percentages are consistent with the numbers observed in the Long 
Island Breast Cancer Project, where 1273 invasive and 235 in situ cases were found (84.4% 
vs. 15.6% respectively). Further distinction between the different kinds of breast cancer will 
be discussed in more depth in Chapter 3 on breast cancer survival. 
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2.3 MECHANISM OF ACTION 
Known risk factors for breast cancer have long pointed to increased endogenous 
estrogen levels as the primary underlying mechanism of action in breast cancer 
carcinogenesis and progression. Estrogen has been suggested to elevate risk of breast 
cancer by promoting tumor development through increased cell proliferation. Rapidly 
dividing cells may be more prone to DNA replication errors, leading to potentially deleterious 
mutations [29]. Although ovaries produce very little estrogen following menopause, post-
menopausal women may be exposed to high endogenous estrogen levels through the 
aromatization of androgens in fat tissue, such as testosterone [30]. Post-menopausal 
obesity elevates estrogen levels further since adipose cells secrete aromatase, leading to 
increased conversion of androstenedione to estradiol [31]. In contrast, pre-menopausal 
women experience consistently high levels of estrogen, particularly during the follicle phase 
of the menstrual cycle, regardless of weight, so that any additional estrogen from the 
aromatization of androgens due to obesity will not have a significant impact on overall 
estrogen levels [4]. Additionally, estrogen metabolism has two primary products: 16α–
hydroxyestrone (16HE) and 2-hydroxyestrone (2HE). Obesity is associated with decreased 
levels of 2HE, which is less bioactive, while maintaining higher levels of 16HE, which 
remains bioactive (see Figure 2.2) [32]. Thus, obesity may impact risk of breast cancer by 
influencing estrogen metabolism. 
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FIGURE 2.2. Major metabolic pathways of estrogen synthesis from Endocrinology: An 
integrated approach [19] 
 
 
More controversially, progesterone has been suggested to work synergistically with 
estrogen to increase risk of breast cancer. This hypothesis, referred to as the “estrogen 
augmented by progesterone” theory, was originally proposed by Key and Pike in 1988 [33], 
but has been met with some opposition. In vivo studies have shown that cell proliferation is 
greatest in the luteal phase of the menstrual cycle, when progesterone levels are increasing 
[33, 34], but it has not clearly been established that progesterone is responsible for this 
increased cell division. As an alternative, this increased cell proliferation has been 
suggested to be a delayed response to peak estrogen levels, occurring 4-5 days earlier in 
the cycle [34]. While some epidemiologic evidence, discussed in section 2.4, suggests that 
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progesterone may play a role in breast cancer, this is not supported by in vivo and 
histological studies [34].  
Insulin and insulin-like growth factor (IGF)-1 have also been suggested to work with 
estrogen to influence breast cancer risk, particularly in pre-menopausal women [35]. These 
findings run contrary to the expected since central adiposity is associated with post-
menopause rather than pre-menopause status. Like estrogen, insulin and IGF-1 have been 
shown to increase cell proliferation while preventing apoptosis [30]. Estrogen has been 
linked to the regulation of IGF signaling with high estrogen levels resulting in an increase in 
IGF activators and a decrease in IGF inhibitors although this remains controversial [36]. 
Insulin and possibly IGF-1 have also been implicated in increased estrogen bioactivity 
through the decreased synthesis of sex-hormone-binding globulin (SHBG) in the liver [30]. 
SHBG is a common transporter of estradiol, and decreased SHBG levels will result in 
increased levels of bioavailable free estradiol [18]. Identifying genetic polymorphisms that 
influence obesity and estrogen bioavailability could play an important role in advancing 
knowledge of breast cancer etiology through these two important growth pathways. 
2.4 RISK FACTOR EPIDEMIOLOGY 
3.4.1 Reproductive factors 
While several risk factors have been found to influence the risk of breast cancer, 
cumulative exposure to estrogen appears to be an important component of breast cancer 
development. Parity, age at first birth, lactation, age at menarche and age at menopause are 
considered established risk factors for breast cancer and have been hypothesized to 
influence circulating levels of estrogen and breast tissue’s lifetime exposure to estrogen [29, 
30]. Breast-feeding, for example, has been suggested to have an inverse relationship with 
breast cancer in both pre- and post-menopausal women by inhibiting ovulation. Ovulation, 
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as mentioned earlier, increases estradiol levels and influences progesterone regulation in 
the luteal phase of the menstrual cycle. High parity and early age at first birth are believed to 
influence risk in a similar manner by reducing the number of ovulatory cycles while early age 
of menarche and late age of menopause may be an indicator of high levels of cumulative 
estrogen exposure. Consistent with Long Island Breast Cancer Study Project (LIBCSP) 
findings [37], this research indicates that the reproductive behaviors of women have an 
important impact on their risk of breast cancer.  
3.4.2 Exogenous hormones 
In premenopausal women, oral contraceptive use is a common source of exposure 
to exogenous hormones. Birth control pills can contain estrogen, typically ethinyl estradiol, 
alone or in combination with progesterone [19, 38] and doses have ranged between 100 µg 
in 1960 to 20 µg currently [38]. In a pooled analysis of 53,297 breast cancer cases and 
100,239 controls, representing 54 study populations, a slightly increased risk of breast 
cancer was observed among current users (RR=1.24; 95% CI: 1.15-1.33) compared to 
never users [39]. This risk decreased after stopping pill use (RR=1.16 for 1-4 years after 
stopping and 1.07 for 5-9 years after stopping) and no elevation in risk was found 10 years 
following the end of pill use (RR=1.01; 95% CI: 0.96-1.05) [39]. The authors also noted that 
tumors in oral contraceptive users are more likely to be early stage disease and localized 
than the tumors in non-users [39].  
Like oral contraceptives, hormone replacement therapy (HRT) can contain estrogen 
alone, typically estradiol or estradiol valerate, or may include progesterone [19]. It can be 
used for short-term alleviation of menopausal symptoms or be used prophylactically to delay 
bone density loss [19]. In a pooled analysis of 52,705 breast cancer cases and 108,411 
controls, representing 51 study populations, an elevated risk of breast cancer was found in 
current versus never users (RR=1.21, SE=0.05, CI not reported) although this risk 
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disappeared 5 years after HRT cessation (RR=1.07, SE=0.04, CI not reported) [40]. 
Similarly, the Million Woman Study, which consisted of 1,084,110 British women aged 50–
64 years, found an elevated risk of breast cancer in current HRT users versus never users 
(RR=1.66; 95% CI: 1.58-1.75) with estrogen-progesterone combinations showing the 
greatest risk (RR=2.00; 95% CI: 1.88-2.12) in comparison to estrogen alone or tibolone, 
which contains neither estrogen or progesterone [41]. Based on these large studies, HRT is 
now regarded as a breast cancer risk factor. These results are consistent with those found 
in the LIBCSP, where the odds of breast cancer were elevated for ever OC use, both OC 
and HRT use, and long-term HRT use [42]. 
Interestingly, non-steroidal anti-inflammatory drug (NSAID) use has emerged as a 
possible chemopreventive breast cancer agent although the evidence remains inconclusive 
[43-45]. Biologically, estrogen plays a role in the inflammatory pathway and NSAIDs may act 
through an estrogen-mediated pathway by targeting cyclooxygenase (COX), which inhibits 
prostaglandin production. NSAID use may reduce breast cancer risk through decreased 
estrogen production from progesterone. Inflammation also results in cell proliferation and 
may promote angiogenesis [46]; thus, NSAID use may influence breast cancer development 
in a non-estrogen related pathway as well.  
In the LIBCSP, ever aspirin use was associated with decreased odds of breast 
cancer than never use (OR=0.80; 95% CI: 0.66-0.97) [45]. These results are consistent with 
a meta-analysis published in 2003 of 9 studies examining the relationship between NSAID 
use and breast cancer (RR=0.77; 95% CI: 0.66-0.88) [47]. In the LIBCSP, NSAID use also 
implicated hormone receptor positive tumor development, where aspirin was associated with 
hormone receptor positive breast cancer. Tumors with one or more positive hormone 
receptor showed decreased odds of breast cancer in ever versus never users compared to 
tumors with no positive hormone receptors (OR=0.74, 95% CI: 0.60-0.93 for ≥ one positive 
hormone receptor; OR=0.97, 95% CI: 0.67-1.40 for no positive hormone receptors) [45]. In 
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contrast, Marshall et al. found an increased risk of breast cancer in hormone receptor 
positive tumors compared to hormone receptor negative tumors in daily versus non-regular 
NSAID users using data from the California Teachers cohort (RR= 1.03, 95% CI: 0.90-1.17 
for ER/PR-positive tumors; RR=1.48, 95% CI: 1.01-1.89 for ER/PR-negative tumors) [48]. 
Thus, while there is a suggestion of differential risk for hormone receptor positive and 
negative tumors with NSAID use, the direction of the effect is not consistent across studies.  
3.4.3 Diet 
Alcohol consumption, the dietary factor for which the evidence of an association with 
breast cancer is strongest [29], has been shown to increase estrogen levels, which may 
explain the elevated association with breast cancer observed in habitual drinkers. An 
international pooled analysis found an elevated risk of 1.32 (standard error (SE)=0.059) in 
women who consumed 35-44 grams of alcohol daily and an RR of 1.46 (SE=0.06) in women 
who consumed over 44 grams daily compared to women who never drink alcohol [49].  
The evidence for an association between breast cancer and fat intake is much less 
convincing. Using a multivariate nutrient density model approach, a pooled analysis of eight 
cohort studies found no association with saturated (RR=1.09; 95% CI: 1.00-1.19), 
monosaturated (RR=0.93; 95% CI: 0.84-1.03) or polysaturated fats (RR=1.05; 95% CI: 0.96-
1.16) for an increment of 5% of energy [50]. This same group also investigated fruit and 
vegetable intake in connection to breast cancer and found similar findings. The relative risk 
for a 100 g/day increment in fruit consumption reflected no association with breast cancer 
risk (RR=0.99, 95% CI: 0.98-1.00 for total fruits; RR=0.99, 95% CI: 0.98-1.00 for total fruits 
and vegetables) in this analysis of eight cohort studies [51] although case-control studies 
show a consistent reduction in breast cancer risk with high fruit and vegetable intake [52]. 
Dietary fiber has also been suggested to reduce risk of breast cancer by preventing 
estrogen absorption in the intestinal track. A meta-analysis of 12 case-control studies in 
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1990, however, found that contrary to this hypothesis, fiber consumption was positively 
associated with breast cancer (RR= 1.46, comparing highest quintile to lowest; CI not 
presented) [53]. Thus, while the association between heavy alcohol intake has been 
consistently observed in epidemiologic studies, the association between fat, fiber and fruit 
and vegetable consumption is much less convincing.  
3.4.4 Environmental Factors 
As with most cancers, ionizing radiation (IR) has also been found to associated with 
an increased risk of breast cancer with odds ratios and relative risks reaching over 9.0 [38]. 
IR is capable of breaking DNA bonds and, consequently, will lead to very high rates of 
mutation [38]. Information from Hiroshima survivors have played an important role in 
defining the role of radiation in breast cancer development and critical windows for disease 
development. In fact, an RR of 2.42 per Sievert was found for women ages 10-19 at the time 
of the atomic bomb while no elevation in risk of breast cancer was observed for women over 
the age of 40 [54], suggesting that puberty may represent a susceptible period for disease 
development. 
Active smoking has not been found to be associated with breast cancer consistently. 
In fact, despite the increased exposure to carcinogens with smoking, it has been suggested 
to reduce risk of breast cancer by minimizing weight gain through appetite suppression and 
through its anti-estrogenic effects, including early initiation of menopause and alteration of 
hormone metabolism [38]. Smoking and alcohol use are strongly correlated. To tease out 
the effects of smoking from alcohol consumption on breast cancer development, a 
collaboration of 53 epidemiologic studies examined breast cancer risk by alcohol 
consumption status. No association was found between active smoking, measured as 
never/ever smoked, and breast cancer risk among individuals who reported consuming 
alcohol (RR= 1.09; SE: 0.018) and among non-drinkers (RR=1.03; SE: 0.023) [49]. This 
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finding is consistent with the hypothesis that the dueling biologic mechanisms of smoking 
will cancel out any evidence of adverse or protective effects. LIBCSP data did indicate, 
however, a positive association with breast cancer for women who resided with a smoking 
spouse for over 27 years (OR=2.10; 95% CI: 1.47-3.02) [55], which is consistent with most 
previous studies that have reported increased breast cancer risk with passive smoke 
exposure [56].  
Polycyclic aromatic hydrocarbon (PAH)-DNA adducts are one of the most 
consistently reported environmental risk factors associated with breast cancer. PAHs 
represent widespread environmental contaminants, most commonly found in cigarette 
smoke as well as in grilled and smoked meats, and are typically measured by the formation 
of DNA adducts. They have been implicated as mammary carcinogens in rodents [57] and 
have been strongly linked to breast cancer in three studies [58-60]. Within the Long Island 
cohort, increased odds of breast cancer were observed comparing individuals in the highest 
PAH quintile to the lowest (OR=1.51; 95% CI: 1.04-2.20) [59].  
3.4.5 Obesity and physical activity 
Large body size appears to reduce the risk of breast cancer in pre-menopausal 
women, possibly due to its role in decreasing ovulation, but has consistently been found to 
elevate risk in post-menopausal women. In a pooled analysis of prospective cohort studies, 
a pooled RR of 1.26 (95% CI: 1.09, 1.46) was found for post-menopausal breast cancer 
comparing women with a BMI less than 21 kg/m2 to women with a BMI greater than 31 
kg/m2 [61]. In LIBCSP, post-menopausal women who gained more than 15 kg since age 20 
had elevated odds of breast cancer compared to those who gained less than 3 kg (OR= 
1.58, 95% CI: 1.11, 2.26) [9]. In pre-menopausal women, the relationship between obesity 
and breast cancer is much less consistent. A decreased risk was observed in the same 
analysis of prospective cohort studies with a pooled RR of 0.58 (95% CI: 0.34, 1.00) 
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comparing women with a BMI less than 21 kg/m2 to women with a BMI greater than 31 
kg/m2 [61]. This pooled RR fits the hypothesis that obesity may decrease risk of pre-
menopausal breast cancer by reducing the number of ovulatory cycles.  
As mentioned earlier, the observed relationship between obesity and breast cancer 
in post-menopausal women is consistent with research indicating that obesity is associated 
with higher levels of estrogen. In post-menopausal women, obesity may be a significant 
source of bioavailable estrogen because the ovaries have stopped estrogen production. In 
contrast, this correlation is not found in pre-menopausal women, who already have high 
levels of estrogen from menstruation. This suggests that the additional estrogen exposure 
from obesity in pre-menopausal women may be of little consequence when compared to the 
naturally higher levels found at this point in life and by its inhibitory effects on ovulation [62].  
The relationship between insulin and IGF-1 and breast cancer is further supported by 
recent literature suggesting an association between breast cancer and Type II diabetes 
mellitus. An estimated 16% of breast cancer cases in women over the age of 65 have also 
been found to have coincident diabetes mellitus [63]. In comparison, according to the 
Behavioral Risk Factor Surveillance System, the median nationwide prevalence of diabetes 
was 7.5% in 2006 [64]. In a recent meta-analysis, presented in Figure 2.3, cohort studies 
conducted in populations of type II diabetics found a slightly elevated but statistically 
significance increase in risk of breast cancer (RR = 1.25; 95% CI: 1.19-1.31) while case-
control studies of breast cancer have found a smaller increase in risk (RR = 1.13; 95% CI: 
0.99-1.28) with diabetes mellitus [63].  
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FIGURE 2.3. Type II Diabetes Mellitus and Breast Cancer from Wolf et al. [63] 
 
 
There is convincing evidence that physical activity reduces risk of breast cancer, 
although this decreased risk is most pronounced in postmenopausal women [65]. In post-
menopausal women, physical activity produces two positive effects, which may account for 
this difference: (1) physical activity reduces obesity, which is the primary source of 
endogenous estrogen in post-menopausal women, and (2) physical activity alone also 
reduces insulin as well as insulin-like growth factor levels [65]. In pre-menopausal women, 
the reduction in obesity is not necessarily an advantage as a means to prevent breast 
cancer development since obesity has been shown to have a protective effect in this group, 
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but may help in weight maintenance and prevention of post-menopausal obesity and 
promote anovulation.  
3.4.6 Genetic Factors 
Perhaps the most consistent risk factor for breast cancer is diagnosis of the disease 
in a first degree relative. Family history of breast cancer does not necessarily imply genetic 
susceptibility, however, but could also indicate shared environment and learned behaviors. 
Among women with a family history of breast cancer, a proportion will carry mutant alleles in 
BRCA1 or BRCA2, which confer a high lifetime risk of breast cancer. In particular, the 
Ashkenazi Jewish population has been estimated to have the highest prevalence of these 
mutations at 2.2% [38]. Only a small proportion of cases carry the BRCA mutations (2-5%), 
but the two genes are believed to be responsible for most hereditary breast cancers, 
particularly early-onset breast cancer [38].  
Research on common, low penetrance polymorphisms, or genetic variation that is 
common in the population and contribute only a slight increase in risk, has primarily focused 
on genes involved in inflammation, oxidative stress, estrogen metabolism and DNA repair. 
This dissertation will focus on the pathways most relevant to PPAR-alpha and obesity, 
specifically inflammation and insulin resistance. The following sub-sections will highlight 
several genes that have been investigated in connection to breast cancer along the 
inflammatory and insulin resistance pathways. 
 
3.4.6.1  Inflammatory pathway. Inflammation has been suggested to increase risk of 
breast cancer two different ways. First, inflammation leads to increased cell proliferation, 
which increases cancer risk and may promote angiogenesis [46]. Second, inflammation may 
operate through an estrogen-mediated response to increase prostaglandin production, 
which is involved in cell differentiation and growth [46]. Cytokines and their receptors are 
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involved in inflammatory response, and polymorphisms in the cytokine genes have been 
hypothesized to be associated with breast cancer although study findings have been 
inconsistent.  
TNFA. Tumor necrosis factor-alpha (TNFA) is well-established in the cancer 
literature and has been the focus of anticancer drug development [66]. Recently, eight TNFA 
SNPs were evaluated in connection to breast cancer development using data from USA and 
Poland Breast Cancer Study pooled together. Gaudet et al. found that heterozygotes of 
rs36152, an intronic polymorphism, had elevated odds of breast cancer development 
compared to common homozygotes (OR = 1.20; 95% CI: 1.05–1.37) [67]. Other studies that 
have examined a common polymorphism resulting in a guanine to adenine substitution at 
position -308 from the TNFA start site [68] have also found positive associations. Smith et al. 
reported differences in common homozygote genotype frequency for this polymorphism 
(79.7 vs. 68.2%, P = 0.03) [69] while Giordani et al., in a small case-control study, found 
elevated odds of breast cancer in rare homozygotes compared to common homozygotes 
(OR=1.62; 95% CI: 0.08–96.42) [70]. 
Interleukins. Research on the interleukin (IL) family has focused primarily on IL6 and 
IL10. In a study of five IL6 polymorphisms, Slattery et al. found elevated odds of breast 
cancer for rs1800796 (OR=1.53; 0.99-2.37) for heterozygotes and rare homozygotes 
combined compared to common homozygotes using data from the 4-Corner’s Study [71]. 
The ORs for the other SNPs were closer to the null or subject to imprecision. IL10 has been 
studied in four case-controls studies, but sample sizes were small [72]. Overall, the studies 
indicate slightly elevated odds of breast cancer but examination in a larger study population 
is needed.  
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3.4.6.1  Insulin resistance pathway. Several genes that lie on the growth pathway in 
addition to promoting cell proliferation have also been hypothesized to have an inflammatory 
effect. Included in this set of growth factor genes is insulin-like growth factor (IGF)-I, which 
has been investigated in connection to breast cancer. 
IGF-1. The IGF-I gene encodes for growth hormones that promote cell division in 
breast tissue. Research has focused on a simple tandem CA repeat that lies in the 5’ region 
of the gene near the transcription start site. The common allele has 19 CA repeats while the 
‘at risk’ variant is typically defined as all other number of repeats. Most studies have 
compared 19 / 19 homozygotes to 19 allele carriers (19 / -) and non-carriers (- / -) 
separately, but results have been inconsistent [73-76]. One study found reduced odds of 
breast cancer with the - / - genotype compared to 19 / 19 individuals (OR=0.50; 95% CI: 
0.23-1.05) [73] while another found elevated odds (OR=1.34; 95% CI: 0.89-2.04) with this 
same comparison [75]. All studies found no association between 19 / - and 19 / 19 
homozygotes [73-76]. In contrast, the LIBCSP data indicate slightly elevated odds of post-
menopausal breast cancer (OR=1.19; 95% CI: 0.94-1.52) and decreased odds of pre-
menopausal breast cancer (OR=0.87; 95% CI: 0.62-1.22) in the 19 / - versus 19 / 19 
genotypes [77]. An elevated risk of post-menopausal breast cancer was also observed 
comparing the - / - to 19 / 19 genotype (OR=1.27; 95% CI: 0.89-1.81) while no difference in 
risk of pre-menopausal breast cancer was found (OR=1.05; 95% CI: 0.63-1.75) [77].  
2.5 CONCLUSION 
Breast cancer affects many families and represents an important public health 
concern. Estrogen, specifically its most bioactive form estradiol, seems to be a key 
component in the breast carcinogenesis pathway although its exact role remains uncertain. 
Because of its implications on the endocrine system, obesity appears to play an important 
role in breast cancer development in post-menopausal women. Given the rising prevalence 
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of obesity, particularly in post-menopausal women, identifying factors that may increase 
susceptibility through this mechanism has become increasingly important. 
 CHAPTER 3 BREAST CANCER SURVIVAL 
3.1 INTRODUCTION 
While breast cancer survival has increased dramatically in the last 30 years due to 
improved therapy options and early detection, survival remains extremely low in patients 
with advanced disease. Additionally, while several tumor markers are used to identify 
patients with poor prognosis or to aid in treatment decision-making, it is uncertain whether 
factors that influence breast cancer risk, such as obesity, also influence survival. This 
section outlines the different types of breast cancer, diagnostic procedures, key pathological 
tumor characteristics, trends in breast cancer survival, and the association between survival 
and obesity.  
3.2 TYPES OF BREAST CANCER 
As discussed in Chapter 2, breast cancers fall under two categories, carcinoma in 
situ, composing approximately 26% of all breast cancers, and invasive carcinoma, 
representing an estimated 74% of all breast cancers. In situ carcinomas are believed to be a 
part of the carcinogenesis continuum and may be an indicator of increased risk of invasive 
breast cancer. Ductal carcinoma in situ (DCIS) is the most common in situ cancer and 
originates in the ductal cells of the breast while lobular carcinoma in situ is much less 
common and originates in the lobule walls [78]. Invasive cancers have spread from their 
origin site into the fatty tissues of the breast, referred to as stromal invasion, and may have 
spread into regional lymph nodes or to other more distant locations through the blood
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stream. Infiltrating ductal carcinoma makes up the bulk of the invasive cancers while 
infiltrating lobular, medullary, colloid, and tubular carcinomas and inflammatory breast 
cancer compose a small percent of the invasive cancers.  
3.3 DIAGNOSIS 
Because DCIS by definition is localized, patients are usually asymptomatic and 
detection occurs during screening mammography [79]. For this reason, the incidence of 
diagnosed DCIS has increased rapidly over the last decade as mammography has become 
more widely available and awareness of its importance has grown. It is important to note, 
however, that DCIS is often difficult to diagnose. First, it is a challenge to differentiate DCIS 
from atypical ductal hyperplasia, a DCIS precursor [80], and, second, approximately 15% of 
DCIS cases are later found to be invasive cancer once additional testing is done [80]. For 
invasive cancers, initial detection may occur during a routine mammogram or a physician 
examination, particularly if the patient is symptomatic or a lump was noted [31]. In both 
situations, a battery of follow-up procedures, including a diagnostic mammogram, 
ultrasonography, and biopsy, may be necessary to further characterize the mass. 
3.3.1 Breast cancer imaging 
Following an abnormal screening mammogram, a diagnostic mammogram is often 
necessary to further define irregularities. It will also be conducted in symptomatic patients to 
aid in diagnosis and assess disease spread [31]. While mammography can be particularly 
useful in patients where physician examination yields uncertain results, such as women with 
heavy, lumpy breasts [31], the imaging quality will be diminished in women with dense 
breasts [79]. In this situation, ultrasound may be the most appropriate tool for detecting 
small non-palpable lesions [79] and allows distinction between tumors and cysts [31, 79]. 
Magnetic resonance imaging (MRI) has also been used following mammography to evaluate 
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newly detected lesions although the expense and time required for this procedure limits its 
utility in most clinical settings [31]. Typically, it is only used in women at a high risk for breast 
cancer, such as known or suspected BRCA carriers [79]. Lastly, positron emission 
tomography (PET) scans may be conducted when metastatic disease is suspected [79].  
3.3.2 Breast cancer biopsies 
After imaging has detected a breast tumor, a biopsy will be performed to examine 
tumor characteristics and pathology. In particular, fine needle and core aspiration biopsies 
are often conducted since they are inexpensive, easy to perform and minimize patient 
discomfort [31, 80]. Unfortunately, the accuracy of results for fine needle aspiration is highly 
dependent on the skill of the physician obtaining the specimen [80] while core aspiration 
may not be able to find the tissue of small breast tumors [31]. To combat this limitation, core 
aspiration may be performed with x-ray technology to help penetrate small tumors [31]. 
Lastly, surgical biopsy may be necessary if the tumor is non-palpable[80].  
3.4 PATHOLOGY 
3.4.1 DCIS 
DCIS tumors are categorized into one of three grading categories: high, intermediate 
and low. These classifications have implications on recurrence rates and the probability of 
progression to invasive cancer. For example, high grade is associated with a high rate of 
recurrence with frequent progression to invasive breast cancer while low grade has low 
probability of recurrence and tends to remain localized [80]. Histological architecture is also 
an important feature of the tumor and plays a role in grading assignment and evaluating 
future recurrences. The comedo type is typically a high grade tumor with a high degree of 
necrosis and low cell differentiation [81]. In contrast, cribriform, papillary and micropapillary 
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subtypes tend to be low grade tumors with infrequent mitoses and varying cell sizes [81]. 
Table 3.1 displays the principle pathologic features of interest in in situ breast cancers. It is 
important to note that hormone receptor status can also be ascertained in these tumors, but 
is not routinely performed because of the high treatment success rate [80].  
 
TABLE 3.1. In situ breast cancer pathology features of interest from Bilous et al. [80] 
 
Nuclear Grade 
• High grade 
• Intermediate grade 
• Low grade 
Lesion size 
Architecture 
• Comedo 
• Solid 
• Cribriform 
• Micropapillary 
• Papillary 
Margin status 
• Margins involved with tumor 
• Margins clear of tumor cells 
 
3.4.2 Invasive breast cancer 
Using surgical biopsy samples, important pathological characteristics of invasive 
tumor can be investigated. These characteristics help define key prognostic and predictive 
markers that may influence treatment choices and allow for grading of the tumor. Table 3.2 
provides a concise description of select pathological tumor characteristics and their 
implications on prognosis and treatment response. 
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TABLE 3.2. Invasive breast cancer pathology features of interest from Bilous et al. [80] 
 
Histological Grade 
• Grades 1-3 based on nuclear grade, tubule formation and mitotic rate 
Tumor size 
Lymph node involvement 
• The number of nodes dissected and the number involved with metastatic 
carcinoma 
Lymphovascular invasion 
• Evidence of tumor cells invading into vessels 
Tumor receptors 
• ER and PR receptor status 
• HER2/neu status 
 
3.4.2.1  Prognostic and predictive factors. Prognostic factors can be described as 
markers that “provide information on the clinical outcome at the time of diagnosis, 
independent of therapy” [82]. Common prognostic factors for invasive breast cancer include 
tumor size, lymph node status, lymphovascular invasion, and histological grade [80, 82]. In 
contrast, predictive factors detail the probability of a positive treatment response to a 
specific therapy [82] and include hormone receptor status. Interestingly, HER-2 is believed 
to be both a prognostic and predictive factor since it indicates a poor prognosis and also 
suggests a specific line of treatment [80, 82]. The following bullets will highlight the two most 
widely accepted prognostic and predictive factors and their implication on either disease 
prognosis or treatment response. 
 
• Estrogen (ER) and progesterone (PR) receptor status 
Hormone receptor status plays an important role in treatment planning and may also 
indicate tumor etiology. For example, obesity has been linked to hormone receptor positive 
tumors, which is consistent with research indicating estrogen levels are a key component of 
breast cancer development [83]. Perhaps most importantly, however, hormone receptor 
status is an indicator of response to endocrine therapy for metastatic disease or as an 
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adjuvant therapy option [82]. Patients with hormone receptive positive tumors, which are the 
most frequently diagnosed tumor in U.S. women, show increased survival compared to 
patients with receptor negative tumors, and hormone receptor status has been linked to 
disease stability or the likelihood of metastasis [84]. Receptor positive tumors are treated 
with hormone therapy, which has been shown to be clinically effective even in metastatic 
breast cancers and has less negative side effects than chemotherapy [84]. The purpose of 
hormone therapy (e.g. Tamoxifen and Fareston) is to block the production of estrogen 
and/or progesterone to minimize the proliferation of the cancer cells. Receptor negative 
tumors do not respond to hormone therapy and, for those patients, systemic chemotherapy 
remains the most appropriate treatment approach [84].  
 
• Human epidermal growth factor receptor (HER-2/Neu, also called c-erbB-2) 
According to the National Comprehensive Cancer Network, approximately 33% of breast 
cancers have highly overexpressed HER-2/neu genes or have multiple copies of the gene, 
leading to high HER-2/neu protein levels [78]. HER-2/neu is a member of the epithelial 
growth factor receptor family and is involved in the signaling cascade that ultimately results 
in cell growth and differentiation [85]. Given this, it is not surprising that HER-2/neu tumors 
are associated with poor prognosis. Recent research has indicated that these tumors will not 
respond to endocrine therapy (although this remains controversial) [85]. Trastuzumab 
(brand name: Herceptin), a HER-2/neu agonist, is typically advocated at treatment in this 
tumor type [78, 85].  
 
3.4.2.2  Grading and Staging. Unlike DCIS tumors, invasive breast cancers are 
graded not only on nuclear grade, but also on tubule formation and mitotic rate, which is an 
indicator of cell proliferation [78, 80]. Based on these three factors, tumors are assigned a 
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grade (I-III) to better characterize the observed histological pattern and give a quantitative 
measure of the tumor’s aggressiveness.  
While both breast cancer stage and grade assist in the treatment decision process 
and in the prognostic evaluation, stage incorporates histological tumor characteristics, such 
as disease spread, and clinical features to provide a more detailed categorization of 
disease. For this reason, integrating cancer stage is a key component in any survival 
analysis. Currently, the TNM staging system [86], developed by the International Union 
Against Cancer, is upheld as the universal standard for breast cancer staging [31]. This 
staging was updated in 2002 to adapt to the widespread use of screening mammography, 
leading to early detection of small tumors, and changes in treatment standards, including 
greater use of sentinel lymph node dissection [87]. The most current TNM staging criteria 
are described below while Appendix C describes in greater detail the differences between 
the 5th and 6th edition of the TNM classifications. 
Briefly, the TNM classification system incorporates information on three 
characteristics: (1) T for tumor size and spread, (2) N for lymph node involvement, which 
has both a clinical and pathological component, and (3) M for metastases to distant organs. 
These three assessments are then combined to assign an overall staging classification of 0, 
I, II (A or B), III (A, B, or C) or IV with 0 indicating in situ cancers and IV representing 
extremely advanced, metastatic disease [31, 78]. The T category will range from Tis, which 
is used to indicate non-invasive cancers, to T4, which indicates a cancer that has spread to 
the chest wall (regardless of tumor size). T3 notes large tumors (> 5cm) that have not 
spread to nearby tissue. For the N category, N0 is the most favorable, where cancer has not 
spread to the lymph nodes, while N2 describes the most diffuse cancer (more than 10 lymph 
nodes involved). Lastly, M0 indicates non-metastatic cancer while M1 notes cancer that has 
spread to distant organs. Table 3.3, adapted from the National Comprehensive Cancer 
Network [78], displays the TNM staging system and the different categories for evaluation. 
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TABLE 3.3. TNM staging system from the National Comprehensive Cancer Network [78]
Overall stage T Category N Category M category 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage IIA T0 
T1 
T2 
N1 
N1 
N0 
M0 
M0 
M0 
Stage IIB T2 
T3 
N1 
N0 
M0 
M0 
Stage IIIA T0 
T1 
T2 
T3 
T3 
N2 
N2 
N2 
N1 
N2 
M0 
M0 
M0 
M0 
M0 
Stage IIIB T4 Any N M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
 
3.5 TRENDS IN BREAST CANCER SURVIVAL 
Before survival trends can be discussed, it is important to define survival. Typical 
statistical analyses will use two different survival outcomes, observed survival and corrected 
survival. Observed survival is simply the proportion of patients alive beginning at date of 
diagnosis and ending at a specific time point without regard to cause of death while 
corrected survival only includes deaths attributable to the breast cancer diagnosis [38]. Most 
published statistics examining trends in survival, however, use relative survival rates, 
defined as the ratio of the observed survival in the cohort of cancer patients and the 
expected survival [38]. Expected survival will depend on the context and relative survival 
rates may compare survival in specific groups, such as women with ER/PR positive tumors 
to women with ER/PR negative tumors.  
As mentioned earlier, stage plays an important role in prognosis and survival. As 
illustrated in Figure 3.1, localized breast cancer has the best prognosis with a 5-year relative 
survival of 98.5% while distant, metastatic breast cancer patients fare the worst with only a 
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27.7% relative survival. Unstaged cancers are also important to consider since a variety of 
relevant factors may influence whether a tumor is staged, including access to care, patient 
health, and metastatic status. Given this, it is not completely surprising to see that unstaged 
cancer patients have a poor prognosis compared to patients with localized and regional 
tumors. 
 
FIGURE 3.1. SEER Relative Survival Rates by Stage at Diagnosis in Whites using data from 
the SEER 9 Registries for 1988-2001 [88] 
 
 
Age at diagnosis has also been shown to influence survival. Pre-menopausal women 
are less likely to have localized cancer and more likely to be diagnosed with regional 
disease (see Figure 3.2). This trend is possibly due to the different etiology of pre-
menopausal breast cancer, leading to more aggressive cancers, or the low prevalence of 
screening in the population [89]. According to Surveillance, Epidemiology and End Results 
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(SEER), the 5-year relative survival is 82% in women under the age of 40, but is 
approximately 88% in women 40 years of age or older independent of disease stage [88, 
89]. Stage at diagnosis in these women could, in part, explain these observed differences in 
survival (Figure 3.2). 
 
FIGURE 3.2. SEER Stage Distribution Age Group in Whites using data from the SEER 9 
Registries for 1988-2001 
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3.6 EPIDEMIOLOGY OF BREAST CANCER SURVIVAL 
Many of the same themes from the breast cancer risk factor epidemiology have 
emerged as important predictors of breast cancer prognosis and survival. For example, 
parity, exogenous hormone use, diet, and obesity have all been extensively studied to 
determine their influence on survival although the mechanism of action remains uncertain 
for many of these factors. The following section will discuss known and suspected 
prognostic factors found in the breast cancer survival literature. 
3.6.1 Reproductive factors 
Parity and time between last birth and diagnosis are emerging as important 
reproductive factors influencing mortality from breast cancer in premenopausal women. For 
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example, several studies have found that the hazards of death are highest in women who 
had given birth 2 years prior to their breast cancer diagnosis (Hazard Ratio (HR)~2.0) [90-
92]. This risk quickly declines with a larger time interval between last birth and diagnosis, so 
that no differences in mortality are observed in women with 5 or more years between last 
birth and diagnosis compared to nulliparous cases [90-92]. These findings are consistent 
with the hypothesis that pregnancy induces cell proliferation, increasing malignancy in the 
short-term, but decreases carcinogenesis in the long term. Several studies have also found 
that parity was associated with decreased survival compared to nulliparity women [90-92], 
suggesting that pregnancy alone may have detrimental effects on prognosis in pre-
menopausal women.  
3.6.2 Exogenous hormones 
As will be discussed in Chapter 5 on research methods, the survival portion of this 
study will use covariate data obtained at the baseline interview; therefore, this literature 
review will focus on cases who were taking exogenous hormones at the time of diagnosis. 
There is a growing body of research detailing the impact of taking HRT following a breast 
cancer diagnosis on survival, but this literature is not relevant to the current study and will 
not be detailed. Instead, this literature review will focus on HRT use before diagnosis. 
Several studies have investigated the impact of HRT use at time of diagnosis in 
connection to breast cancer survival. In a Swedish cohort of 948 cases, ever use of HRT 
was associated with higher overall survival compared to never users even after adjusting for 
tumor stage (HR=0.78; 95% CI: 0.65-0.93) [93]. This finding is consistent with several other 
studies that have examined this association, all of which found improved survival with HRT 
use prior to the breast cancer diagnosis [94-96]. In addition, HRT use has been investigated 
as potentially influencing histological and prognostic tumor characteristics. The Women’s 
Health Initiative, a clinical trial of 16,608 post-menopausal women randomized to receive 
 39
either placebo or a specific estrogen-progesterone HRT regimen, found HRT use was 
associated with larger tumor size and more advanced disease compared to placebo [97]. 
These results, however, oppose the majority of observational study findings that have 
indicated HRT use is associated with decreased tumor size, better tumor differentiation and 
more localized disease. The authors suggest that these differences could suggest 
surveillance bias in the observational studies since HRT users may be more likely to see a 
physician regularly and be screened more frequently or it could be a function of an older 
WHI study population than those typically found in the observational studies (approximately 
66% of the WHI population was over the age of 60). An estimated 25% of WHI participants 
in both the active and placebo groups were either current or past HRT users at the start of 
the trial, so selection bias by HRT use is not likely to explain this difference [97]. 
The relationship between oral contraceptive (OC) use and breast cancer survival 
remains controversial. The three studies that have investigated ever versus never use of 
OCs and breast cancer survival have found different results: one found null results [98], one 
found a slightly elevated hazard ratio [99] and one improved survival [100]. Further, among 
the studies examining duration of OC use, differing results were also found with one finding 
no difference with duration of use [98], one finding increased survival with short term use 
[101] and another with long term use [100]. Thus, while there is a suggestion of a prognostic 
impact with OC use, the direction of the associations is not consistent and the importance of 
duration of use has not been clearly established. 
3.6.3 Diet 
Research on diet and breast cancer survival has primarily focused on dietary factors 
that have been found to influence risk of breast cancer, but have been met with very limited 
success. Differences in exposure categorizations and range of dietary values observed in 
the cohort (particularly relevant when percentiles are used as cut points) make comparison 
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difficult. For example, several studies have investigated the association between alcohol 
intake and breast cancer survival [102-105], but the magnitude of effects differed 
dramatically. Two studies found null results [103, 105] for hazard ratios per two drinks a 
week and comparing individuals who drank 5.0-14.9 grams per day to non-drinkers 
respectively. In contrast, Zhang et al. found an inverse hazard of death comparing women 
who drank more than 4 grams/day to non-drinkers (HR=0.7; 95% CI: 0.3, 1.5) [102] while 
Ewertz et al. reported decreased survival with consumption of over 121 grams of alcohol per 
week to no alcohol consumption (HR=1.26; 95% CI: 0.90, 1.74) [104].  
Similarly, several studies have examined dietary fiber intake and breast cancer 
survival [106] although considerable variation in the point estimates is evident. In particular, 
the Nurses’ Health Study found a HR of 0.69 (95% CI: 0.50, 0.97) comparing cases who had 
eaten over 20 grams of fiber per day to those who had consumed less than 12.5 grams of 
fiber per day [105]. Another study found increased hazard of death with fiber consumption 
(HR=1.17; 95% CI: 0.83, 1.66 per 20 grams/day).  
While the evidence of an association between fat intake and risk of breast cancer 
was not convincing, it may influence survival. Among studies that investigated total fat intake 
and breast cancer survival [102-104, 107, 108], hazard ratios ranged from 0.96 (95% CI: 
0.75, 1.22) comparing fourth to first total fat quartiles (values not presented) [104] to 2.1 
(95% CI: 0.11, 4.3) comparing women who consumed 56-76 grams/day to 19-56 grams/day 
[102]. When only saturated fat consumption is examined, a consistent trend towards 
decreased survival with high saturated fat intake is seen. Among the five studies that 
examined saturated fat in connection to breast cancer survival [102, 103, 105, 107, 108], 
HRs ranged from 1.13 (95% CI: 1.05-1.22) for a twofold increase in percent energy [108] to 
1.72 (95% CI: 1.00, 2.96) per 20 grams/day [103]. It is important to note, however, that 
residual confounding may be present. Fat intake is correlated with energy consumption and 
obesity [106]. Because of this, it may be necessary to adjust for these possible confounders 
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in the analysis although some consider energy consumption and obesity to be causal 
intermediates, and therefore, should not be adjusted for in analyses. 
3.6.4 Smoking 
Although only a small number of studies have investigated smoking and breast 
cancer prognosis, they consistently show reduced survival in smokers compared to non-
smokers. In a study of 792 breast cancer cases in Malmo, Sweden, a breast cancer-specific 
HR of 2.14 (95% CI: 1.47-3.10) comparing current smokers to never smokers, adjusting for 
stage and age [109]. This finding aligns with two other studies which both found decreased 
survival in smokers but no histological, size or stage differences in the cancers [110, 111]. 
Several explanations have been presented to explain this observation including 
compromised immune systems in smokers as well as dietary and socio-economic status 
differences between smokers and non-smokers that may confound the association [109].  
3.6.5 Obesity and Physical Activity 
Many epidemiologic studies have examined the association between obesity and 
breast cancer survival. Appendix B highlights recent research examining this association 
along with study characteristics and important findings. Hazard ratios and relative risks 
range between 0.60 to 3.3 and most studies adjusted for ER/PR status, age at diagnosis 
and hormone therapy use. Like breast cancer incidence, a growing body of literature 
suggests an association with obesity and negative prognosis in post-menopausal women. 
Recent research has also implicated obesity and decreased survival in pre-menopausal 
women, however.  
Using data from the LIBCSP, Cleveland et al. found decreased overall survival with 
obesity (BMI ≥ 30 kg/m2) compared to normal weight (BMI < 24.9 kg/m2) in pre- and post-
menopausal women (HR=2.62, 95% CI: 1.26, 5.45; HR=1.63, 95% CI: 1.08, 2.45 
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respectively) [112]. Consistent with these results, Abrahamson et al. observed increased all 
cause mortality with obesity (BMI ≥ 30 kg/m2 versus BMI between 18.5 and 24.9) in a 
population of primarily pre-menopausal women (HR=1.65; 95% CI: 1.23, 2.21) [113]. Similar 
results for all cause mortality were noted in a cohort of pre- and post-menopausal women 
comparing obese patients (BMI ≥ 30 kg/m2) to normal weight cases (BMI < 25.0 kg/m2) 
(HR=1.53; 95% CI: 1.37, 1.72) [114]. In contrast, while the Million Women Study in the 
United Kingdom found an association with increased mortality in post-menopausal women 
(HR=1.49; 95% CI: 1.27, 1.75) an inverse association with mortality was noted in pre-
menopausal women comparing obese to normal weight women (HR=0.64; 95% CI: 0.34, 
1.21) [115]. Thus, while obesity is consistently associated with decreased survival in post-
menopausal women, the association remains controversial in pre-menopausal women. In 
the LIBCSP, however, obesity clearly implicates mortality in both pre- and post-menopausal 
women.  
In addition to its association with poorer survival in both pre- and post-menopausal 
women [112-115], high BMI has also been linked to later stage at diagnosis [116, 117], 
larger tumor size [116, 118], and positive estrogen receptor status [83]. This difference in 
prognosis has been suggested to be the result of increased breast density with obesity, 
which hinders the diagnostic ability of mammograms [116], but this would not explain the 
observed negative impact of obesity on survival in early stage breast cancer [119-121]. 
Alternative explanations have ranged from obesity leading to more aggressive forms of 
breast cancer due to increased levels of insulin and leptin in these patients to differences in 
adjuvant therapy use in obese versus normal weight patients [121]. An article by Colleoni et 
al. suggest that obese patients with hormone receptor negative breast cancer are often 
given reduced chemotherapy doses and that this reduction has negative implications on 
prognosis [122].  
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Very few studies have investigated physical activity prior to breast cancer diagnosis 
in connection to breast cancer survival [123-125]. Two studies found no associations with 
any kind of physical activity at diagnosis and breast cancer mortality or consistency when 
women were stratified by menopause status [123, 124]. These studies may have been 
hampered by small sample sizes, however, since they only included 412 and 603 patients 
respectively. In contrast, Abrahamson et al. using data from a cohort of 1,264 primarily pre-
menopausal women found physical activity one year prior to diagnosis was associated with 
decreased mortality (HR=0.78; 95% CI: 0.56, 1.08), comparing highest quartile to lowest 
quartile of activity [125]. The effect of PA was modified by obesity with overweight or obese 
women showing a greater survival benefit than women of normal weight.  
3.6.6 Genetic Factors 
3.6.6.1  BRCA1 and BRCA2. BRCA1-related breast cancers have been suggested to 
have a negative impact on survival. These cancers tend to be hormone receptor negative, 
poorly differentiated and HER-2/neu negative [126], factors which are known to have an 
adverse effect on prognosis. Studies examining this relationship range from linkage studies 
and smaller clinic-based explorations to larger cohorts of Ashkenazi Jews, who have much 
higher BRCA1 prevalence than those found in the general population. While previous 
studies have demonstrated negative impact on survival among carriers of the BRCA1 
mutation [126], recent research has been much less conclusive [127-129]. In a national 
cohort of 1,794 Israeli women, Rennert et al. found no evidence of a 10-year overall survival 
difference in BRCA1 carriers (n=76) compared to non-carriers (HR=1.09; 95% CI: 0.79, 
1.51) [127]. It is important to note that no prognostic differences were found with tumor 
stage and nodal status in this cohort, casting doubt on the validity of their findings [130]. 
This finding is consistent with El-Tamer et al. who found no evidence of a survival difference 
comparing Kaplan-Meier curves [129], but not with Brekelmans et al. who found elevated 
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hazard of death in BRCA1 carriers compared to sporadic breast cancer cases (HR=1.30; 
95% CI: 0.91, 1.85) [128]. 
Like BRCA1 cancers, BRCA2 breast cancers tend to be of higher grade than 
sporadic breast cancers although BRCA1 and 2 cancers differ histologically from one 
another [131]. BRCA2 breast cancers tend to be more tubular and have a larger intraductal 
component than cancers associated with BRCA1 [131]. Based on eight studies, survival 
appears to be slightly worse for BRCA2 carriers compared to non-carriers although the 
evidence is much less convincing than the BRCA1 literature [127-129, 131]. In general, 
sample sizes were small and studies were based primarily on convenience samples. 
 
3.6.6.2  Low penetrance polymorphisms. Very few studies have investigated low 
penetrance genetic polymorphisms in relation to breast cancer survival, but they are 
becoming more common in the literature. Research has focused on mutations in xenobiotic 
metabolizing genes, such as the cytochrome P450 (CYP) family, and oxidative stress, like 
GST family and MnSOD, although small sample sizes have limited the ability of these 
studies to detect associations.  
Xenobiotic metabolism. Several studies have investigated the association between 
CYP2D6 and breast cancer survival, particularly among patients receiving tamoxifen. 
CYP2D6 is a Phase I enzyme and genetic variants have implications on the rapidity of 
metabolism [132]. All four studies investigating CYP2D6 in connection to breast cancer 
survival have suggested carriers of CYP2D6 to show improved survival compared to non-
carriers [133-136]. For example, Nowell et al. found carriers of the CYP2D6*4 allele to have 
a HR of 0.77 (95% CI: 0.32, 1.81) compared to non-carriers [135]. Wegman et al., 
examining recurrence-free survival, noted inverse hazards of death in CYP2D6 
heterozygotes and *4 homozygotes combined compared to *1 homozygotes (HR=0.33; 95% 
CI: 0.08, 1.43) [136].  
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Oxidative stress. In addition to being examined as a risk factor for breast cancer 
incidence, the MnSOD polymorphism leading to a valine to alanine amino acid substitution 
at codon 16 has also been investigated in connection to breast cancer survival. In a cohort 
of 251 women identified through the Arkansas Tumor Registry, individuals homozygous for 
the Ala allele showed improved survival compared to Val homozygotes (HR=0.66; 95% CI: 
0.34-1.29) even after adjustment for stage, race, and ER and PR status [137]. Using this 
same study population, deletions in the GSTM1 and GSTT1 gene were also investigated in 
relation to breast cancer survival [138]. In both genes, the null genotype was associated with 
increased survival (HR=0.50, 95% CI: 0.36-0.97 for GSTM1; HR=0.51, 95% CI: 0.29-0.90 
for GSTT1) with adjustment for age, race, stage and node status [138]. These results are 
comparable to those found by Syamala et al. who examined GSTM1 and GSTT1 deletions 
in a small cohort 222 sporadic breast cancer cases in South India [139]. More recently, 
Yang et al. found no differences in survival for cases with the null GSTM1 and GSTT1 
genotype (HR=1.1, 95% CI: 0.8, 1.5 and HR=1.0, 95% 0.7, 1.4 respectively) in a cohort of 
1,034 cases in Shanghai [140].  
3.7 CONCLUSION 
While breast cancer survival has improved in women with localized disease, 
prognosis is still poor for women with metastatic breast cancer. Advances in tumor 
pathology have helped to determine appropriate treatment options for various breast cancer 
subtypes, but options remain limited for women with systemic disease. Lastly, recent 
research has implicated BMI at diagnosis and increased mortality. PPARA has been linked 
to obesity (discussed in the next section) and examining this gene in connection with breast 
cancer survival could help elucidate this pathway. 
 CHAPTER 4 PPARA 
4.1 THE BIOLOGY OF PPARA 
4.1.1. Introduction 
The peroxisome proliferator-activated receptor (PPAR) family is composed of three 
nuclear hormone receptor genes: PPAR-gamma (PPARG), PPAR-alpha (PPARA) and 
PPAR-delta (PPARD). In general, hormone nuclear receptor genes encode proteins that 
induce gene transcription by binding to the promoter region of a target gene [141]. The 
protein structure of nuclear hormone receptors has implications for its role in the regulation 
of gene expression and its potential involvement in breast cancer carcinogenesis. Please 
note that the PPAR proteins will be referred to using Greek letters (e.g. PPARα) while the 
gene names will be abbreviated using alphanumeric values (e.g. PPARA). 
4.1.2 Nuclear Hormone Receptors (NHR) 
4.1.2.1 Mechanism. NHRs are activated when small, lipophilic molecules (e.g. hormones 
for PPARA), called ligands, travel across the membrane of the target cell and bind to the 
ligand-specific NHR [141]. PPARα ligands include palmitic acid, arachidonic acid and stearic 
acid although exogenous compounds, like fenofibrate, bezafibrate and non-steroidal anti-
inflammatory drugs, have also been shown to target the PPARα receptor [142, 143]. After 
the ligand has bound to the receptor, PPARα will heterodimerize, which allows it to bind with 
a specific regulatory DNA sequence (i.e. the peroxisome proliferator response element 
(PPRE)), in the target gene. By binding to the PPRE, PPARα induces transcription of the
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 target gene. The PPRE is typically located in the 5’ flanking region of the gene [144] and, 
for the PPAR family, consists of direct repeats separated by one base pair (DR1) [142, 144]. 
Retinoid X receptor (RXR) has also been shown to work synergistically with PPARα to 
activate expression of the target gene through the ligand-dependent activation function 2 
(AF-2) [142, 144]. Figure 4.1 illustrates the mechanism of action of PPARα, including ligand 
diffusion into the cytoplasm, the heterodimeric complex traveling into the nucleus and RXR 
acting as a co-factor to increase gene expression.  
FIGURE 4.1. PPARα mechanism of action to induce gene expression, adapted from Kiec-
Wilk et al. [145] and Kota et al. [142] 
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4.1.2.2 Structure. As depicted in Figure 4.2, NHRs are composed of 4 different regions: 
(1) the A/B domain, (2) the DNA binding domain (DBD), (3) the hinge region, and (4) the 
ligand binding domain (LBD) [142, 144]. The A/B domain is located at the N terminus and is 
highly variable within the family of NHR genes; in fact, spliced isoforms will often occur in 
this region [144]. In PPARα, this region also contains a transcriptional activation function 
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(AF-1) that allows for transcription activation without the presence of the ligand. Through the 
AF-1, the phosphorylation of mitogen-activated protein kinase can lead to PPARα activation 
[144]. For example, insulin has been shown to activate PPARα through this mechanism 
[143]. In contrast, the DNA binding domain is well conserved and is responsible for 
recognizing and binding to the PPRE. The hinge region is not well characterized and varies 
by NHR. Research suggests that it is the link between the DBD and the LBD [144] and the 
binding domain for cofactors [142]. Lastly, the LBD contains the AF-2 site for ligand-
dependent gene transcription and contains the binding “pocket” for the ligand. Once the 
ligand has bound to the receptor, the LBD provides the dimeritization surface for travel 
across the nucleus [144].  
 Interestingly, two PPARA isoforms have been characterized (PPARA1 and 
PPARA2). PPARA1 encodes the entire gene while PPARA2 is truncated at exon 6. This 
truncation results in the absence of the ligand-binding domain in the gene’s protein and, 
consequently, prevents activation by the ligand. Therefore, this study is interested in 
PPARA1 because of its protein’s known activity. 
 
FIGURE 4.2. Schematic depiction of the functional domains of PPARα, adapted from 
Aranda and Pascual [144] and Kota et al. [142] 
 
 
4.1.3 Biologic Mechanisms of PPARα 
PPARα has been implicated in fatty acid and lipoprotein metabolism, particularly 
triglyceride metabolism, as well as atherosclerosis but has not been studied in cancer. 
Figure 4.3 displays current knowledge about the biologic effects of PPARα activation in 
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different organ systems while Figure 4.4 uses this information to demonstrate the potential 
role of PPARα in the obesity-breast cancer relationship. 
 
FIGURE 4.3. Biologic effects of PPARα activation in different organ systems, adapted from 
Kota et al. [142] 
 
 
As Figure 4.3 suggests, PPARα is primarily expressed in organs with increased fatty 
acid oxidation rates [143, 146]. In particular, PPARα is largely found in the liver, kidney, 
heart, skeletal muscle, brown adipose tissue, vascular endothelial cells, vascular smooth 
muscle cells and macrophages and in small quantities in white adipose tissue [142]. It has 
also been implicated in multiple pathways, including obesity, inflammation and insulin 
sensitivity, which are key components of carcinogenesis and illustrate PPARα’s potential 
role in breast cancer development (Figure 4.4). The next section will detail research 
investigating these three pathways to further describe the associations starred in Figure 4.4. 
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FIGURE 4.4. A conceptual diagram of PPARα and obesity-mediated breast cancer 
development, adapted from Calle and Thun [147] 
 
 
4.1.3.1 Obesity. PPARα has been shown to regulate lipid metabolism by controlling the 
uptake and oxidation of fatty acids [143]. This regulation influences the availability of free 
fatty acids, which contribute to insulin resistance [148]. Given this, it is not surprising that 
PPARα has been shown to influence fat storage in the liver and reduce steatosis although 
this remains controversial [146]. PPARα also increases glucose levels through its 
involvement in gluconeogenesis and plays a role in the synthesis of apolipoproteins, 
including apoAI and apoAII [146]. Fibrates, which are PPARA agonists, have also been 
shown to reduce the expression of multiple cytokines, including interleukin-6, fibrinogen, and 
C reactive protein in humans [143].  
 
4.1.3.2 Inflammation. PPARα has also been suggested to reduce the expression of 
multiple cytokines, including interleukin (IL)-1 and IL-6, and inhibit COX-2 activity [143]. For 
example, fibrates have been shown to reduce IL-6, fibrinogen, C reactive protein, and tumor 
necrosis factor (TNF)-α [143]. Interestingly, TNF-α suppresses insulin signaling and has 
been linked to insulin resistance, suggesting a role of PPARα in Type 2 diabetes and insulin 
sensitivity. Additionally, PPARα decreases monocytic tissue factor expression, found on the 
surface of monocytes and macrophages in human atherosclerotic lesions [143], and may 
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induce apoptosis in cytokine-activated macrophages [149]. PPAR’s involvement in the 
inflammatory pathway is consistent with the growing body of literature linking PPARα to 
atherogenesis and could suggest a possible role in breast cancer development. 
 
4.1.3.3 Insulin Resistance. While the evidence for a relationship between PPARα and 
insulin resistance is not as convincing as that for inflammation, research suggests that the 
two could be related. As mentioned earlier, PPARα influences the expression of TNF-α, a 
cytokine involved in insulin resistance. Additionally, recent research has suggested that 
PPARα may lead to insulin sensitivity by increasing insulin production in beta cells, possibly 
due to its involvement in the regulation of free fatty acids [150]. These facts point to a link 
between PPARα and insulin resistance and sensitivity although the exact mechanism 
remains uncertain. Given the association between breast cancer incidence and Type II 
Diabetes Mellitus, described in Chapter 2, these facts point to PPARA’s possible 
involvement in breast cancer development through an insulin resistance pathway. 
4.2 EPIDEMIOLOGY OF PPARA 
4.2.1 Introduction 
Given its role in energy homeostasis, it seems feasible that genetic variation in 
PPARA could have implications on disease development. In particular, the epidemiologic 
literature has focused on one functional polymorphism, representing a cytosine to guanine 
base change. This base change occurs in the DNA binding domain region of the PPARA 
protein and results in a leucine to valine substitution at codon 162 of exon 5 (L162V). This 
missense polymorphism has been shown to have functional impact on the receptor. Using 
co-transfection assays, the V162 allele showed elevated ligand-dependent transcription 
activity compared to the L162 while no differences in activity were seen in the absence of 
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PPARA ligands.[151] Figure 4.5 details the sequence alignments across 11 mammalian 
species to assess the evolutionary conservation of PPARA across species using the 
genome browser from the University of California, Santa Cruz. It is interesting to note that 
exon 5, which contains the L162V SNP, (highlighted with a red box) is not well-conserved 
across most species. As indicated by the bar labeled “Mammalian Conservation”, the fifth 
exon of PPARA varies from species to species, suggesting some evolutionary pressure. 
Other studied single nucleotide polymorphisms (SNP) include an adenine to cytosine base 
change in intron 1 of PPARA, a guanine to cytosine base change in the intron 7 region and 
a guanine to adenine base change in the second intronic region. These intronic SNPs have 
been evaluated in several studies [152-159] although most PPARA research has centered 
on the L162V polymorphism.  
 
FIGURE 4.5. Conservation of L162V across 11 mammalian species from the University of 
California, Santa Cruz genome browser 
 
 
 
The frequencies of these SNPs vary tremendously by study population. For example, 
in a cohort study of 292 hypertriglyceridemic patients in Quebec, Canada, 27% of the 
population was determined to be carriers of the V162 allele [160]. In contrast, 2.8% of 395 
Finnish men who participated in the LOCAT trial were estimated to carry the V162 allele 
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[158]. Genetic databases, such as the Program for Genetic Applications (PGA) and 
HapMap, have estimated the frequency of the V162 allele to be 2.2% and 4.2% respectively 
in Caucasian populations, pointing to the variability surrounding these allele frequencies. 
The intronic SNPs are much more prevalent with frequencies ranging from 31.2% [154] to 
13.4% [158] for the C Intron 7 allele.  
A total of 29 epidemiologic articles have investigated genetic variants of PPARA in 
association with multiple health outcomes, including lipoprotein levels, obesity, fibrate 
treatment response, Type 2 diabetes and atherosclerosis (see Appendix A) [151-179]. Of 
these 24 articles, seven publications used clinical trial populations [153, 154, 158, 159, 166, 
177, 179], seven used data from cohort studies [152, 158, 160-162, 165, 167, 176], 
including the Framingham Offspring study and the Quebec Family study, five represent 
case-control studies [155, 157, 163, 170, 174], primarily convenience samples from hospital 
clinics (cases) and the general population (controls), and five were cross-sectional studies 
using convenience samples [164, 168, 169, 175, 178]. One study [158] published data using 
two different study populations, LOCAT, a clinical trial population, and the Second Northwick 
Park Heart Study, a cohort study. While most studies have not found an association, there 
are many possible explanations for this. Small sample sizes, particularly in the case-control 
studies and cross-sectional studies, and a failure to account for genetic variation across the 
entire gene could play an important role in limiting the power of these studies for finding an 
association. Similarly, many of these studies used convenience sampling, which will 
dramatically influence the quality and accuracy of their findings. The following summary of 
the literature has been categorized by outcome to help clarify the state of the literature for 
PPARA and a summary of findings is presented in Table 4.1. 
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4.2.2 Lipoprotein levels 
Fifteen studies have examined the association between L162V (rs1800206) and 
lipoprotein levels [152, 157, 160-164, 166, 167, 174-179]. The evidence of an association is 
most convincing for apolipoprotein (apo) B. Carriers of the V162 allele showed elevated 
levels of apoB compared to non-carriers in healthy controls [157, 164, 174] and women 
[162], although lower levels were noted in Familial Combined Hyperlipidemia patients [157]. 
Similarly, in a study of 3,012 men in the Second Northwick Park Heart Study, however, apoB 
levels were slightly lower in V162 carriers compared to L162 homozygotes (0.84±0.28 and 
0.88±0.28 respectively) [158].  
For LDL and triglycerides (TG), the relationships with PPARA are much less 
consistent. Recent studies have not observed an association between LDL and L162V [158, 
175-179] while older studies have noted higher LDL levels in V162 carriers in the 
Framingham Offspring Study [161], women [162], and healthy controls [163, 174]. More 
recent studies were typically larger in size and better designed (e.g. did not use 
convenience samples). Higher LDL levels appear more common in L162 homozygotes in 
diseased cohorts, including Type II Diabetes Mellitus [163] and obese [166] patients. 
Similarly, V162 carriers appear to have higher TG levels than L162 homozygotes in a wide 
range of study populations, including clinical trial cohorts [159, 177, 179], young adults 
[175], men [164]. It is important to note, however, that no differences in LDL levels were 
noted for several studies, including a large cross-sectional study of healthy adults [174, 
178], a Type II DM cohort [174, 176], and the Second Northwick Park Heart and LOCAT 
studies [158].  
In summary, there is evidence of an association between PPARA genetic variants 
and ApoB and limited evidence of an association with LDL and triglyceride levels. HDL does 
not appear to be associated with PPARA. In general, the V162 allele appears to influence 
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lipoprotein levels in diseased and non-diseased populations although the direction of V162 
activity varies by disease status.  
4.2.3 Obesity 
In general, PPARA does appear to be associated with obesity, measured as mean 
BMI in all studies. The direction of the effects is inconsistent and differences in effect by 
genotype were minimal. Of the 10 studies examining this association [157, 163-165, 168, 
174-176, 178, 179], BMI was slightly higher in V162 homozygotes and heterozygotes 
compared to L162 homozygotes in four studies [157, 175, 178, 179]. No differences in mean 
BMI were evident for three studies [163, 164, 174, 176], and V162 carriers had slightly lower 
BMI values than non-carriers in two studies of Type II DM patients [163, 168] and in a cohort 
of 393 women [165]. Among studies that examined obesity in more detail, Nieters et al. 
found increased odds of obesity, defined as BMI > 35.0 compared to BMI between 18.5 and 
25.0, in V162 allele carriers versus L162 homozygotes (OR=1.35, p=0.45; no CIs reported) 
[170]. Consistent with that finding, Bosse et al. noted an obesity (BMI > 30 vs. BMI ≤ 30) OR 
of 1.77 (p=0.04, no CIs reported) for V162 carriers compared to non-carriers, adjusting for 
age, gender and alcohol consumption [165]. While multiple studies have investigated 
PPARA in connection to obesity, the literature is primarily limited to studies using very 
rudimentary statistics to compare BMI means in carriers versus non-carriers. The two 
studies that have used multivariable methods are of dubious quality and failed to report 
valuable information (e.g. confidence intervals) that would have aided the interpretation of 
their results. 
4.2.4 Coronary Heart Disease (CHD) 
Among Type II Diabetes Mellitus patients, no difference in V162 allele frequency was 
observed between patients with or without CHD (6.6% vs. 6.4% respectively) [173]. In 
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contrast, another study examining the L162V polymorphism and CHD found the variant had 
no influence on risk of CHD in the non-diseased control group (OR=1.03, 95% CI: 0.12-8.7) 
but may play a role in CHD development in diabetics (OR=0.44, 95% CI: 0.18-1.11) [163]. 
Using survival analysis, Flavell et al. [158] reported a hazard ratio of 0.75 (95% CI: 0.45-
1.26) for the risk of ischemic heart disease in V162 carriers vs. L162 homozygotes, 
suggesting that the V162 allele may reduce risk of IHD.  
Studies focusing on the common L162V polymorphism and atherosclerosis have 
been more consistent with one study suggesting lower odds of atherosclerosis among 
individuals with Type II diabetes (OR=0.49, 95% CI: 0.21-1.15) and in controls (OR=0.68, 
95% CI: 0.20-2.33) [163]. Another implicated the polymorphism in atherosclerotic 
progression, measured as change in average diameter of coronary segments and change in 
minimum luminal diameter [158]. This research provides limited evidence that PPARA 
influences risk of atherosclerosis (although more research is needed), but the results are 
less convincing for CHD. 
4.2.5 Type II Diabetes Mellitus 
Only four studies have examined PPARA in connection to Type II DM [152, 176, 178, 
179]. Comparing the percentage of individuals with diabetes in V162 carriers versus L162 
homozygotes yielded inconsistent results with one study finding no differences (13.0%, 
n=144 in L162 homozygotes vs. 12.6%, n=12 in V162 carriers) [178] and one indicating 
slightly higher prevalence of Type II DM in V162 carriers (25.0% in L162 homozygotes vs. 
37.0% in V162 carriers) [179]. Interestingly, Tai et al. found increased hazards of stroke, 
non-fatal myocardial infarction and CHD death (combined) in V162 carriers among 
individuals with no history of insulin resistance or diabetes mellitus (HR=1.63; 95% CI: 0.82, 
3.24) but an inverse association for the same outcome among those with diabetes mellitus 
or insulin resistance (HR=0.40; 95% CI: 0.17, 0.92). Thus, Type II DM status may modify 
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associations with PPARA and cardiovascular disease outcomes. Another study found V162 
carriers to have an earlier age of diagnosis with Type II DM compared to non-carriers 
although effect estimates were imprecise (beta coefficient=2.6, 95% CI: 0.2, 5.1) [176]. 
Related to Type II DM, fasting glucose levels have also been investigated in 
connection to L162V. While Robitaille et al. found no difference in glucose levels in V162 
carriers versus L162 homozygotes (5.39±0.75 mmol/L, 5.36±0.72 mmol/L respectively) 
[164], V162 carriers had lower levels in three other studies [167, 174, 175]. Less studied, 
fasting insulin levels were slightly lower in V162 carriers compared to non-carriers in two 
studies [167, 174], suggesting more research is needed to confirm these findings.  
4.2.6 Fibrate Response 
Interest in PPARA’s potential role in predicting reduced efficacy of fibrate treatment 
was spurred initially by Flavell et al. who showed larger changes in total cholesterol and 
non-HDL cholesterol in V162 allele carriers (6.31 mmol/L, 1.09 mmol/L respectively) 
compared to L162 homozygotes (5.77 mmol/L, 0.99 mmol/L respectively) and a slight 
difference in change in ApoB levels (1.48 mmol/L in V162 carriers, 1.34 in L162 
homozygotes) in 2000 [151]. Since then, an additional seven studies [153, 154, 158-160, 
166, 172] have been published on this subject with mixed results. Most recently, Chen et al. 
found no association between PPARA haplotypes and response to fluvastatin [153]. Two 
studies that examined changes in lipoprotein levels following gemfibrozil therapy found no 
difference in triglyceride levels or LDL [158, 166] although a slight difference in HDL levels 
was suggested [166]. Similarly, Brisson et al. [160] and Foucher et al. [154] both 
investigated response to fenofibrate treatment by L162V genotype and found no association 
with residual hypertriglyceridemia or triglyceride level reduction respectively. These results 
are more consistent with Puckey et al. [172] who reported that the L162V polymorphism was 
not associated with changes in HDL, total cholesterol or triacylglycerol in a group of patients 
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treated with fibrates. Interestingly, among individuals who received bezafibrate, the V162 
allele was associated with a decrease in triglyceride levels but not fibrinogen [159]. These 
results suggest that PPARA variants do not influence response to fibrate treatment even 
though fibrates are known PPARA agonists. 
4.2.7 Other diseases 
Lastly, the one case-control study that has examined the association between the 
L162V polymorphism and PPARA found increased odds of Alzheimer’s disease with the 
V162 allele (OR=2.24, 95% CI: 1.12-4.50) after adjusting for gender and BMI, suggesting 
that PPARA could be involved in Alzheimer’s disease development [155]. Additionally, 
Ishiguro et al. investigated the Val227Ala polymorphism in connection to schizophrenia and 
alcohol dependence but found no differences in minor allele frequency between the two 
diseases and the control group [171].  
 
TABLE 4.1. Summary of evidence based on epidemiology studies of PPARA and 
various disease outcomes 
 Association 
Outcome Probable Possible Not Likely Insufficient data 
Lipoproteins     
 apoA1    X 
 apoB X    
 apoC    X 
 HDL   X  
 LDL  X   
 Triglyceride  X   
Obesity  X   
Coronary Heart Disease  X   
Type II Diabetes Mellitus X    
 Insulin  X   
 Glucose  X   
Atherosclerosis  X   
Metabolic Syndrome  X   
Fibrate Response   X  
Alzheimers    X 
Alcohol Dependence    X 
Schizophrenia    X 
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4.3 CONCLUSION 
Although no research to date has investigated the possible link between PPARA and 
breast cancer, the biology of PPARα and the epidemiology of PPARA suggest it could play a 
role in breast cancer development. PPARα has been shown to increase fatty acid oxidation 
and decrease cytokine levels and may be involved in insulin production, supporting its 
involvement in three critical pathways for breast cancer development. Additionally, genetic 
variants of PPARA have been linked to several lipoprotein levels, cardiovascular disease, 
obesity and type II diabetes, diseases that share many mechanistic similarities with breast 
cancer.  
 
 CHAPTER 5 RESEARCH DESIGN AND METHODS 
5.1 STUDY OVERVIEW 
 This study proposed to assess whether interindividual variability in PPARA 
influences breast cancer risk and survival. PPARA has been hypothesized to affect breast 
cancer development and survival through two different but related mechanisms: (1) insulin 
sensitivity, and (2) anti-inflammatory effects. This study explored whether genetic 
polymorphisms in PPARA were associated with breast cancer incidence and survival, and 
whether they interacted with body mass index (BMI), weight gain and NSAID use to 
influence disease development and prognosis. 
 To determine whether PPARA was associated with breast cancer or interacted with 
body mass index or weight gain to influence risk or breast cancer survival, data from the 
Long Island Breast Cancer Study Project (LIBCSP), a large population-based case-control 
study, was used. First, genotyping for PPARA was conducted using available, banked DNA 
from 1,052 breast cancer cases and 1,098 controls. The prevalence of the PPARA alleles 
was determined in this population-based sample of breast cancer cases and women without 
breast cancer. Second, maximum likelihood estimates of the haplotype frequencies were 
determined. Third, statistical analyses were conducted to determine whether PPARA 
haplotypes were associated with breast cancer risk and survival. Fourth, genotype data was 
then coupled with baseline questionnaire data (that was already collected as part of the 
parent case-control study) to explore gene-environment interactions with BMI, post-
menopausal weight gain (prior to diagnosis) and NSAID use. Corresponding survival 
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analyses were also conducted. 
 The following details the LIBCSP and follow-up study population and design, 
followed by a description of the laboratory assays, statistical analyses, and study power, 
ending with a discussion on the strengths and limitations of this ancillary study. 
5.2 LONG ISLAND BREAST CANCER STUDY PROJECT 
5.2.1 Subject Eligibility 
 Women newly diagnosed with a primary in situ or invasive breast cancer between 
August 1, 1996, and July 31, 1997, and who were 20 years of age or older at diagnosis and 
were residents of Nassau or Suffolk counties in Long Island, New York, were eligible as 
subjects for the case-control study. Controls were selected from among female residents of 
the same two Long Island counties and were frequency matched to the expected age-
distribution of case subjects by 5-year age group. At the request of the National Cancer 
Institute, there were no upper age restrictions on study subjects. All subjects were required 
to speak English and census data indicates that over 97% of all residents on Long Island 
are English-speaking. Figure 5.1 displays a map of Long Island, including Suffolk and 
Nassau counties as well as the surrounding area. 
 
 
 
 
FIGURE 5.1. Map of Long Island 
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5.2.2 Case Identification 
 For this case-control study, cases were identified using a "super" rapid reporting 
system established by the study investigators for the LIBCSP, resulting in a 96 day period 
between diagnosis and interview for cases on average [37]. A concerted effort was made to 
contact eligible cases prior to commencement of chemotherapy. For the case-control study, 
the 33 hospitals that were known to treat or diagnose Long Island women with breast cancer 
were considered part of the rapid reporting network. This network was established in the first 
year of the ongoing study, in an area where a population-based case-control study of cancer 
had not been conducted in over a decade. During case identification, most hospitals were 
contacted on a daily basis, but a few hospitals that were expected to identify only a few 
cases per year were contacted weekly. Study personnel contacted the hospital pathologist, 
or his/her designee in the pathology department, to identify any patients who were newly 
diagnosed with in situ or invasive breast cancer. The patient's name, birthday, date of 
diagnosis, preliminary diagnosis, and the diagnosing physician's name were obtained. 
 The potentially eligible case's physician was then contacted to confirm eligibility for 
the study and to seek permission to contact the patient for possible participation in the case-
control study. To speed this process, the study team established contact in the first year of 
the study, prior to field activities, with nearly 450 primary care physicians, surgeons, and 
oncologists who could possibly treat or diagnose Long Island breast cancer patients. The 
reason for the study and the need for timely approval was explained to the Long Island 
physicians, and they were asked to fax back a signed form indicating their willingness to 
participate in the study. Prior to commencing the field activities, all physicians who were 
contacted returned such a form or indicted their willingness to participate through a 
telephone conversation. 
 Using these case identification methods, 2,271 women were identified, of whom 
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2,030 were ultimately eligible. Of these, physician approval to contact cases was obtained 
for 1,837 (90.3%) cases. No physician systematically refused permission. Physician refusal 
was most common for older patients with co-morbid conditions. Prognosis is poor for these 
women, and physicians perceived them as too fragile for study participation.   
5.2.3 Control Identification 
 Potentially eligible control women were identified by Waksberg’s method of random 
digit dialing (RDD) [180] for those under 65 years of age, and by Health Care Finance 
Administration (HCFA) rosters for those 65 years of age and older. HCFA selection occurred 
twice during the 12-month identification period that coincided with the 12 months of case 
ascertainment. RDD selection began July 1, 1996, and continued in eight waves over the 
following twelve months. The response rate to the RDD telephone screener was 77.9% 
although this response rate is only applicable to the control respondents who are under age 
65 years (approximately 57.9% of all control respondents).   
5.2.4 Subject Recruitment 
 Eligible case women, with physician permission, and potentially eligible control 
women, were sent a "recruitment" package by overnight mail that included a letter inviting 
them to participate in the study along with a descriptive brochure. Within days of receiving 
the package, a skilled, trained recruiter telephoned the subject to answer questions, 
describe the study, invite the subject to participate, and, if possible, schedule an 
appointment for the interview. The main questionnaire was completed by 1,508 (82.1%) of 
eligible case women and 1,556 (62.7%) of eligible control women. The reasons for non-
response to the interview among cases and controls included subject refusal (n = 218 
(12.4%) and 573 (21.6%), respectively); too ill, cognitively impaired, or deceased (76 (4.1%) 
and 193 (7.8%)), and non-locatable, moved out of area, or other (26 (1.4%) and 195 
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(7.9%)). Study subjects ranged in age from 24 to 98 years and response to the interview 
varied by respondents' age with 88.9% of cases and 76.1% of controls under age 65 years 
participating versus 71.6% of cases and 43.3% and controls over the age of 65 participating.    
5.2.5 Case-Control Study Interview 
 The interview included four components, which were administered in the following 
order: (1) signed informed consent; (2) the interview-administered main questionnaire; (3) 
collection of biologic samples (blood and urine) and administration of a specimen checklist; 
and (4) a self-administered food frequency questionnaire (FFQ). These components 
required between 2 and 3 hours to complete. Completion of all components of the interview 
was done in the respondent's home. All interviewers, who were certified phlebotomists in the 
state of New York, received a one-week, standardized, intensive training course in all 
aspects of interview administration. Among case and control respondents who completed 
the interviewer-administered questionnaire, 98.2% and 97.6%, respectively, self-completed 
the food frequency questionnaire, 73.0% and 73.3% donated a blood sample, and 93.0% 
and 83.3% donated a urine sample. Not surprisingly, women who donated blood tended to 
be younger than non-donating women, but no differences in donation proportions by case 
control status were evident [37]. Figure 5.2 diagrams the participation rates, including 
subject recruitment and case identification, for the LIBCSP.  
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FIGURE 5.2. Participation in the Long Island Breast Cancer Study Project and Follow-up 
Study 
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5.2.5.1 Informed consent. Prior to commencing the interview, the interviewer explained 
the contents of the informed consent form to each eligible subject, and if the participant 
wished to continue, she was asked to sign the informed consent forms.  
 
TABLE 5.1. Distribution of select demographic characteristics by 
cases and control status, Long Island Breast Cancer Study Project, 
1996-1997 [37] 
 Cases Controls 
 (n=1,508) (n=1,556) 
Characteristic No. % No. % 
Age at interview*     
 < 35 years 39 2.6 45 2.9 
 35-44 years 181 12.0 245 15.7 
 45-54 years 397 26.3 423 27.2 
 55-64 years 372 24.7 403 25.9 
 65-74 years 365 24.2 310 19.9 
 75-84 years 134 8.9 112 7.2 
 85+ years 20 1.3 18 1.2 
 Missing 0  0  
Race     
 White 1411 93.8 1429 91.8 
 Black 69 4.6 85 5.5 
 Other 25 1.7 42 2.7 
 Missing 3  7  
Education     
 < High School 183 12.2 150 9.7 
 High school graduate 538 35.8 526 33.9 
 Some college 360 24.0 415 26.7 
 College graduate 191 12.7 236 15.2 
 Post college 230 15.3 225 14.5 
 Missing 6  4  
Income     
 <$15,000 115 8.9 84 6.4 
 $15,000-19,999 70 5.4 83 6.3 
 $20,000-24,999 78 6.0 98 7.5 
 $25,000-34,999 176 13.6 139 10.6 
 $35,000-49,999 192 14.8 203 15.5 
 $50,000-69,999 214 16.5 245 18.7 
 $70,000-89,999 169 21.7 177 13.5 
 $90,000+ 281 13.1 281 21.5 
 Missing 213  246  
Parity status     
 Nulliparous 198 13.1 171 11.0 
 Parous 1310 86.9 1385 89.0 
  1 child 166 12.7 148 10.7 
  2 children 508 38.8 518 37.4 
  3 children 358 27.3 379 27.4 
  4+ children 278 21.2 340 24.5 
 Missing 0  0  
Menopausal Status     
 Pre-menopausal 468 31.0 500 32.1 
 Post-menopausal 1010 67.0 993 63.8 
 Missing 30 2.0 63 4.1 
*frequency matched variable 
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5.2.5.2 Main questionnaire. The comprehensive questionnaire took an average of 101 
minutes to complete. The instrument included assessment of known and suspected risk 
factors for breast cancer in the following order: reproductive history; occupational history; 
residential history and history of exposure to environmental pollutants; history of living or 
working on a farm; medical history; family history of cancer; body size and physical activity; 
alcohol consumption; smoking history; menstruation and menopause history; contraceptive 
history; hormone medication use; pregnancy related problems; background information; and 
conclusion. Table 5.1 highlights select demographic and population characteristics.  
 To assess weight and weight gain, subjects were asked about their weight in 
pounds by decade from age 20 to age 70 and the year prior to the reference date. Height at 
age 20 and one year prior to the reference data was also obtained to calculate BMI.  
 
5.2.5.3 Biologic Samples. After completing an additional informed consent form, 
participants were asked to donate blood and urine samples. From each participant, about 40 
mL of blood were donated (5 EDTA-treated lavender-top tubes) as well as urine. At the time 
of sample donation, a specimen checklist was also administered by the interviewer. The 
checklist queried subjects about drugs, foods, and behavior they may have engaged in the 
few days prior to the sample donation, which may influence interpretation of the blood and 
urine assay findings (e.g., hormone use, intake of cruciferous vegetables, etc.). After 
collection of the biologic samples at the participants’ homes, the samples were shipped 
overnight to Dr. Regina Santella's laboratory at Columbia University for processing. The 
blood samples were shipped at ambient temperatures, and the urine was shipped on ice. 
Aliquots of plasma from the 40 mL of blood and aliquots of urine were stored at –80o C.  
 Of the 1,102 cases who donated blood, 19 samples (1.7%) were later found to be 
insufficient for a total of 1,083 cases with available blood for genotyping. Similarly, of the 
1,141 control blood donors, 22 samples (1.9%) were found to be insufficient for a total of 
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1,119 controls. We also anticipated that genotypes for an additional 2% of the samples 
would be unable to be determined based on previous genotype analyses using the LIBCSP 
data [181, 182]. Therefore, we anticipated a final sample size of 1,061 cases and 1,097 
controls for the case-control study. The 1,061 cases would also be included in the survival 
analysis. In fact, a slightly higher number of cases and controls were successfully genotyped 
(n=1,073 and 1,112, respectively). 
 
5.2.5.4 Food frequency questionnaire (FFQ). Participants were asked to self-complete a 
food frequency questionnaire after collection of the biologic samples, or if no samples were 
donated, after completion of the main questionnaire. The instrument used to assess diet in 
the past year was a modification of the NCI-Block questionnaire that was adapted by Dr. 
Nancy Potischman [183] to assess intake of fat and micronutrients more completely. The 
instrument was further modified by the study team to allow adequate assessment of 
isoflavonoids [184]. The interviewer remained at the respondent's home until the FFQ was 
completed.  
5.2.6 Case Subjects’ Medical Record Retrieval and Abstracting 
As part of the case-control study, signed medical record release forms were obtained 
from study participants. For cases, the relevant medical records and pathology records for 
the initial primary breast cancer were obtained from the appropriate hospital. Data 
abstracted from the case medical records included stage, nodal involvement, hormone 
receptor status (estrogen and progesterone), and treatment.  
5.2.7 Interview Data Management and Statistical Analyses 
 All subjects were tracked by computer. All data collected by questionnaire has been 
entered onto computer, and thoroughly checked for consistency and accuracy. Selected 
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relevant results of LIBCSP case-control distributions are presented in Table 5.1.  
5.2.8 Summary 
 Detailed statistical analyses of the LIBCSP data have linked post-menopausal breast 
cancer to obesity and weight gain, particularly in women over the age of 50 [9]. Because of 
its large sample size, including 1,083 cases and 1,119 controls that have donated a blood 
sample and completed an interview, the LIBCSP represented an efficient and appropriate 
population to address this study question. 
5.3 LONG ISLAND BREAST CANCER STUDY PROJECT FOLLOW-UP 
5.3.1 Subject Eligibility for Follow-up 
Women with newly diagnosed in situ or invasive breast cancer between August 1, 
1996 and July 31, 1997, who were 20 years of age or older at diagnosis and a resident of 
Nassau or Suffolk counties in Long Island, NY, and who completed the main questionnaire 
for LIBCSP were eligible to participate in the proposed follow-up study. 
5.3.2 Subject Recruitment for Follow-up 
Ninety-four women who refused re-contact at the end of the case-control study were 
not recruited for a total of 1,414 potential cases in the follow-up study. Eligible case 
participants were re-contacted initially by mail and then by telephone to invite them to 
participate in the Follow-up Study. In the event that a case could not be located using this 
approach, the next of kin were contacted based on information provided at the end of the 
case-control study interview. Lastly, patient physicians were contacted if a subject could not 
be traced. Interviews were conducted using computer assisted telephone interviewing 
(CATI).  
 70
Of the 1508 women with in situ or invasive breast cancer identified through LIBCSP, 
1,098 were successfully contacted and re-interviewed in 2002-2004 (72.8%). For 1,033 
women, complete treatment and demographic follow-up interview data were available while 
65 cases only completed a short questionnaire detailing their treatment therapies. For the 
410 women who were not successfully interviewed, failure to obtain follow-up information 
was due to refusal (n=237), passive refusal (n=22), inability to locate (n=55) and death with 
no identifiable proxy (n=96).  
For the 1,098 patients who were successfully interviewed, 177 (16.1%) had in situ 
breast cancer while 921 (83.9%) were invasive cases based on information provided in the 
initial case-control study. Of these 1,098 patients who were successfully interviewed, 823 
have given blood as part of the original case-control study. This subset of the LIBCSP cases 
were used to assess for modification by treatment since complete treatment information and 
blood were available for these women (discussed in section 5.5 and highlighted in Figure 
5.2).  
5.3.3 Follow-up Study Interview 
The interview included two components: (1) signed informed consent and (2) the 
follow-up questionnaire administered by telephone. Completion of all components of the 
interview was done using CATI by trained interviewers. For the survival analyses, 
information from the follow-up questionnaire was only used to obtain complete treatment 
information. This treatment information was used to evaluate confounding by treatment in 
the subset of 823 cases that have both donated blood and completed a follow-up interview.  
Three different interviews – subject, proxy and critical – were used to maximize the 
number of participants. Of the 1,098 women with follow-up data, 784 completed the subject 
interview (71.4%). Case subjects were asked to recall all treatments and procedures 
undergone since the diagnosis date of the initial breast cancers, such as needle biopsies, 
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tumor biopsies, modified mastectomy, radiation, chemotherapy and hormone treatments. 
For each type of procedure, subjects were asked to recall the number of times the 
procedure was performed, the frequency, data and location of institution. Breast cancer 
recurrences and any second primary cancer diagnoses were also queried.  
The proxy interview was a full length questionnaire, identical to the subject interview 
except for minor wording changes to reflect the questions referred to the index subject 
rather than the proxy. A brief section asking about the proxy’s relationship to the subject was 
also added. Of the 1,098 cases, 84 proxy interviews were conducted (7.7%), which is 
consistent with the expected mortality rate of breast cancer according the Surveillance, 
Epidemiology, and End Results Program (SEER) [88].  
The critical interview was designed to be less detailed than the subject interview for 
subjects or proxies that did not have the time or were too ill to complete the full length 
questionnaire. Of the 1,098 subjects with follow-up information, 165 respondents completed 
the critical interview (15.0%). Participants were still questioned on various treatments and 
outcomes as well as changes in their behaviors following their diagnosis, but only the most 
necessary (or “critical”) questions were included in the questionnaire.  
Lastly, 65 respondents (56 subject women, 9 proxies) were unwilling to complete a 
questionnaire, but did volunteer the most basic treatment information (5.9%). For this, a 
series of three questions were developed, oncologist, treatment institution and hormonal 
medicine use (yes/no), designed to take less than five minutes to complete but maximize the 
treatment information provided. Therefore, for these subjects, no demographic follow-up 
information will be available but treatment data could be included in all analyses.  
5.3.4 Case Subjects’ Medical Records and Abstracting 
 As part of the study, subjects were asked to authorize the release of their 
medical records for abstracting by study personnel. Of the 1,414 potential cases, 600 
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women signed the release form (42.3%). One record of the 600 authorized could not be 
located. These medical records were used to evaluate the reliability of subject reported 
outcomes and treatments.  
 Of the 600 women who signed a medical record release form as part of the 
follow-up study, 587 completed a follow-up interview. There was a high degree of 
concordance between treatments reported by subject and those reported in the medical 
record, with less than 1% discordance for radiation (Kappa (κ) = 0.99) and chemotherapy 
(κ=0.98), and 3.2% discordance for hormone therapy (κ=0.93). Women who completed a 
proxy interview showed less concordance with 10.0% discordance for radiation therapy 
(κ=0.78) and 11.1% discordance for chemotherapy (κ =0.78) although the hormone therapy 
data was 100% concordant (κ=1.00). Concordance between subject reported recurrences 
and/or second primary cancer diagnoses and the medical record were much lower than 
those found for treatment. For example, concordance of the medical record abstraction and 
interview for whether a woman had a recurrence was 8.6% discordant but concordance for 
whether a woman had a second primary breast cancer was 33.3% and an additional 25% 
referred to the second primary in the medical records as a recurrence in the interview. Thus, 
the data on recurrence was not used as part of this investigation. 
5.3.5 Outcome Ascertainment 
 Of the 1508 women, 198 were identified as deceased by the National Death 
Index (NDI) while the rest of the cohort (n=1,310) were presumed alive through December 
31, 2002, the last date that the NDI considered the death data to be accurate. Thus, for the 
survival analyses, 198 women were deceased and 1,310 alive through the end of the follow-
up period. For the 1,083 cases who donated blood and are, therefore, eligible for the 
survival analysis, 949 were alive (87.6%) and 134 dead (12.4%) at the end of the follow-up 
period. Among the subset of 823 cases that completed a follow-up interview and donated 
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blood, 759 were alive (92.2%) and 64 deceased (7.8%) at the end of the follow-up study 
(see Figure 5.2).  
 Death certificate data, provided by the NDI, were then used to determine 
underlying cause of death, primary cause of death, and breast cancer related deaths as well 
as date of death. A primary cause represents the most immediate cause of death while an 
underlying cause is the condition that gave rise to the primary cause. Table 5.2 highlights 
the NDI codes used to create the underlying cause of death and primary cause of death 
variables while Table 5.3 and Table 5.4 depicts the frequencies of these causes of death for 
the 1,083 women eligible to be included in the survival analysis and the 823 women who 
donated blood and completed a follow-up interview respectively.  
 
TABLE 5.2. NDI death codes used to create the broad categorical variables for underlying, 
primary and breast cancer-related death 
Variable and 
Coding 
Broad Categories of 
Death 
NDI codes 
NDI_under   
0 Alive  
1 Breast cancer 1749, C509 
2 Lung cancer 1629, C349 
3 Other cancer 1919, 1991, 2050, B49, C169, C259, C482, C541, 
C56, C80, C920, C97 
4 CVD I269, I38, I499, I509, I619, I639, I711, I509, 3949, 
4029, 410, 4140, 4275, 436, I10, I119, I219, I250, 
I251 
5 Other B146, A219, 1619, 5609, 856, G309, G419, J189, 
J449, J841, K440, K572, K801, N19, N390, R99 
NDI_primary   
0 Alive  
1 Breast cancer 1749, C509 
2 Lung cancer 1629, C349 
3 Other cancer C56, C80, C920, 1509, 1619, 1919, 1970, 1988, 
2050, B49, C169, C189, C259, C482, C541 
4 CVD 3949, 4029, 410, 4140, 4275, I10, I119, I219, I251, 
I254, I469 
5 Other 0389, A402, A415, A419, D649, E039, E149, G20, 
G309, G934, J449 
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TABLE 5.3. Frequencies of causes of death for the 1,083 women who donated blood and 
completed the baseline case-control interview 
NDI 
Variable 
Alive Breast 
Cancer 
Lung 
Cancer 
Other 
Cancer 
CVD Other 
NDI_under 949 74 (55.2%) 6 (4.5%) 13 (9.7%) 27 (20.1%) 14 (10.4%) 
NDI_primary 949 85 (63.4%) 6 (4.5%) 12 (9.0%) 17 (12.7%) 14 (10.4%) 
 
TABLE 5.4. Frequencies of causes of death for the 823 women who donated blood and completed 
a follow-up interview 
NDI 
Variable 
Alive Breast 
Cancer 
Lung 
Cancer 
Other 
Cancer 
CVD Other 
NDI_under 759 41 (64.1%) 2 (3.1%) 6 (9.4%) 10 (15.6%) 5 (7.8%) 
NDI_primary 759 44 (68.8%) 2 (3.1%) 6 (9.4%) 8 (12.5%) 4 (6.3%) 
 
5.3.6 Follow-up Interview Data Management and Statistical Analyses 
 All subjects were tracked by computer. Because data were collected using CATI, 
programming edits and consistency checks were built into the questionnaire as well as 
automatic question skips for complex questions. Therefore, data management efforts for the 
follow-up study were less than those required for the case-control study. Table 5.5 highlights 
preliminary distributions of reported treatment therapies by vital status for the 823 individuals 
who donated blood and completed a follow-up interview. 
TABLE 5.5. Distribution of treatment by vital status for the 823 women who 
donated blood and completed a follow-up interview 
  Alive Dead Total 
  (n=759) (n=64) (n=823) 
Treatment No. % No. % No. % 
Radiation therapy       
 Yes 431 60.4 38 63.3 469 60.6 
 No 283 39.6 22 36.7 305 39.4 
 Missing 45  4  49  
Hormone therapy       
 Yes 433 61.0 34 61.8 467 61.0 
 No 277 39.0 21 38.2 298 39.0 
 Missing 49  9  58  
Chemotherapy       
 Yes 262 36.8 37 61.7 299 38.7 
 No 450 63.2 23 38.3 473 61.3 
 Missing 47  4  51  
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5.3.7 Summary 
 Of the 1,508 potential cases, 1,098 subjects or their proxies completed a follow-
up interview (72.8%). Comparisons between the medical record and self-report indicate that 
treatments can be accurately recalled; therefore, we used this self-reported treatment 
information with little concern of misclassification. Among the 1,083 cases that donated 
blood, vital status, assessed by the NDI through December 31, 2002, indicated that 134 
women were dead and 949 were alive for the survival component of the study. Complete 
treatment data are available on 823 of these cases. Of these 823 cases, the NDI has 
indicated that 759 were alive and 64 dead at the end of the follow-up period.  
5.4 GENOTYPING 
5.4.1 SNP selection and Haplotypes 
Interindividual variation in the human genome is the product of DNA changes that 
arose on ancestral segments of chromosomes [185]. Genetic recombination disrupted tightly 
linked regions (i.e., regions in linkage disequilibrium) of the genome that contain 
polymorphic loci [186]. The contribution of individual SNPs to disease susceptibility may be 
difficult to determine because of SNPs in linkage disequilibrium (LD) and cis-acting effects 
between SNPs on the same allele [186, 187]. Therefore, a broader multilocus haplotype 
approach, where multiple markers on the same chromosome are used, has been advocated 
to provide greater power [188, 189] and is considered more powerful to detect susceptibility 
alleles than single locus SNPs, especially when the causal SNPs are unknown or when the 
interaction of multiple mutations on the same chromosome has a particularly large effect on 
the disease phenotype. Methods for selecting haplotype tagging SNPs within regions of high 
linkage disequilibrium are in their infancy. Initial approaches focused on selecting SNPs 
based on known or hypothesized functions, usually within coding exons and regulatory 
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regions. However, potentially important areas of genetic variation exist throughout the gene 
and should be considered comprehensively.  
To study associations between inter-individual variation of PPAR and breast cancer, 
we examined polymorphisms of PPARA using a multi-locus haplotype approach (Table 5.6). 
This gene was chosen because it plays a critical role in the inflammation process and insulin 
sensitivity. For PPARA, sequencing data was available for 23 European-Americans and 24 
African-American Coriell samples on the University of Washington-Fred Hutchinson Cancer 
Research Center Variation Discovery Resource website, http://pga.gs.washington.edu/ (or 
Program for Genomic Applications (PGA)). Given the racial homogeneity of the LIBCSP 
study population (92.8% Caucasian and 5.0% African American), we identified haplotype 
tagging SNPs using the 23 European-Americans only. The haplotype tagging SNPs were 
produced using the PGA LDSelect Program [190] run only for European Americans. This 
program has been shown to select a maximally informative set of common SNPs that 
distinguishes 80% of common haplotypes and is based on the r2 LD statistic [191].  
The r2 statistic represents a measure of correlation between two SNPs. For example, 
an r2=1 implies “perfect LD”, which happens only when the minor allele frequency (MAF) for 
two SNPs are the same. In contrast, when D΄, another measure of LD, is equal to one, 
“complete LD” is implied and the MAF for the two SNPs do not have to be the same. This 
characteristic of the D΄ can create arbitrary block boundaries, making it a less desirable 
measure of LD than r2 [190]. Because of power concerns for rare alleles, we focused on 
alleles with a MAF of 10% or more, which capture common variation while minimizing 
expense.  
The LDSelect algorithm begins with all SNPs above the MAF threshold (in this case 
10%) and calculates the pairwise r2 between one SNP and all other SNPs. SNPs in which 
the r2 is greater than 0.80 are then put together into a bin or the minimum set of informative 
SNPs. This iterative process continues until no unbinned SNPs remain. SNPs that do not 
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meet the correlation threshold value with any other SNPs are placed into their own unique, 
singleton bin. The algorithm then determines the tag SNP for each bin, or the SNP that can 
act as a marker for all other SNPs in that bin. Collectively, this group of tag SNPs represents 
the maximally informative set of SNPs for the gene. When multiple possible tag SNPs were 
identified for a bin, non-synonymous SNPs were given priority. SNPs in repetitive regions 
were avoided due to the difficulty in genotyping these polymorphisms successfully. Based 
on this program, fourteen PPARA SNPs were identified for sequencing and are presented in 
Table 6.6.  
 In addition to LDSelect, other software packages, including Tagger [192], were 
considered for tag SNP identification. Tagger uses aggressive tagging to identify tag SNPs 
and was developed by Paul de Bakker (http://www.broad.mit.edu/mpg/tagger/). For this 
software, the CEU population (30 Utah trios with ancestry from northern and western 
Europe) from the International HapMap Project was used as the reference panel [193]. Like 
ldSelect, Tagger identified fourteen tag SNPs although there was very little overlap in the 
SNPs selected with the two programs. These differences could be due to random variation 
since the programs are expected to perform similarly when the same reference population is 
used. LDSelect was ultimately chosen as the preferable method for tag SNP selection 
because it uses resequencing data from the PGA website rather than the density SNPs from 
HapMap. In general, resequencing data permits a more comprehensive assessment of the 
genetic variation compared to density SNPs and is, therefore, considered the gold standard.  
5.4.2 Genotyping 
 For this study, genotyping was conducted by Dr. Santella’s laboratory at Columbia 
University, New York, NY. All LIBCSP DNA samples are available on 96 well master plates. 
Plates have a 10% duplication rate with laboratory personnel blinded to case control status 
and duplication. Genotyping was carried out using iPLEX technology (Sequenom, 
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SanDiego, CA) on a MassARRAY Compact Analyzer. This multiplex method uses the mass 
of the incorporated nucleotide for identification of genotype. For SNPs that could not be 
mulitplexed (rs4253623 and rs4253699), Taqman (Applied Biosystems, Foster City, CA) 
assays were used. For Taqman, samples were run on an ABI 7500 Real Time PCR system. 
For Taqman, the rs#s for the SNPs of interest were given to Applied Biosystems for the 
preparation of the specific kits.  
TABLE 5.6. Haplotype tagging SNPs of PPARA to be evaluated identified using ldSelect 
and the PGA European-American population as the reference panel 
Minor Allele 
Frequency     rs# SNP Location
Base Pair 
Change 
(major>rare) African-Americans 
European-
Americans 
Reference 
rs4253730 Intron 3 A>G 0.479 0.182 LDSelect 
rs4253760 Intron 6 T>G 0.667 0.196 LDSelect 
rs4253705 Intron 2 T>C 0.375 0.190 LDSelect 
rs135543 Intron 2 C>T 0.391 0.283 LDSelect 
rs135542 Intron 2 T>C 0.348 0.205 LDSelect 
rs4253649 Not Validated C>G 0.783 0.370 LDSelect 
rs4253758 Intron 6 T>C 0.810 0.217 LDSelect 
rs4253699 Intron 2 T>C 0.312 0.182 LDSelect 
rs4253655 Intron 2 G>A 0.022 0.143 LDSelect 
rs4253681 Intron 2 T>C 0.167 0.136 LDSelect 
rs4253755 Intron 5 G>A 0.042 0.130 LDSelect 
rs4253706 Intron 2 G>A 0.043 0.119 LDSelect 
rs4253623 Intron 2 A>G 0.021 0.109 LDSelect 
rs1800206 Exon 5 
Leu>Val 
C>G 0.021 0.032 
0.022 
SNP500 
PGA 
 
5.5 COVARIATES 
5.5.1 Overview 
This section highlights the selection and coding of covariates, including weight gain 
and BMI as effect modifiers and all potential confounders, in the case-control and survival 
analyses. Outcomes of interest for both analyses are also presented. Confounders were 
chosen a priori using directed acyclic graphs (DAG) and modeling strategies for these 
variables are discussed in section 5.7.2 as part of the data analysis. The previous section 
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(Section 5.4) detailed the SNP selection process and genotyping for PPARA, the main 
exposure of interest, and the construction of the PPARA haplotypes from these SNPs are 
discussed in section 5.7.2.  
For the case-control study, exposure information was derived from the baseline  
questionnaire (http://epi.grants.cancer.gov/LIBCSP/projects/Questionnaire.html) [37], which 
was interviewer-administered to participants in the their home within a few months of 
identification. Respondents were asked about their pregnancy, occupational, residential and 
environmental histories; family history of breast cancer; medical history including use of 
aspirin and other NSAID; self-reported weight and height by decade of life; recreational 
physical activities since menarche; active and passive cigarette smoking; alcohol use; 
menstrual history; use of exogenous hormones; and demographic characteristics.  
For the survival analysis, information from the baseline case-control study interview 
was used for most confounders and effect modifiers, including obesity and weight gain. Vital 
status through the end of 2002 was determined through the National Death Index (NDI). 
Although treatment was not believed to be a confounder, it was investigated as a possible 
effect modifier. Treatment information was available from four different sources: (1) the 
baseline interview (n=1,508 cases), (2) the baseline medical record (n=1,508 cases), (3) the 
follow-up questionnaire (n=1,098 cases), and (4) the abstracted medical records at follow-up 
(n=599 cases). Treatment information obtained at the initial case-control study interview and 
case-control medical abstraction were incomplete since the average time of interview 
occurred within three months of diagnosis [37]. Therefore, it was important to do sub-group 
analyses using the more complete treatment information. Treatment data from the follow-up 
interview was used to determine the influence of treatment because of the larger number of 
cases who completed the follow-up interview compared to those with follow-up abstracted 
medical records.  
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Appendix D Table D.1. presents the table of variables that were included in both the 
case-control and survival analyses, highlighting their definition and coding. Discussions in 
the text are below. 
5.5.2 Outcome of interest 
For the case-control study, the outcome of interest was defined by case/control 
status while two outcomes were investigated in the survival analysis. As mentioned earlier, 
vital status was ascertained using the NDI and is accurate through December 31, 2002. 
Based on the information available through the NDI and the death certificates, both vital 
status based on all cause mortality and breast cancer-related death, where ICD codes 174.9 
and C-50.9 are cited as either primary or secondary causes of death, were evaluated as 
potential outcomes.  
5.5.3 Obesity as an effect modifier 
Obesity could act as an effect modifier for PPARA based on the gene’s involvement 
in the insulin and inflammatory pathways. Increased levels of estrogen, insulin and cytokines 
from obesity could act synergistically with the “at risk” PPARA genotypes to increase breast 
cancer risk by a greater quantity than their separate effects would suggest.  
In the case-control study questionnaire, participants were asked about their weight 
by decade of life, beginning at age 20 as well as height at age 20 and at the date of 
interview. Using these variables, BMI by decade and weight change throughout life were 
ascertained. In particular, based on the results of Eng et al. using LIBCSP data, weight 
change from age 20 to one year prior to the interview date and post-menopausal weight 
gain were associated with an increased risk of post-menopausal breast cancer even after 
adjusting for BMI at age 20 and 50 respectively [9].  
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For the survival analysis, both pre- and post-menopausal cases were included. As 
highlighted in Section 3.6 and Appendix B, obesity has an impact on survival in both pre- 
and post-menopausal women. This is consistent with LIBCSP, which found decreased 
survival with obesity in both pre- and post-menopausal women [112]. Therefore, in this 
study, we combined pre- and post-menopausal cases for the survival analyses. Stratification 
by menopausal status was done to confirm that menopausal status did not modify the 
association. Weight change from age 20 to reference and BMI at reference were considered 
as potential effect modifiers. Table 6.7 presents the distribution of BMI at the reference date 
by case-control status. 
 
TABLE 5.7. Distribution of Body Mass Index among Cases 
and Controls, Long Island Breast Cancer Study Project, 1996-
1997 [37] 
 Cases Controls 
 (n=1,508) (n=1,556) 
 No. % No. % 
BMI at reference     
 < 25.00 700 46.4 778 50.0 
 25.00-29.99 476 31.6 455 29.2 
 ≥ 30.00 332 22.0 323 20.8 
 Missing 0  0  
      
 
5.5.4 Confounders for the case-control study 
For the association between post-menopausal breast cancer and PPARA, minimal 
confounding was expected. As the DAG indicates (Figure 5.3), race and religion appear to 
be the only factors that might confound this relationship. Given the small percentage of 
African-Americans in the LIBCSP population (5%), it was unlikely that race would play an 
important role in these analyses, however. To address the potential impact of Judaism, 
which is essentially acting as a surrogate for increased prevalence of the BRCA1 mutation 
(see section 3.4.6), adjustment for religion was important, particularly since 17.2% of case 
and 15.4% of controls are Jewish in this population [37]. Initial analyses in the LIBCSP 
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population did not find an association between the Jewish ethnicity and breast cancer 
incidence, suggesting that it would not be a confounder (OR=1.16; 95% CI: 0.95-1.42) [37]. 
Consistent with the DAG and previous analyses, neither race nor Jewish ethnicity was found 
to be a confounder in the case-control study analyses (see Appendix D, Tables D.8-D.21 
model building procedures for each polymorphism individually). 
It was also possible that family history of breast cancer could be important to include 
in the analysis if it was associated with PPARA. Since no studies have investigated breast 
cancer and PPARA, the relationship between family history and PPARA was unknown. This 
study found that family history of breast cancer was not a confounder and, therefore, it was 
not included in analyses (see Appendix D, Tables D.8-D.21). 
 
FIGURE 5.3. Directed acyclic graph for the association between post-menopausal breast 
cancer risk and PPARA. 
PPARA Post-menopausal breast cancer
Obesity
Jewish Ethnicity
PA
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5.5.5 Confounders for the survival analysis 
For the association between breast cancer prognosis and PPARA, minimal 
confounding was expected. As the DAG indicates (Figure 5.4), race and Jewish ethnicity 
appear to be the only factors that might confound this relationship. Once again, because of 
the small number of African-Americans in the LIBCSP, race was unlikely to play a role in this 
population. This research did not find any evidence of confounding by Jewish ethnicity or 
race (see Appendix D, Tables D.23-D.28 for model building procedures for each SNP 
individually). Treatment could modify the association if PPARA affects tumor characteristics. 
Consequently, treatment and several tumor characteristics were evaluated as potential 
effect modifiers. Stage, ER and PR status were available for all genotyped cases while 
treatment data was considered using the 823 cases that completed the follow-up interview 
and donated blood. Stratification by select tumor characteristics and treatment information 
did not yield any evidence of effect modification (see Table D.29, Appendix D). It is 
important to note that stratification by stage and treatment data led to small cell sizes and 
very imprecise effect measures; therefore, it was difficult to assess modification by these 
variables. A comparison of survival in all cases versus invasive breast cancer cases only 
yielded similar results (see Table D.39, Appendix D). 
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FIGURE 5.4. Directed acyclic graph for the association between breast cancer prognosis 
and PPARA. 
 
5.5.6 Summary 
No variables confounded the association between breast cancer risk (see Appendix 
D, Tables D.8-D.21) and survival (Appendix D, D.23-D.28) and PPARA. For the case-control 
study, race, Jewish ethnicity and family history of breast cancer were included as potential 
confounders while race and Jewish ethnicity were considered confounders in the survival 
analysis. As discussed in Section 3.4, breast cancer treatment will vary by tumor 
characteristics with certain tumors more likely to respond to treatment than others. PPARA 
could influence tumor type. Therefore, treatment and select tumor characteristics were 
examined as potential effect modifiers (see Appendix D, Table D.29). Sample size 
limitations prevented these stratified analyses from being conclusive, however. These 
covariates along with their coding and variable descriptions are included in Appendix D. 
5.6 DATA MANAGEMENT FOR CASE-CONTROL AND FOLLOW-UP STUDIES 
Baseline data from LIBCSP have been published [37]. Standard data cleaning 
procedures, which include range checks and distributions on all variables to detect outliers 
or implausible values, have already been performed on LIBCSP. To confirm data cleaning, 
univariate analyses for all potential confounders, PPAR genotype frequencies and measures 
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of obesity were conducted to ensure that the range of values were consistent with the 
questionnaire and were biologically feasible. 
Standardized procedure manuals and extensive interviewer training including 
probing procedures and questionnaire administration exist for all studies. Epidemiologic field 
staff were trained to implement protocols for subject identification and recruitment, 
questionnaire administration, biological specimen collection and handling in a standardized 
fashion to avoid introduction of bias. All data were double keyed and discrepancies 
reconciled. 
For this study, genotype data were entered into a database and then merged with 
questionnaire and survival data by participant ID number. Individuals with missing genotype 
and covariate data were excluded from analyses. To address the impact of missing data on 
this study, a comparison of select tumor and demographic characteristics, including age, 
stage and tumor size, was performed. This analysis revealed no differences between 
genotyped cases (n=1,073) and all cases (n=1,508) by vital status (see Table D.30 in 
Appendix D). Additionally, in analyses in which risk factors for breast cancer among all 
women in the study were compared to those among women who donated blood, similar 
results were found.  
Haplotypes were determined for individuals with genotyping data available for more 
than 50% of the included SNPs. Data were imported into a SAS data file for analysis. 
Quality control procedures for laboratory assays included a blinded 10% repeat sample 
embedded throughout the case-control plates. In addition, positive and negative controls 
were included in each assay. Laboratory personnel did not know case-control information. 
The genotyping core was unaware of the exposure status of the study participants. 
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5.7 DATA ANALYSIS 
5.7.1 Overview 
 Important contributions of this project are to determine the prevalence of PPARA 
polymorphisms and to evaluate PPARA SNPs and haplotypes to breast cancer risk and 
survival among a population-based sample of women in the United States. There were four 
major goals of the study analyses: (AIM 1) to estimate the association between breast 
cancer risk and PPARA polymorphisms in post-menopausal women, (AIM 2) to explore 
possible interactions between PPAR polymorphisms and obesity (measured as BMI> 30 and 
weight gain), and their influence on post-menopausal breast cancer risk, (AIM 3) to estimate 
the association between PPAR variants (SNPs and haplotypes) and breast cancer survival 
in pre- and post-menopausal women, and (AIM 4) to explore interactions between PPAR 
polymorphisms and obesity and their influence on breast cancer survival in pre- and post-
menopausal women.  
5.7.2 Haplotype Analysis 
 Using the selected PPARA SNPs (discussed in Section 5.4) as building blocks, 
haplotypes were constructed and analyzed in both case-control and survival analyses. 
These tag SNP haplotypes captured most common genetic variation over the entire gene to 
evaluate cis-cis interactions (discussed in Chapter 8). The statistical methods involved in 
this analysis of genetic data can be divided into five main components. These components 
contain elements of Hardy-Weinberg Equilibrium (HWE) calculation, haplotype construction, 
and statistical modeling. 
• Calculation of Genotype and Allele Frequencies 
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As mentioned earlier, no studies have investigated the association between PPARA and 
breast cancer. To the best of our knowledge, this is the first large population-based study to 
determine the allele and genotype frequencies for each SNP and is an important 
contribution to the PPARA literature. These frequencies were calculated using SAS version 
9.1. 
• Testing Hardy-Weinberg Equilibrium 
HWE was tested among the controls to ensure assumptions of parametric statistical 
tests were met [194] using SAS / Genetics. After the allele frequencies were calculated, the 
HWE equation, p2+2pq+q2 = 1, where p equals the frequency of the major allele and q 
equals the frequency of the minor allele, were applied to determine the expected genotypic 
proportions if the conditions of HWE were met. The observed and expected genotypic 
proportions were then compared using a chi-square test with one degree of freedom. In this 
case, the null hypothesis was that the population is in HWE; therefore, a χ2 ≥ 3.85 led to the 
rejection of the null hypothesis that the population is in HWE. Due to stringent quality control 
measures in the genotyping procedures, violations in HWE were not anticipated. In these 
analyses, no SNPs were out of HWE in the control group. SNPs not in HWE would have 
been removed from the analysis to avoid possible errors in the estimation process. 
Additionally, HWE was also calculated among the cases to confirm that no major deviations 
were present in this group as well. While two polymorphisms were out of HWE in the cases, 
these deviations could be explained by evolutionary change and most likely do not reflect 
genotype error [195]. 
• Characterization of Linkage Disequilibrium between SNPs 
Although the tag SNPs and functional SNP (rs1800206) were initially identified to 
determine a set of the minimally sufficient number of SNPs necessary to characterize the 
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gene in the Caucasian reference population, it was still important to describe the linkage 
disequilibrium between the tag SNPs in our study population. Therefore, we computed 
pairwise LD [196] for each loci combination [197] using Haploview. This allowed for 
comparison with the SeattleSNP population that was used as the reference panel of tag 
SNP selection. Because the tag SNPs were selected to have an r2 < 0.80, we expected our 
polymorphisms to show little LD. We found LD patterns consistent with this expectation with 
little to no LD evident in pair-wise comparisons. 
• Haplotype Reconstruction 
Unknown phase is a problem in a sample of unrelated individuals, where no genetic 
information is available from related family members. Several statistical methods such as 
Clark’s algorithm [198] and expectation-maximization (EM) algorithm [199] have emerged as 
effective and cost-efficient for inferring and reconstructing phase of alleles. The EM 
algorithm is inefficient with a large number of polymorphisms due to its iterative process in 
haplotype construction, but is more than adequate for handling this study’s six SNPs. 
Additionally, EM is able to use partially missing genotypes, where some but not all the 
alleles are missing, by iteratively updating the frequency of a partially missing genotype and 
then updating all existing haplotypes that have alleles identical to the non-missing alleles of 
the partially missing haplotypes. The EM algorithm is the default for SAS / Genetics and was 
used in the determination of this study’s haplotypes. Based on this program, 12 haplotypes 
in all women and 14 in post-menopausal women only were identified with a frequency 
greater than 5% (see Table D.22 in Appendix D).  
• Modeling associations of interest with haplotypes 
Currently, there is no consensus on the best method to analyze haplotype data from 
association studies. As part of SAS / Genetics, SAS has added the HAPLOTYPE procedure, 
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which first constructs the haplotypes and then allows for easy transformation to a data set 
that can be used to perform regression analyses. This unique feature of SAS / Genetics 
eliminates the need for other programs, including Haplo Stat, which requires transforming a 
SAS data set into one compatible with R programming [200, 201]. Because of its facility, it 
has been used widely since its conception [202, 203]. For haplotype-disease associations, 
each haplotype will be examined for associations with breast cancer relative to all other 
haplotypes. 
5.7.2.1 AIM 1. The polymorphisms were examined individually and as haplotypes using 
unconditional logistic regression [204] to estimate the odds ratios (OR) of post-menopausal 
breast cancer risk and corresponding 95% confidence intervals. Confounding was 
investigated using a backwards elimination strategy, where the full model was initially 
specified and covariates were removed from the model using a 10% change in estimate 
approach (i.e. covariates that resulted in a 10% or greater change in a genotype effect 
estimate were considered confounders). Covariates included in the full model were family 
history of breast cancer, Jewish ethnicity, and race based on the DAG in Section 6.5.4. This 
study did not find evidence of confounding by these three variables in each SNP evaluated 
individually (see Appendix D, Tables D.8-D.21). 
 
5.7.2.2 AIM 2. To evaluate the role of genetic polymorphisms as modifiers of the 
associations between obesity and breast cancer risk, several statistical methods were 
employed, including likelihood ratio tests [204], the Breslow-Day test [205], and the 
interaction contrast ratio [206]. Interaction terms were included in the full model and the 
likelihood ratio test comparing a model with and without the interaction terms was used 
to assess model fit [204]. The Breslow-Day (BD) test was also be used to evaluate OR 
effect measure modification for modeling the individual SNPs [205]. Additive interaction 
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was assessed using the interaction contrast ratio (ICR). ICRs were calculated using the 
following formula, ICR = OR11 - OR10 - OR01 + 1. ICRs greater than zero imply 
superadditivity while ICRs of zero suggest no interaction on the additive scale. ICRs less 
than zero indicate less than additive effects (but interaction is still present on the additive 
scale) [206]. The results of the BD tests by individual SNP as well as the effect 
modification tables for covariates with BD p-value of less than 0.15 are found in 
Appendix D, Tables D.2-D.7. 
 
5.7.2.3 AIMS 3 & 4. Kaplan-Meier survival curves were first created for PPARA 
haplotypes to portray the cumulative incidence for survival. Cox regression was then 
implemented to estimate the crude and adjusted hazard ratio (HR) and its 95% confidence 
intervals between haplotypes of PPARA and breast cancer mortality in both pre- and post-
menopausal case women. Cox regression was also used to determine the crude and 
adjusted HR between breast cancer survival and BMI and weight gain by PPARA 
polymorphisms individually. As described above, effect modification of the obesity-breast 
cancer survival association was assessed using two methods, likelihood ratio tests and the 
interaction contrast ratios.  
 A log-rank test was conducted to evaluate the statistical significance of the difference 
between the cumulative incidence curves in common homozygotes versus heterozygotes 
and rare homozygotes combined for each SNP. There was no evidence of a difference 
under the dominant inheritance model for all investigated polymorphisms. The Kaplan-Meier 
curves and log rank tests can be found in Appendix D, Figures D.1-D.6 for all cause 
mortality. 
 To assess the assumption of proportional hazards, both statistical testing and 
graphical techniques were used. First, log-minus-log survival curves were examined under 
the dominant inheritance model. If the resulting curves appear non-parallel (such as 
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crossing hazards), the assumption of proportional hazards was deemed violated. Future 
models were then specified using time-varying interaction terms to relax this assumption. 
Formal tests of the proportional hazards assumption were also conducted by adding a time-
dependent covariate into the model. If the interaction covariate was not statistically 
significant, the proportional hazards assumption was met for that covariate and the 
interaction term could be eliminated from the model. If the interaction was significant, 
however, the assumption was violated and the time-dependent variable was retained in the 
model. All results were then stratified by the time cut-off point specified by the interaction 
term. Only rs4253760 violated the proportional hazards assumption and a continuous time 
interaction term was necessary to include in the analysis to relax this assumption (see 
Appendix D, Tables D.23-D.28 and D.31-D.36 for model building procedures for each SNP 
individually, including the continuous time interaction term). 
5.7.3 Hierarchical Modeling 
 Hierarchical regression involves multistage modeling, where the first stage can be 
expressed as ordinary logistic regression using maximum likelihood methods, and additional 
stages or “prior models” increase estimation accuracy by providing additional background 
information, such as physical distance between the SNPs [207, 208]. These additional 
stages use probabilistic methods, like shrinkage estimators, to weigh the data and the prior 
to give the posterior estimate greater stability [207, 208]. For example, empirical Bayes, a 
common shrinkage estimator, is based on the assumption of exchangeability, which states 
that the target parameters are indistinguishable in the absence of data [209]. Under the 
assumption of exchangeability, a summary parameter can be determined by weighing target 
parameters using the observed data, such as study sample size [209]. Initial semi-Bayesian 
analyses included SNP location (intron vs. coding) to better group the polymorphisms. Since 
functionality is not well understood and is not necessarily correlated with SNP location, 
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however, this additional classification was removed from the analyses. Thus, all semi-
Bayesian analyses assumed the SNPs were exchangeable and no Z-matrix was specified.  
Despite the additional computation complexity, hierarchical modeling offers two 
advantages over the more conventional logistic regression: (1) shrinkage estimation 
methods reduces Type II error rate, so that multiple comparisons are no longer a concern 
[208, 210], and (2) it reduces instability in the effect estimates due to multiple correlated 
exposures, such as multiple SNPs in the same model [208]. With multiple SNPs included in 
the model, over-parameterization with highly correlated exposure data was a concern. 
Hierarchical modeling neatly addressed this problem and provided a solution for multiple 
comparisons.  
5.7.4 Sample Size and Power 
5.6.4.1 Aims 1 and 2. Because these aims were restricted to post-menopausal women, 
genotyping data were estimated to be available for 870 cases and approximately the same 
number of controls. For the case-control analyses, the estimates for study power varied with 
the prevalence of the at-risk genotype or inferred haplotype (range 10% to 30%) and the 
expected ORs for the association between the genotypes and risk of breast cancer. The 
study had more than adequate power to detect modest associations. For the main gene or 
inferred haplotype effects, power was estimated at greater than 80% for ORs ≥ 2.0 for the 
postmenopausal women alone. Table 5.8 shows the estimates for the expected study power 
for varying prevalences of the at-risk genotype and varying odds ratios. These power 
calculations were done using Episheet.xls and the methods are described in detail in 
Rothman et al [211].  
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TABLE 5.8. Study power for main gene effects 
assuming an alpha of 0.05 and a 1:1 control/case ratio 
Genotype  Odds  Study 
Prevalence Ratio   Power 
30%  3.0 >99%  
  2.5 >99%  
  2.0 >99%  
  1.5 98%  
      
20%  3.0 >99%  
  2.5 >99%  
  2.0 >99%  
  1.5 95%  
      
10%  3.0 >99%  
  2.5 >99%  
  2.0 >99%  
    1.5  78%   
 
 For effect modification, the power was 80% or greater to detect substantial 
interactions of an OR ≥ 3.2. This interaction OR represents the OR for the doubly 
exposed (genotype and exposure positive) compared to the doubly non-exposed 
(genotype and exposure negative), and is calculated by the software program. These 
power calculations were conducted using POWER version 3.0 software available 
through the National Cancer Institute. This software is described in detail in Garcia-
Closas et al [212]. The following assumptions were made to determine study power: 
o The prevalence of obesity at the time of diagnosis for cases and reference date 
for controls, defined as BMI greater than 30.0, is 25% in this sample. [37]  
o The prevalence of breast cancer in normal weight individuals is 1%.  
o An OR of 1.80 was assumed for the effect of obesity on breast cancer risk based 
on preliminary analyses of the Long Island Breast Cancer Study Project.  
Table 5.9 shows the estimates for study power for varying prevalences of the at-risk 
genotype and varying odds ratios for the genotype-breast cancer relationship.  
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5.6.4.2 Aims 3 and 4. For the survival analysis, power estimates were calculated 
assuming different underlying hazard ratios using the NQuery Advisor (v. 5.0) program. The 
survival rate in the wildtype group was assumed to be 0.124, which is consistent with the 
number of deaths observed in the LIBCSP follow-up study. The time period was set at five 
years and an alpha of 0.05 was used. The smallest detectable hazard ratios ranged from 
1.5-2.0 assuming 80% study power and varied by genotype prevalence (10%-30%) and 
expected hazard ratio for the association between the genotype and risk of death in this 
cohort (see Table 6.10).  
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TABLE 5.9. Study power for gene-environment interactions assuming 
an alpha of 0.05 and a 1:1 case/control ratio 
Prevalence OR OR OR* Study 
Genotype Exposure Genotype Exposure Interaction Power 
      
30% 25% 3.0 1.8 10.8 88% 
  2.5  9 88% 
  2.0  7.2 89% 
  1.5  5.4 89% 
      
20% 25% 3.0 1.8 10.8 83% 
  2.5  9 83% 
  2.0  7.2 83% 
  1.5  5.4 83% 
      
10% 25% 3.0 1.8 10.8 63% 
  2.5  9 62% 
  2.0  7.2 61% 
    1.5   5.4 60% 
*OR (Odds Ratio) for genotype positive/exposure positive as compared  
with genotype negative/exposure negative subjects.  
 
 
TABLE 5.10. Study power for main gene effects 
assuming an alpha of 0.05 for survival analysis 
(n=1,061) 
Genotype  Risk  Study 
Prevalence Ratio   Power 
30%  3.0 >99%  
  2.5 >99%  
  2.0 >99%  
  1.5 96.7%  
      
20%  3.0 >99%  
  2.5 >99%  
  2.0 >99%  
  1.5 91.3%  
      
10%  3.0 >99%  
  2.5 >99%  
  2.0 99%  
    1.5  72.0%   
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 For effect modification in the survival analysis portion of the study, this study was 
slightly under powered (see Table 5.11). Given the lack of literature on this subject, 
however, this question was important to address despite the sample size limitations. 
These power calculations were conducted using POWER version 3.0 software available 
through the National Cancer Institute. This software is described in detail in Garcia-
Closas et al [212]. The following assumptions were made to determine study power: 
o The prevalence of obesity at the time of diagnosis for cases, defined as BMI 
greater than 30.0, is 25% in this sample [37].  
o The prevalence of death in normal weight individuals is 12.4%, the prevalence 
observed across the entire cohort.  
 An HR of 1.80 was assumed for the effect of obesity on breast cancer survival based 
on hazard ratios and risk ratios presented in the literature (see Appendix B). 
TABLE 5.11. Study power for survival analysis gene-environment 
interactions assuming an alpha of 0.05 (n=1,061) 
Prevalence HR HR HR* Study 
Genotype Exposure Genotype Exposure Interaction Power 
      
30% 25% 3.0 1.8 10.8 51.1% 
  2.5  9 51.0% 
  2.0  7.2 50.4% 
  1.5  5.4 48.7% 
      
20% 25% 3.0 1.8 10.8 42.8% 
  2.5  9 42.8% 
  2.0  7.2 42.2% 
  1.5  5.4 40.5% 
      
10% 25% 3.0 1.8 10.8 27.8% 
  2.5  9 27.9% 
  2.0  7.2 27.6% 
    1.5   5.4 26.4% 
*OR (Odds Ratio) for genotype positive/exposure positive as compared  
with genotype negative/exposure negative subjects.  
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 Study power to examine associations were mostly adequate (see Tables 5.8, 5.9, 
5.10 and 5.11), particularly for the main effects of the various genotypes. For the gene-
environment interaction component, however, power was reduced for the less prevalent 
genotypes. For example, if the gene frequency is 10% in the case-control study, we will only 
have 60% power to detect an association. In the survival analysis, study power is even 
lower. Because of the novelty of this research question, however, the question of potential 
gene-environment interaction in the survival analysis was explored despite these limitations. 
5.8 STUDY ADVANTAGES AND LIMITATIONS 
A major advantage of the proposed project is that the cases and controls were drawn 
from a population-based sample, which will increase the generalizability of the prevalence 
and estimates of risk associated with the PPARA polymorphisms. Another advantage of this 
investigation is the large sample size, which allowed examination of gene-environment 
interactions with sufficient statistical power. This project was also cost-effective since the 
biological specimens and exposure information had already been collected and were 
available to this study. 
 Despite the large overall sample size, a limitation of the study is the relatively 
restricted power to evaluate modification by certain breast cancer subtypes, such as 
estrogen receptor positive tumors. Small sample size is an inherent limitation of most 
investigations in molecular epidemiology due to the rarity of some minor alleles and the 
expense of both obtaining the blood samples needed and performing the assays. Despite 
these limitations, the project offered adequate power to detect interactions of substantial 
public health significance. 
 The detailed and extensive exposure information from LIBCSP enabled us to explore 
two different measures of obesity and their potential interaction with PPARA to influence 
breast cancer risk and survival. To the best of our knowledge, LIBCSP is the only case-
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control study of breast cancer to inquire about weight by decade beginning at the age of 20, 
which afforded the unique opportunity to explore weight gain by decade and BMI by decade 
to determine critical time periods of risk for obesity mediated breast cancer. This proposal 
expands upon this research by investigating variants of PPARA that might play a role in 
breast cancer development and survival.    
 Reported weight at age 20 and other past exposures are subject to recall bias and 
nondifferential misclassification since disease diagnosis has occurred before exposure 
ascertainment. Several studies have found a high degree of recall in weight over time [213-
216] although it has been suggested that underweight women may overestimate their past 
weight while overweight women may underestimate their past weight [216]. It is important to 
note, however, that the main gene effect relationship will not be subject to recall bias since 
participants are unlikely to know their PPARA status. Additionally, if abdominal adiposity is 
the most biologically relevant obesity measure, then BMI and weight gain may not fully 
capture the relationship between breast cancer, obesity and PPARA.  
 It has become increasingly apparent that examination of a single polymorphism 
within a given gene has not been particularly fruitful in identifying subgroups of women who 
may be genetically susceptible to breast cancer. A haplotype approach comprehensively 
assesses common variation over the entire gene to pinpoint haplotypes of potential 
functional importance without assuming any knowledge of functionality. Additionally, 
identifying tag SNPs reduces genotyping costs while maximizing the ability to capture 
genetic variation in a gene region [213]. Contributions by rare variants are missing using this 
approach, however.  
 Differences in participation rates between the cases and controls (82.1% vs. 62.7% 
respectively) suggest that participation bias may be present. In particular, response rates 
differences are most apparent in women over the age of 65, where cases showed a 71.2% 
response rate and controls demonstrated a 43.3% response. In comparison, the evidence of 
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participation bias is much less in women under the age of 65 with 88.9% and 76.1% 
response rate in cases and controls respectively. It is difficult to quantify the impact of 
participation bias on the frequency of the PPAR genotypes.  
Approximately 73.0% of cases donated blood, suggesting missing data may bias our 
results. Additionally, complete treatment data is only available for a small subset of patients 
who participated in the follow-up interview. To address the impact of missing data on this 
study, a comparison of select tumor and demographic characteristics, including age, stage 
and tumor size, was performed. This analysis revealed no differences between genotyped 
cases (n=1,073) and all cases (n=1,508) by vital status (see Table D.30 in Appendix D). 
 Participants of this study are a population-based sample of women who reside on 
Long Island, of which 92.7% are whites, 5.0% are African-American and 2.3% are Asian-
Americans or other. Because the ethnic distribution of our Long Island subjects differs from 
that of the American population as a whole, results from this project may not be readily 
applied to the U.S. population in general. Although the underlying prevalence of specific 
alleles and exposures may vary with ethnicity, it seems unlikely that the biological relations 
with breast cancer among participants in this study will differ from women in general. 
 Although PPARA has been studied in cardiovascular disease, no studies have 
examined PPARA in connection to breast cancer despite its involvement in insulin sensitivity 
and the inflammatory process. This study is the first to evaluate this possibility in a large 
population-based sample.  
5.9 SUMMARY  
Over the past 30 years, considerable progress has been made in describing the 
epidemiology of breast cancer. Obesity appears to reduce risk of breast cancer in pre-
menopausal women, but has consistently been found to elevate risk in post-menopausal 
women. These differences suggest that post-menopausal women may be most vulnerable 
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to obesity-related breast cancer. Obesity is also one of the only non-clinical factors 
considered an indicator of prognosis for breast cancer survival in both pre- and post-
menopausal women. Weight gain, particularly in adulthood, leads to many endocrine 
changes, including increases in cytokines, insulin and progesterone. Peroxisome 
proliferators-activated receptor alpha (PPARA) has been suggested to promote insulin 
sensitivity by decreasing cytokine activity, and, thus may play an important role in breast 
cancer development in post-menopausal women.  
We conducted an ancillary study using interview data and blood samples from the 
Long Island Breast Cancer Study Project. LIBCSP was a large population-based case-
control study of breast cancer in Nassau and Suffolk counties in New York and was 
conducted from August 1996 to July 1997. Controls were frequency matched to cases on 
age and identified using random digit dialing for individuals under the age of 65 and Health 
Care Finance Administration rosters for controls aged 65 and older. 1,508 eligible cases and 
1,556 eligible controls consented to participate in the study and approximately 73% of 
participants donated blood samples. Participants were questioned on their weight by 
decade, beginning at age 20, and on the reference date and case medical records were 
abstracted for tumor clinical and histological characteristics. We examined the association 
between genetic variations in PPARA and risk of breast cancer in post-menopausal women; 
evaluated interaction between PPARA polymorphisms, obesity and risk of breast cancer in 
post-menopausal women; examined the association between genetic variations in PPARA 
and breast cancer survival in pre- and post-menopausal women; and assessed interaction 
between PPARA, obesity and survival from breast cancer in pre- and post-menopausal 
women. This research helped advance knowledge of breast cancer etiology and prognosis 
through obesity mediated mechanisms. 
 CHAPTER 6 CASE CONTROL STUDY MANUSCRIPT 
6.1 ABSTRACT 
 Peroxisome proliferator-activated receptor-alpha (PPARA) has been shown to 
increase fatty acid oxidation and decrease cytokine levels, and has been implicated in 
insulin production. Genetic variants of PPARA have been associated with cardiovascular 
disease, obesity and type II diabetes mellitus. Although no research to date has investigated 
the possible link between PPARA and breast cancer, the function of this gene suggests that 
it could play a role in breast cancer development. Six PPARA polymorphisms were 
evaluated in association with incident breast cancer in a population-based case-control 
study (n=1073 cases, n=1112 controls), using unconditional logistic and multilevel 
regression, and haplotype-based analyses. The odds of breast cancer were doubled among 
women with PPARA polymorphism rs4253760 (OR=1.97 for rare vs. common homozygote 
alleles; 95% CI: 1.14, 3.43). This association remained constant with the inclusion of all 
interrogated polymorphisms studied in hierarchical models. No additive interactions with 
body mass index or weight gain were present, but there was some evidence of interaction 
with aspirin use, defined as use at least once per week for six months or longer, for 
rs135542 and rs4253699. Fourteen haplotypes were imputed with frequencies greater than 
1% among post-menopausal women, but no statistically significant differences in haplotype 
frequencies between cases and controls were evident. Our results are the first to evaluate 
the relationship between PPARA and breast cancer incidence and suggest that replication in 
an independent cohort is warranted.
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6.2 INTRODUCTION 
 The peroxisome proliferator-activated receptor (PPAR) family is composed of three 
nuclear hormone receptor (NHR) genes: PPAR-gamma, PPAR-alpha (PPARA) and PPAR-
delta. In general, NHRs encode proteins that induce gene transcription by binding to the 
promoter region of a target gene. PPARs are activated when small lipophilic hormones 
(ligands) bind to a ligand-specific NHR [141]. PPARA ligands include palmitic acid, 
arachidonic acid and stearic acid in addition to compounds such as fenofibrate, bezafibrate 
and non-steroidal anti-inflammatory drugs (NSAIDs) [142, 143].  
 PPARA is primarily expressed in organs with high fatty acid oxidation rates [143, 
146], such as the liver, kidney, heart, brown adipose tissue, and, in small quantities, white 
adipose tissue [142]. PPARA has also been found in human breast cancer cell lines, where 
its activation has been associated with increased proliferation [217]. PPARA has been 
shown to regulate lipid metabolism by controlling the uptake and oxidation of fatty acids 
[143]. This regulation can lead to an excess of free fatty acids, which may contribute to 
insulin resistance [148]. Fibrates, which are PPARA agonists, have also been shown to 
reduce the expression of multiple cytokines, including interleukin-6, fibrinogen, and C 
reactive protein in humans [143].  
 Two PPARA isoforms have been characterized (PPARA1 and PPARA2). Both 
isoforms are expressed in human tissue [218, 219]. PPARA1 encodes the entire gene while 
PPARA2 is truncated at exon 6. This truncation results in the absence of the ligand-binding 
domain in the gene’s protein and, consequently, prevents activation by the ligand. 
Therefore, all study inferences pertain to PPARA1 because of its protein’s known activity. 
 Given its role in energy homeostasis, it seems feasible that genetic variation in 
PPARA could influence disease incidence. The epidemiologic literature has focused on a 
functional polymorphism that results in a leucine to valine substitution at codon 162 of exon 
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5 (L162V, rs1800206) and a subsequent cytosine to guanine base change in the DNA 
binding domain region of PPARA protein. This missense polymorphism has been shown to 
have a functional impact based on co-transfection assays; specifically, the V162 allele 
showed elevated ligand-dependent transcription activity compared to the L162 allele [151]. 
Although no research to date has investigated the possible link between PPARA and 
breast cancer, the biology and epidemiology of the gene suggest it could play a role in 
breast cancer incidence. Genetic variants of PPARA have been linked to lipoprotein levels 
[162, 220, 221], cardiovascular disease [176, 179, 222], obesity [165, 169] and type II 
diabetes [152, 167, 223]. These conditions operate on the same pathways as breast 
carcinogenesis, including inflammation and insulin resistance. Therefore, the goals of this 
study were to examine the association between PPARA genetic polymorphisms and breast 
cancer development using single polymorphism and haplotype-based approaches and semi-
Bayesian techniques. Interactions with body mass index (BMI), weight gain, aspirin use and 
menopausal status were also explored.  
6.3 MATERIALS AND METHODS 
 To evaluate the study aims, we utilized data and samples from the Long Island 
Breast Cancer Study Project (LIBCSP), a large population-based case-control study; details 
of the parent study population and data collection methods have been previously published 
[37]. The study protocol was approved by the institutional review boards of participating 
institutions.  
6.3.1 Study population 
English speaking women newly diagnosed with a primary in situ or invasive breast 
cancer between August 1, 1996, and July 31, 1997 were eligible to be study cases if they 
were 20 years of age or older at diagnosis and were residents of Nassau or Suffolk counties 
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on Long Island, New York. Cases were identified through daily contact with the 33 Long 
Island and New York City hospitals that served women with breast cancer in these two 
counties. Physician permission was obtained prior to case contact.  
Controls were randomly selected from among English-speaking female residents of 
the same two Long Island counties, and were frequency matched to the expected age-
distribution of case subjects by 5-year age group. Potentially eligible controls were identified 
by Waksberg’s method of random digit dialing [180] for women under 65 years of age, and 
by Health Care Finance Administration rosters for women 65 years of age and older.  
Participants in the LIBCSP included 1,508 (82.1%) of eligible case women and 1,556 
(62.7%) of eligible control women. Study subjects ranged in age from 24 to 98 years, and 
93.8% of cases and 91.8% of controls were Caucasian while 4.6% and 5.5% were African 
American, respectively. Approximately 68% of cases and 67% of controls were post-
menopausal (n=1,010 and 993 respectively).  
6.3.2 Exposure assessment 
6.3.2.1 Questionnaire. Case-control interviews were administered by trained interviewers 
in respondents’ homes. Interviews took an average of 101 minutes to complete, and 
included assessment of known and suspected risk factors for breast cancer. In previous 
analyses, an increase in weight and weight gain, particularly after age 50, was positively 
associated with postmenopausal breast cancer [9], and aspirin use was inversely associated 
with breast cancer among women of all ages [45]. Other factors found to be associated with 
breast cancer in the LIBCSP have also been previously described [37].   
 
6.3.2.2 Biologic specimens. Among respondents who completed the interview, 73.0% of 
cases and 73.3% of controls donated a blood sample. DNA was isolated using methods 
previously described [59]. Of the 1,102 cases and 1,141 controls who donated blood, 19 
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(1.7%) and 22 (1.9%), respectively, were later found to have insufficient DNA. Thus, there 
were a total of 1,083 case and 1,119 control samples available for genotyping. For analyses 
restricted to post-menopausal women, genotyping was available for 708 cases and 692 
controls. 
6.3.3 Genetic polymorphisms 
6.3.3.1 Selection of tagging SNPs.  Tag single nucleotide polymorphisms (SNP) were 
selected to represent comprehensive coverage of the PPARA gene by binning SNPs with a 
minor allele frequency greater than 0.10 and an estimated minimum pairwise correlation of 
0.80. For PPARA, sequence data were available for 23 European-Americans and 24 
African-American Coriell samples on the University of Washington-Fred Hutchinson Cancer 
Research Center Variation Discovery Resource website, http://pga.gs.washington.edu/ (or 
Program for Genomic Applications (PGA)). Haplotype tagging SNPs were identified using 
the PGA LDSelect Program [190] run for European Americans only (given the relative racial 
homogeneity of the LIBCSP population). This program has been shown to select a 
maximally informative set of common SNPs that distinguish 80% of common haplotypes, 
and is based on the r2 linkage disequilibrium (LD) statistic [191]. Because of its low 
prevalence but functional importance, L162V was forced into the program. Based on this 
program, fourteen PPARA SNPs were identified for genotyping (Table 6.1). 
 
6.3.3.2 Genotyping.  Genotyping was conducted at Columbia University, New York, NY. 
All LIBCSP DNA samples are available on 96 well master plates. Approximately 10% of the 
samples on each plate were duplicates, and laboratory personnel were blinded to case-
control and duplicate status. Genotyping was carried out using iPLEX technology 
(Sequenom, San Diego, CA) on a MassARRAY Compact Analyzer. This multiplex method 
uses the mass of the incorporated nucleotide for identification of genotype. For SNPs that 
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could not be mulitplexed (rs4253623 and rs4253699), Taqman (Applied Biosystems, Foster 
City, CA) assays were developed and were run on an ABI 7500 Real Time PCR system.  
 Kappa statistics were estimated to determine concordance between blinded repeat 
samples on each plate, and only those SNPs with a minimum kappa statistic of 0.90 were 
included in analyses. Six of the 14 identified tag SNPs for PPARA met this criterion (Table 
II). 
6.3.4 Statistical methods 
 Hardy-Weinberg equilibrium (HWE) was tested among controls to ensure 
assumptions of parametric statistical tests were met using a permuted version of the exact 
test in SAS/Genetics version 9.1 (Cary, NC) [194, 224]. Pairwise LD [196, 197] for the six 
assayed SNPs was determined using Haploview 4.0 [225]. Unconditional logistic 
regressions including individual PPARA SNPs and all SNPs together were conducted using 
SAS. Main gene effects were modeled by using the full genotype model and by combining 
heterozygotes and rare homozygotes. All models were adjusted for age, the frequency 
matched variable, and common homozygotes were the reference group for all analyses. 
Linear trend tests for allelic effects were also performed by coding each genotype as 0, 1, or 
2 based on the number of risk alleles. Separate genetic models were also used to estimate 
effects among post-menopausal women only. We hypothesized a priori that the gene’s 
effect would be most pronounced in post-menopausal women because of the relationship 
between obesity and breast cancer incidence in these women [4, 61].  
 In addition to conventional unconditional logistic regression modeling, hierarchical 
modeling using a semi-Bayesian approach was performed among all women and among 
post-menopausal women only. SAS IML commands developed by Witte et al. [226] were 
used to fit the multilevel models. Hierarchical models assumed that all SNPs were 
exchangeable. The first hierarchical model specified a τ2, or prior residual variance, of 0.169 
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while the second hierarchical model assumed a τ2 of 0.345. A residual variance equal to 
0.345 specifies that the odds ratio will fall within a 10-fold range with 95% confidence, while 
a τ2 of 0.169 specifies a five-fold range.  
 Confounders were chosen a priori using directed acyclic graphs (DAG). Race 
(White/non-White), family history of breast cancer (yes/no), and Jewish ethnicity (Jewish/not 
Jewish) were examined as potential confounders based on the DAG. Covariates that 
resulted in a 10% or greater change in the beta coefficient of the genotype effect estimate 
were considered confounders. Using this criterion, no confounders were identified.  
 Product interaction terms were added to conventional logistic and Bayesian models 
for gene variants and aspirin use, defined as use at least once per week for six months or 
longer, (among all women), and for BMI at reference and weight gain since age 50 (among 
post-menopausal women). Due to small sample sizes, heterozygotes and rare homozygotes 
were combined for all interaction models. Interactions were considered for each SNP 
separately with adjustment for all other SNPs and age. Weight gain models were also 
adjusted for BMI at age 50 to account for the potential influence of body mass on weight 
gain. Interaction contrast ratios and 95% confidence intervals (CI) were calculated to assess 
departures from additive risks [227]. Departures from additivity were defined as having the 
95% confidence interval for the interaction contrast ratio excluding the null value of zero.  
 Haplotype reconstruction was performed using an expectation maximization (EM) 
algorithm [199]. EM haplotype inference uses an individual’s genotype data to impute the 
probability of having a certain haplotype pair [187]. Haplotype specific odds ratios (OR) and 
95% CIs were estimated relative to all other haplotypes for all women and for post-
menopausal women only. All haplotype analyses were conducted using unconditional 
logistic regression in SAS/Genetics.  
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6.4 RESULTS 
 Six PPARA SNPs were included in analyses: rs135542, rs1800206, rs4253623, 
rs4253699, rs4253755, and rs4253760 (as ordered in Figure 1). All six SNPs were in HWE, 
and MAFs ranged from 5% to 22.4% (Table 6.2). We found very low correlation between the 
PPARA polymorphisms (Figure 6.1), suggesting the PGA population is an appropriate 
reference for tag SNP selection in the LIBCSP.  
 As shown in Table 6.2, PPARA polymorphism rs4253760 was associated with nearly 
a 100% increase in the risk of postmenopausal breast cancer (OR=1.97 for rare versus 
common homozygotes; 95% CI: 1.14, 3.43) and showed evidence of linear trend (p=0.02). 
Consistent findings were noted when all SNPs were assessed in one model and also for the 
hierarchical models (Table 6.3).  
 In general, hierarchical models produced more precise estimates compared to 
conventional analyses. This effect is most evident for the most unstable estimates, such as 
SNPs with a low prevalence in this population. For example, the OR for the association 
comparing rare to common homozygotes in rs1800206 was 4.14 (95% CI: 0.43, 39.79) 
among post-menopausal women, adjusting for all other PPARA SNPs (model labeled 
Conventionalb in Table 6.3); using multi-level modeling, this OR decreased to 1.29 (95% CI: 
0.58, 2.87; Hierarchicald).  
 Statistically significant interaction by aspirin use was present for rs135542 and 
rs4253699 in analyses including all women although comparable departures from additivity 
were evident for all SNPs except rs1800206 (Table 6.4). Among post-menopausal women, 
there was no evidence of interaction by BMI at reference or by weight gain since age 50, 
both measured as three level categorical variables, with no consistent pattern of elevated 
additive effects with increasing levels of obesity (results not shown).  
 109
 The haplotype reconstruction and analysis created 12 haplotypes with frequencies 
greater than 1% from the six SNPs analyzed in all women, and 14 haplotypes in the post-
menopausal women. Haplotype distributions were similar between cases and controls 
among all women (data not shown) and among post-menopausal women only (Table 6.5). 
Due to the low prevalence of select haplotypes in this population, effect estimates were 
imprecise, particularly those for associations among postmenopausal women only. For 
example, although the OR for haplotype 10 among post-menopausal women (n=30 cases 
and 11 controls) was elevated relative to all other haplotypes, the 5-fold width of the 
confidence interval indicated substantial imprecision (OR=5.02; 95% CI: 1.45, 17.39).  
6.5 DISCUSSION 
 We found that the PPARA genetic polymorphism rs4253760 was associated with a 
two-fold increase in the odds of post-menopausal breast cancer. This association persisted 
in the hierarchical models which were adjusted for the other five PPARA SNPs. This finding 
is consistent with our prior expectation of a more pronounced effect in post-menopausal 
women. rs4253760 is located in intron six and tags ten SNPs (MAF>10%) based on 
LDSelect and PGA data. This polymorphism may be correlated with the causal SNP in the 
PPARA gene although it does not tag any non-synonymous coding polymorphisms and the 
haplotype analyses with the rare variant of rs4253760 are not supportive of a causal effect.  
 Our results also implicate aspirin use as a possible effect modifier, particularly for 
rs135542 and rs4253699. In the LIBCSP population, aspirin use was associated with a 20% 
reduction in the odds of breast cancer [45]. In this study, NSAID users with the reference 
genotype showed a slight inverse association with breast cancer. Non-users with the variant 
genotype demonstrated a weak positive association while a strong inverse association is 
evident among users with the variant genotype. These findings suggest that aspirin use may 
modify the PPARA gene effect. 
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 Despite the additional computational complexity, hierarchical modeling offers two 
advantages over conventional logistic regression: (1) the shrinkage estimation method 
reduces Type II error rate [208, 210], and (2) it reduces instability in the effect estimates due 
to multiple correlated exposures, such as multiple SNPs in the same model [208]. For this 
study, two different τ2 values were considered: 0.169 and 0.345. The difference between the 
hierarchical and conventional models was most apparent for the fully specified conventional 
model, where each genotype was modeled simultaneously. Here the τ2 0.169 models 
consistently produced estimates that were closer to the null and more precise than either the 
τ2 0.345 hierarchical models or the conventional logistical models.  
 It has become increasingly apparent that studies of a single polymorphism are not 
necessarily the best approach to identifying deleterious variants [228]. Haplotypes that use 
tag SNPs selected from bins comprehensively assess variation over the entire gene to 
identify cis-cis interactions, where tag SNPs are interacting on the same chromosome to 
increase disease risk. Our study implicates haplotype 10 in breast cancer incidence, 
although the low precision of the estimate makes interpretation difficult.  
 One limitation of this data is the low concordance of eight tag SNPs with their blinded 
repeats, which prevented us from including them in our analyses. Five of the requested 
SNPs were found in repeat regions of the PPARA gene and, therefore, would have been 
difficult to genotype successfully. The low concordances found for the remaining three 
polymorphisms (rs4253730, rs4253655 and rs135543) with their blinded repeats are not 
easily explained and could be the result of genotyping error.  
 Although these omissions reduced gene coverage, this study still provides more 
coverage than previous studies and analyses a well-characterized population. Only two 
studies have examined PPARA haplotypes to date, none of which examined cancer 
outcomes or included more than three SNPs [152, 176]. Flavell et al. [152] investigated 
three SNPs in connection to age of onset and progression of Type II diabetes mellitus while 
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Doney et al. [176] explored the link between myocardial infarction risk among individuals 
with Type II diabetes mellitus and two PPARA polymorphisms. Thus, even with reduced 
gene coverage, this study advances scientific knowledge of PPARA and its role in breast 
cancer incidence.  
 Reported weight at age 50 and other past exposures may be subject to recall bias 
and non-differential misclassification since disease diagnosis has occurred before exposure 
ascertainment. Several studies have found a high degree of recall in weight over time [213-
216] although it has been suggested that underweight women may overestimate their past 
weight while overweight women may underestimate their past weight [216]. This study 
examined body size as a potential modifier of the gene’s effect; therefore, for recall bias to 
be present, cases and controls would have to recall their weight differentially by PPARA 
genotype. Since women are unlikely to know their PPARA status, recall bias is unlikely to 
play a role in these analyses.  
 Although a benefit of our study is that it is population-based, only 73% of cases and 
controls donated blood. However, the distributions of risk factors for breast cancer among all 
women in the study were comparable to those of women who donated blood (data not 
shown). Lastly, the ethnic distribution of our Long Island subjects differs from that of the 
American population as a whole, with 92.7% of our study population being Caucasian; thus, 
results from this study may not be readily applied to the U.S. population in general. Although 
the underlying prevalence of specific alleles and exposures may vary with ethnicity, it seems 
unlikely that the biological relations with breast cancer among participants in this study will 
differ from women in general. In fact, as expected, the minor allele frequencies differed only 
slightly between the PGA European-American population and our Long Island women, with 
the greatest difference noted for rs4253755 (18.2% versus 22.0%, respectively). This 
difference is most likely due to PGA’s small sample (n=23) for determining the allele 
frequencies in European-Americans.  
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 Lack of reproducibility among genetic studies has called into question the utility of 
association studies in genetic epidemiology [229]. This is the first study to examine the 
association between PPARA polymorphisms and breast cancer development. While our use 
of semi-Bayesian techniques minimizes many issues inherent with small cell sizes, such as 
large but imprecise effects and low p-values, further replication is needed to confirm our 
findings.  
 In summary, although PPARA has been studied in cardiovascular disease, no 
studies have examined PPARA in connection to breast cancer. This study is the first to 
investigate its relationship to breast cancer risk and interaction by aspirin use and obesity in 
a large population-based sample. This study suggests that variants of PPARA modify the 
association between breast cancer and aspirin use. Research investigating PPARA’s 
possible involvement in the inflammatory pathway is needed. We found that among 
postmenopausal women carrying the homozygous alleles for rs4253760, the odds of breast 
cancer was nearly doubled. These findings warrant further investigation in an independent 
cohort.  
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6.7 TABLES  
 
TABLE 6.1. PPARA haplotype tagging SNPs identified using LDSelect and the PGA 
European-American population as the reference panel 
    rs# SNP Location 
Base Pair Change 
(major>minor) 
Minor Allele 
Frequencya Reference 
rs4253730 Intron A>G 0.182 LDSelecta 
rs4253760b Intron T>G 0.196 LDSelect 
rs4253705 Intron T>C 0.190 LDSelect 
rs135543 Intron G>A 0.283 LDSelect 
rs135542b Intron A>G 0.205 LDSelect 
rs4253649 Intron C>G 0.370 LDSelect 
rs4253758 Intron T>C 0.217 LDSelect 
rs4253699b Intron T>C 0.182 LDSelect 
rs4253655 Intron G>A 0.143 LDSelect 
rs4253681 Intron T>C 0.136 LDSelect 
rs4253755b Intron G>A 0.130 LDSelect 
rs4253706 Intron G>A 0.119 LDSelect 
rs4253623b Intron A>G 0.109 LDSelect 
rs1800206b Exon 
Leu>Val 
C>G 0.022 PGAa 
aSequence data on 23 European-Americans Coriell samples are available on the 
University of Washington-Fred Hutchinson Center Research Center Variation 
Discovery Resource (PGA) website (http://pga.gs.washington.edu/). 
bSNPs included in analyses 
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TABLE 6.2. Summary table of ORs for association between six PPARA polymorphisms and 
breast cancer risk by menopausal status in LIBCSP 
   Cases Controls P for   
Genotype Genotypea MAFb N %c N %c trendd ORe 95% CI 
All women          
rs135542 AA 602 59.4 634 59.3  1.00  
 AG 370 36.5 392 36.7  1.01 0.84, 1.21 
 GG 41 4.1 43 4.0 0.90 1.01 0.65, 1.57 
 AG+GG 
0.224 
411 40.6 435 40.7  1.01 0.85, 1.21 
 Total  1013  1069     
           
rs1800206 CC (L/L) 927 89.7 973 89.7  1.00  
(L162V) CG (L/V) 100 9.7 109 10.1  0.97 0.73, 1.30 
 GG (V/V) 7 0.7 3 0.3 0.72 2.44 0.63, 9.50 
  L/V+V/V 
0.054 
107 10.4 112 10.3  1.01 0.76, 1.34 
  Total  1034  1085     
           
rs4253623 AA 811 77.5 849 77.0  1.00  
 AG 218 20.8 236 21.4  0.97 0.79, 1.19 
 GG 17 1.6 17 1.5 0.77 0.98 0.49, 1.93 
 AG+GG 
0.123 
235 22.5 253 23.0  0.97 0.79, 1.19 
 Total   1046  1102     
          
rs4253699 TT 624 60.0 671 61.5  1.00  
 CT 358 34.4 362 33.2  1.06 0.88, 1.27 
 CC 58 5.6 59 5.4 0.52 1.07 0.73, 1.57 
 CT+CC 
0.220 
416 40.0 421 38.6  1.06 0.89, 1.27 
 Total  1048  1092     
          
rs4253755 GG 803 76.5 845 77.4  1.00  
 AG 231 22.0 231 21.2  1.05 0.85, 1.29 
 AA 16 1.5 16 1.5 0.64 1.05 0.52, 2.12 
 AG+AA 
0.120 
247 23.5 247 22.6  1.05 0.86, 1.29 
  Total   1050  1092     
           
rs4253760 TT 675 66.2 713 67.2  1.00  
 GT 293 28.7 302 28.5  1.02 0.84, 1.24 
 GG 52 5.1 46 4.3 0.41 1.25 0.83, 1.87 
 GT+GG 
0.186 
345 33.8 348 32.8  1.05 0.88, 1.26 
  Total  1020  1061     
           
Post-
menopausal 
         
rs135542 AA 395 59.0 397 60.0  1.00  
 AG 247 36.9 239 36.1  1.07 0.85, 1.35 
 GG 27 4.0 26 3.9 0.61 1.04 0.59, 1.81 
 AG+GG 274 41.0 265 40.0  1.07 0.86, 1.33 
 Total 
0.220 
669  662     
          
rs1800206 CC (L/L) 610 89.3 609 89.7  1.00  
(L162V) CG (L/V) 68 10.0 69 10.2  1.01 0.71, 1.44 
 GG (V/V) 
0.052 
5 0.7 1 0.2 0.51 5.07 0.59, 
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43.71 
 L/V+V/V 
 
73 10.7 70 10.3  1.06 0.75, 1.51 
 Total  673  679     
          
rs4253623 AA 533 77.4 522 75.9  1.00  
 AG 145 21.0 150 21.8  0.96 0.74, 1.24 
 GG 11 1.6 16 2.3 0.43 0.66 0.30, 1.45 
 AG+GG 156 22.6 166 24.1  0.93 0.72, 1.20 
 Total 
0.132 
689  688     
          
rs4253699 TT  411 59.8 425 62.2  1.00  
 CT 0.217 243 35.4 220 32.2  1.13 0.90, 1.42 
 CC  33 4.8 38 5.6 0.62 0.92 0.56, 1.49 
 CT+CC  276 40.2 258 37.8  1.10 0.88, 1.37 
 Total  687  683     
          
rs4253755 GG 532 76.3 535 78.8  1.00  
 AG 153 22.0 135 19.9  1.12 0.86, 1.46 
 AA 12 1.7 9 1.3 0.29 1.36 0.57, 3.27 
 AG+AA 
0.113 
165 23.7 144 21.2  1.14 0.88, 1.47 
 Total  697  679     
          
rs4253760 TT 441 65.0 454 69.6  1.00  
 GT 199 29.4 177 27.2  1.14 0.90, 1.46 
 GG 38 5.6 21 3.2 0.02 1.97 1.14, 3.43 
 GT+GG 237 35.0 198 30.4  1.23 0.98, 1.55 
 Total 
0.168 
678  652     
aThe combined heterozygotes and rare homozygotes were modeled separately and compared to 
common homozygotes 
bMinor allele frequency calculated among controls 
cMay not add up to 100.0 due to rounding 
dP-value for trend was calculated by coding each genotype as 0, 1, or 2 based on the number of 
risk alleles 
eAdjusted for age, measured in five year intervals 
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TABLE 6.3. Odds ratios and 95% CIs for six PPARA polymorphisms and breast cancer among post-
menopausal women in the LIBCSP for conventional and hierarchical models with varying priors 
  Conventionalb Conventionalc Hierarchicald Hierarchicale 
SNP Allelesa ORf 95% CI ORf 95% CI ORf 95% CI ORf 95% CI 
         
rs135542 AG 1.07 0.85, 1.35 1.05 0.82, 1.34 1.06 0.84, 1.34 1.06 0.83, 1.34 
 GG 1.04 0.59, 1.81 1.13 0.63, 2.02 1.13 0.69, 1.83 1.13 0.67, 1.91 
rs1800206 CG 1.01 0.71, 1.44 0.93 0.60, 1.46 0.98 0.67, 1.43 0.96 0.64, 1.43 
 GG 5.07 0.59, 43.71 4.14 0.43, 39.79 1.29 0.58, 2.87 1.47 0.51, 4.27 
rs4253623 AG 0.96 0.74, 1.24 1.15 0.86, 1.52 1.14 0.87, 1.49 1.14 0.86, 1.51 
 GG 0.66 0.30, 1.45 0.61 0.26, 1.43 0.83 0.46, 1.53 0.76 0.38, 1.52 
rs4253699 CT 1.13 0.90, 1.42 0.97 0.73, 1.28 1.00 0.77, 1.29 0.99 0.76, 1.29 
 CC 0.92 0.56, 1.49 0.89 0.49, 1.62 1.02 0.64, 1.62 0.98 0.59, 1.64 
rs4253755 AG 1.12 0.86, 1.46 1.06 0.74, 1.52 1.07 0.78, 1.47 1.06 0.76, 1.49 
 AA 1.36 0.57, 3.27 1.29 0.44, 3.76 1.20 0.62, 2.30 1.22 0.56, 2.69 
rs4253760 GT 1.14 0.90, 1.46 1.17 0.85, 1.61 1.13 0.85, 1.49 1.15 0.85, 1.54 
 GG 1.97 1.14, 3.43 2.19 1.17, 4.13 1.71 1.05, 2.80 1.90 1.10, 3.28 
aMinor alleles in bold 
bModels included one SNP and age only  
cAll SNPs plus age in one model  
dAll SNPs exchangeable and prior τ2 = 0.169  
eAll SNPs exchangeable and prior τ2 = 0.345 
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TABLE 6.4. Odds ratios, interaction contrast ratios and 95% CIs for six 
PPARA polymorphisms and breast cancer by aspirin use in all LIBCSP 
women under the dominant inheritance model 
 Conventionala Interactiona 
Interactionb ORc 95% CI ICR 95% CI 
rs135542     
AA*(Aspirin Use)d 0.92 0.69, 1.23   
(AG+GG)*(Non-Use) 1.09 0.88, 1.36   
(AG+GG)* (Aspirin Use) 0.56 0.39, 0.81 -0.45 -0.87, -0.04 
     
rs1800206     
CC*(Aspirin Use) 0.73 0.57, 0.92   
(CG+GG)*(Non-Use) 1.05 0.71, 1.56   
(CG+GG)*(Aspirin Use) 0.94 0.46, 1.89 0.16 -0.59, 0.91 
     
rs4253623     
AA*(Aspirin Use) 0.64 0.49, 0.84   
(AG+GG)*(Non-Use) 0.94 0.73, 1.22   
(AG+GG)*(Aspirin Use) 1.07 0.71, 1.61 0.48 -0.01, 0.98 
     
rs4263699     
TT*(Aspirin Use) 0.60 0.45, 0.80   
(CT+CC)*(Non-Use) 0.85 0.66, 1.09   
(CT+CC)*(Aspirin Use) 0.91 0.62, 1.32 0.46 0.08, 0.84 
     
rs4253755     
GG*(Aspirin Use) 0.65 0.50, 0.84   
(AG+AA)*(Non-Use) 0.93 0.68, 1.27   
(AG+AA)*(Aspirin Use) 1.08 0.67, 1.75 0.50 -0.05, 1.05 
     
rs4253760     
TT*(Aspirin Use) 0.62 0.47, 0.82   
(GT+GG)*(Non-Use) 0.92 0.70, 1.21   
(GT+GG)*(Aspirin Use) 0.97 0.65, 1.44 0.42 -0.01, 0.85 
aInteraction by each SNP was modeled separately although all models were adjusted for 
all SNPs 
bMinor allele in bold 
cAdjusted for age, measured in five year age intervals 
dAspirin use was defined as use at least once per week for six months or longer 
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TABLE 6.5. Odds ratios and frequencies by case-control status for 14 PPARA haplotypes relative to all other haplotypes among post-menopausal 
women in LIBCSP 
Haplotype 
Numbera 
rs135542 rs1800206 rs4253623 rs4253699 rs4253755 rs4253760 Control 
N (%) 
Case 
N (%) 
OR (95% CI)b 
1 A C A C A G 55 (5.5) 53 (5.3) 1.01 (0.49, 2.09) 
2 A C A C A T 18 (1.9) 32 (3.2) 2.03 (0.71, 5.82) 
3 A C A C G G 18 (1.8) 14 (1.4) 0.97 (0.23, 4.18) 
4 A C A C G T 55 (5.5) 53 (5.2) 0.89 (0.40, 1.99) 
5 A C A T A G 25 (2.5) 32 (3.2) 1.64 (0.61, 4.46) 
6 A C A T G G 19 (1.9) 36 (3.6) 2.83 (0.93, 8.65) 
7 A C A T G T 414 (41.7) 396 (39.2) 0.92 (0.70, 1.20) 
8 A C G C G T 13 (1.5) 10 (1.0) 0.77 (0.12, 4.91) 
9 A C G T G T 104 (10.5) 103 (10.2) 0.97 (0.59, 1.59) 
10 A G A C G G 11 (1.1) 30 (3.0) 5.02 (1.45, 17.39)
11 A G A T G G 13 (1.3) 8 (0.8) 0.47 (0.08, 2.83) 
12 G C A C G T 15 (1.5) 8 (0.8) 0.42 (0.05, 3.55) 
13 G C A T G G 11 (1.1) 11 (1.1) 1.07 (0.13, 8.67) 
14 G C A T G T 173 (17.4) 182 (18.0) 1.19 (0.79, 1.80) 
aHaplotypes with frequency ≥ 0.01, minor alleles in bold 
bAdjusted for age, measured in five year age intervals 
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6.8 LEGENDS TO FIGURES 
 
 
 
 
FIGURE 6.1. Linkage disequilibrium (r2) between six PPARA tag SNPs among LIBCSP 
controls 
 
 CHAPTER 7 SURVIVAL STUDY MANUSCRIPT 
7.1 ABSTRACT 
Peroxisome proliferator-activated receptor-alpha (PPARA) is part of the nuclear 
hormone receptor family that encodes proteins that induce gene transcription by binding to 
the promoter region of a target gene. PPARA has been linked to obesity and Diabetes 
Mellitus, but has not yet been studied in relation to breast cancer survival. Because breast 
cancer survival is believed to operate through similar pathways, this gene could contribute to 
breast cancer survival. Six PPARA polymorphisms were evaluated for an association with 
survival among a population-based cohort of women diagnosed with a first primary breast 
cancer in 1996-1997 (n=1073). Interviews and blood samples were collected shortly after 
diagnosis. The National Death Index was used to determine vital status through December 
31, 2002. Cox regression and haplotype-based analyses were performed for all-cause and 
breast cancer-specific mortality (n = 132 (12.3%) and 88 (8.2%), respectively). PPARA 
polymorphism rs4253760 was associated with a two-fold increase in all-cause mortality with 
inclusion of a continuous time interaction term (HR=2.25 for rare vs. common homozyote 
alleles; 95% CI: 1.00, 5.08 at baseline). This interaction term implies that survival improves 
over time; thus, caution is necessary when interpreting this HR. Haplotype reconstruction 
created 12 haplotypes with frequencies greater than 1%, but no clear differences in 
haplotype frequencies by all cause or breast cancer-specific mortality
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were evident. Although the confidence intervals for the effect estimates are wide, 
these results suggest PPARA may be involved in survival among women with breast cancer 
and attempts to replicate in an independent cohort are warranted. 
7.2 INTRODUCTION 
The peroxisome proliferator-activated receptor (PPAR) family is composed of three 
nuclear hormone receptor genes: PPAR-gamma, PPAR-alpha (PPARA) and PPAR-delta. In 
general, hormone nuclear receptor genes encode proteins that induce gene transcription by 
binding to the promoter region of a target gene [141]. PPARA is activated when compounds 
such as fenofibrate, bezafibrate and non-steroidal anti-inflammatory drugs, bind to its 
receptor [142, 143]. 
The PPARA epidemiologic literature has focused on one functional polymorphism, 
rs1800206 or L162V. A cytosine to guanine base change occurs at codon 162 of exon 5, 
resulting in a leucine to valine substitution in the binding domain region of the PPARA 
protein. This missense polymorphism has been shown to have a functional impact on the 
receptor, increasing ligand-dependent transcription activity in rare homozygotes [151].  
L162V has been linked to atherosclerosis [158, 163, 179], lipoprotein levels [162, 
174, 178], obesity [165, 169], and Type II Diabetes Mellitus [152, 167, 223], but has not yet 
been studied in relation to breast cancer survival. Because breast cancer survival is 
believed to operate through similar pathways, including inflammation and insulin resistance, 
this research could elucidate a genetic contributor to breast cancer survival. 
  122
7.3 MATERIALS AND METHODS 
7.3.1 Study Population 
The 1,508 cases who participated in the Long Island Study Project (LIBCSP) were 
eligible for this follow-up study. Women were eligible for the current study if they had newly 
diagnosed in situ or invasive breast cancer between August 1, 1996 and July 31, 1997, were 
20 years of age or older at diagnosis, were residents of Nassau or Suffolk counties in Long 
Island, NY, and completed the baseline LIBCSP questionnaire. 
7.3.2 Data and Biological Sample Collection 
The baseline interview was administered by a trained interviewer in the respondents’ 
home and took an average of 101 minutes to complete. Details of the parent study 
population and data collection methods have been previously published [37]. Among 
respondents who completed the baseline interview, 73.0% of cases and 73.3% of controls 
donated a blood sample. DNA was isolated using methods previously described [59]. 
Of the 1508 LIPCSP case participants, 198 (13.1%) died during follow-up according 
to the National Death Index (NDI), while the rest (n=1,310) were alive through December 31, 
2002, the last date that the NDI considered mortality data to be accurate. For the 1,073 
cases that were successfully genotyped, 941 were alive (87.7%) and 132 dead (12.3%) at 
the end of the follow-up period. Eighty-eight deaths (8.2%) were breast-cancer related while 
44 (4.1%) were from other causes, such as lung cancer and cardiovascular disease. 
7.3.3 Selection of tagging SNPs 
A minimal number of tag single nucleotide polymorphisms (SNP) were selected to 
represent comprehensive coverage of the PPARA gene using an estimated minimum 
pairwise correlation of 0.80 between SNPs. The haplotype tagging SNPs were identified 
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using the Program for Genomic Applications’ LDSelect Program [190] run for 23 European-
Americans Coriell samples (given the relative racial homogeneity of the LIBCSP population). 
This program has been shown to select a maximally informative set of common SNPs, and 
is based on the r2 LD statistic [191]. Based on this program, 14 SNPs were identified for 
genotyping. 
7.3.4 Laboratory Analysis 
Genotyping was conducted at Columbia University, New York, NY. All LIBCSP DNA 
samples are available on 96 well master plates. Plates include an approximately 10% 
duplication rate, and laboratory personnel were blinded to case-control and duplication 
status. Genotyping was carried out using iPLEX technology (Sequenom, San Diego, CA) on 
a MassARRAY Compact Analyzer. For SNPs that could not be mulitplexed (rs4253623 and 
rs4253699), Taqman (Applied Biosystems, Foster City, CA). SNP assays were used. Six of 
the 14 identified tag SNPs for PPARA met an a priori minimum kappa statistic of 0.90 for 
concordance among the blinded repeat samples, and were included in subsequent 
analyses. 
7.3.5 Statistical Analysis 
Hardy-Weinberg Equilibrium (HWE) was calculated using exact p-values due to the 
low expected prevalence of rare homozygotes. Pairwise linkage disequilibrium (LD) [196] 
was determined using Haploview 4.0 [225]. Kaplan-Meier survival curves were created for 
all SNPs individually and PPARA haplotypes (data not shown). Cox regression was used to 
estimate crude and adjusted hazard ratios (HR) and 95% confidence intervals (CI) for all 
cause and breast cancer specific mortality. All analyses were conducted in SAS version 
9.1.3 (Cary, N.C.). 
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Haplotype reconstruction was performed using an expectation maximization (EM) 
algorithm [199]. Haplotype frequencies were compared by vital status, and haplotype 
specific HRs and 95% CIs, using all other haplotypes as the reference, were calculated 
using Cox regression for all cause and breast cancer specific mortality. All haplotype 
analyses were conducted using SAS/Genetics version 9.1.3.  
To assess the assumption of proportional hazards, both statistical testing and 
graphical techniques were used. First, log-minus-log survival curves were examined for 
each SNP to see if the resulting curves appear non-parallel. Second, categorical and 
continuous time interaction variables were tested using the likelihood ratio test (LRT). If the 
LRT yielded a p-value less than 0.05, the proportional hazards assumption was deemed 
violated and the time-dependent variable was retained in the model. 
Race (White/non-White) and Jewish ethnicity (Jewish/not Jewish) were identified as 
potential confounders based on a priori knowledge and directed acyclic graphs (DAG) [230]; 
however, neither variable met a pre-specified 10% or greater change in effect estimate 
criterion for inclusion as confounders in final models. 
7.4 RESULTS 
Two SNPs, rs1800206 and rs4253760, deviated from HWE (p=0.03, p=0.01, 
respectively) when examined in the cases. For both deviations, excesses of common and 
rare homozygotes were observed compared to expected numbers under HWE. We found 
very low correlation between the PPARA polymorphisms (Figure 7.1), suggesting the PGA 
population is an appropriate reference for tag SNP selection in the LIBCSP.  
No differences in survival were evident for all PPARA SNPs evaluated individually 
(Table 7.1). There is a suggestion of decreased survival for rs4253760 at baseline, the only 
SNP that required the inclusion of a continuous time interaction term (HR=2.25; 95% CI: 
1.00, 5.08 for overall mortality at time=0, or at diagnosis) in both the all cause and breast 
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cancer-specific mortality analyses. In this model, however, the time interaction beta-
coefficient is negative, implying survival improves with each day after baseline. Therefore, 
five years following diagnosis, the rs4253760 HR will decrease from 2.25 to 0.69 (95% CI: 
0.36, 1.29). Thus, caution is necessary when interpreting the results for this polymorphism. 
The haplotype reconstruction created 12 haplotypes with a frequency greater than 
0.01. No haplotypes were clearly associated with survival in this cohort (Table 7.2). Due to 
the low prevalence of select haplotypes, several estimates lacked precision. For example, 
haplotype 10, occurring in 1% of alive and <1% of dead cases, had a confidence interval 
width of 721, measured by dividing the upper by the lower interval. Results were similar for 
breast cancer-specific mortality although the imprecision of the effect estimates makes 
interpretation difficult (data not shown). 
7.5 DISCUSSION 
We found PPARA polymorphism rs4253760 was associated with all cause and 
breast cancer specific mortality at baseline when the hazard model was correctly specified 
by including a continuous time interaction variable. The inclusion of the interaction term also 
implies that survival is improving over time for carriers of the rare allele; therefore, this HR 
should be interpreted with caution. This association is consistent with other LIBCSP results 
implicating rs4253760 in breast cancer development [231]. Additionally, the stronger 
association found with breast cancer-related deaths compared to all cause mortality suggest 
that the gene’s known connection to cardiovascular disease risk factors is not driving our 
results. This SNP also tags 10 other SNPs with a frequency greater than 10% according to 
the PGA and may act as a marker for the true causative polymorphism although the 
haplotype analyses are not supportive of a causal effect.  
Caution is necessary in interpreting our findings, given that estimates were based on 
small numbers of observations. Further, the SNP was not in HWE although recent research 
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has suggested that deviations from HWE in the cases may reflect evolutionary survival 
mechanisms rather than laboratory error; therefore, these deviations may not bias the 
resulting effect estimate [195]. 
Approximately 73.0% of cases donated blood, suggesting that missing data may be 
concern. However, in a comparison of select tumor and demographic characteristics, 
including age, stage and tumor size, no differences between genotyped cases (n=1,073) 
and all cases (n=1,508) were found (data not shown). 
The number of SNPs included in our study was limited because of the low 
concordance of some of the genotyped SNPs with their blinded repeats. Out of the 14 tag 
SNPs identified, only six polymorphisms that achieved the a priori kappa statistic cut-off of 
0.90 were included in our analyses; however, no studies to date have investigated the link 
between breast cancer survival and any PPARA SNPs.  
In conclusion, while no current research has examined the association between 
breast cancer survival and PPARA polymorphisms, the biology and epidemiology of the 
gene suggest it could play a role in disease prognosis. PPARA has been linked to obesity, 
inflammation and insulin resistance, pathways which have also been implicated in breast 
cancer survival. One PPARA SNP, rs4253760, was inversely associated with survival in this 
unique cohort of 1,073 breast cancer cases from the LIBCSP.  
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7.6 TABLES AND FIGURES 
 
TABLE 7.1. Hazard ratios and frequencies by vital status for six SNPs in relation to all-cause (n=132) and 
breast cancer specific mortality (n=88) mortality among a cohort of women with breast cancer (n=1073) 
 Overall Mortality Breast Cancer-Specific Mortality 
 N HR HR* N HR HR* 
Genotype Cases/Cohort (95% CI) (95% CI) Cases/Cohort (95% CI) (95% CI) 
rs135542       
 AA 78/602 1.00 1.00 45/569 1.00 1.00 
 AG+GG 44/411 0.82  
(0.57, 1.19) 
0.80 
(0.34, 1.86) 
36/403 1.14 
(0.73, 1.76) 
0.67 
(0.25, 1.82) 
rs1800206       
 CC 115/927 1.00 1.00 76/888 1.00 1.00 
 CG+GG 10/107 0.76  
(0.40, 1.46) 
1.17 
(0.30, 4.58) 
8/105 0.91 
(0.44, 1.89) 
1.54 
(0.33, 7.06) 
rs4263623       
 AA 97/811 1.00 1.00 65/779 1.00 1.00 
 AG+GG 28/235 1.00  
(0.66, 1.52) 
1.54 
(0.65, 3.68) 
19/226 1.01 
(0.60, 1.68) 
0.88 
(0.28, 2.78) 
rs4253699       
 TT 75/624 1.00 1.00 51/600 1.00 1.00 
 CT+CC 52/416 1.05  
(0.74, 1.50) 
1.16 
(0.45, 2.96) 
35/399 1.04 
(0.68, 1.60) 
1.06 
(0.41, 2.76) 
rs4253755       
 GG 97/803 1.00 1.00 68/774 1.00 1.00 
 AG+AA 32/247 1.08  
(0.72, 1.61) 
1.18 
(0.54, 2.60) 
18/233 0.87 
(0.52, 1.47) 
0.99 
(0.32, 3.07) 
rs4253760       
 TT 80/675 1.00 1.00 57/652 1.00 1.00 
 GT+GG 44/345 1.10  
(0.76, 1.59) 
2.25 
(1.00, 5.08) 
25/326 0.89 
(0.55, 1.42) 
2.50 
(0.90, 6.96) 
*Adjusted for a continuous time interaction term; interaction term necessary only for rs4253760 based on 
likelihood ratio test 
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TABLE 7.2. Hazard ratios and frequencies by vital status for haplotypes in relation to all-cause mortality (n=132) among a cohort of women with 
breast cancer (n=1073) 
       All-cause Mortality 
Haplotype 
Number* 
rs135542 rs1800206 rs4253623 rs4253699 rs4253755 rs4253760 Alive 
N (%) 
Dead 
N (%) 
HR 
(95% CI) 
1 A C A C A G 74 (5.6%) 14 (6.8%) 1.01 
(0.36, 2.86) 
2 A C A C A T 41 (3.0%) 6 (3.1%) 0.93 
(0.21, 4.14) 
3 A C A C G G 23 (1.7%) 0 (<1%) 0.31 
(0.03, 3.76) 
4 A C A C G T 60 (4.6%) 16 (8.3%) 2.11 
(0.67, 6.58) 
5 A C A T A G 37 (2.8%) 5 (2.6%) 0.90 
(0.18, 4.53) 
6 A C A T G G 43 (3.3%) 11 (5.7%) 1.77 
(0.57, 5.46) 
7 A C A T G T 520 (39.7%) 76 (38.3%) 0.79 
(0.51, 1.23) 
8 A C G T G T 134 (10.2%) 24 (12.2%) 0.98 
(0.45, 2.10) 
9 A G A C G G 32 (2.4%) 4 (2.3%) 0.77 
(0.11, 5.21) 
10 A G A C G T 15 (1.2%) 0 (<1%) 0.19 
(0.01, 7.21) 
11 G C A C G T 17 (1.3%) 2 (1.0%) 0.12 
(0.00, 6.45) 
12 G C A T G T 241 (18.4%) 33 (16.5%) 0.69 
(0.35, 1.36) 
*haplotypes with frequency ≥ 0.01 
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FIGURE 7.1. Linkage disequilibrium (r2) between the six PPARA polymorphisms 
 
 
 CHAPTER 8 DISCUSSION 
8.1 SPECIFIC AIMS 
The overarching goal of this doctoral research was to determine whether genetic 
variation in PPARA was associated with breast cancer risk and survival, utilizing a 
haplotype-based approach. To address this goal, four specific study aims were completed, 
as discussed below, utilizing population-based data from the Long Island Breast Cancer 
Study Project. Genotyping was completed for 1,073 women with breast cancer and 1,112 
controls, for whom demographic, risk factor, and clinical data was available from personal 
interviews and medical record abstraction.   
The first specific study aim was to examine the association between genetic 
variations in PPARA and risk of breast cancer in all women and post-menopausal women 
only. Three different analytic strategies were employed to meet this objective: (1) 
conventional logistic models were constructed for all SNPs separately and collectively under 
dominant inheritance and full genotype specification; (2) semi-Bayesian methods were used 
to model all polymorphisms jointly, and (3) haplotypes were created and analyzed. To be 
included in all three analytic strategies, SNPs were required to have a minimum kappa 
statistic of 0.90 with their replicates. Based on this a priori cut-off, six of the fourteen 
genotyped polymorphisms were included in all analyses.  
Few differences in precision and estimate effects were observed between the 
conventional and semi-Bayesian results under dominant inheritance, although the fully 
specified genotype models showed substantial pull towards the null value of one in the 
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Bayesian models. These findings are consistent with expected results as the specified 
residual prior variance (τ2) will place more weight on the null value than the data. rs4253760 
was associated breast cancer incidence among post-menopausal women in conventional 
and semi-Bayesian models. This polymorphism is located in the fifth intronic region of 
PPARA and “binned” ten other SNPs with MAFs of 0.10 or greater. The haplotype analyses 
were constrained by small cell sizes and their imprecision makes interpretation difficult. 
The second specific aim was to evaluate interaction by PPARA polymorphisms with 
the association between obesity, measured using body mass index (BMI), and weight gain 
and risk of breast cancer in all women and post-menopausal women only. Using 
conventional logistic regression and semi-Bayesian techniques, this research examined 
additive interaction by three different variables: (1) BMI at reference, (2) weight gain since 
age 50, and (3) aspirin use. BMI was analyzed as a three level categorical variable (normal 
weight, overweight and obese) based on the definitions from the World Health Organization 
[5]. Weight gain was also analyzed as a three level variable and classification was based on 
levels used in Eng et al. [9] which used this population. All weight gain models were 
adjusted for BMI at age 50 to better distinguish the impact of post-menopausal weight gain 
on disease risk apart from weight at baseline. Additive interaction was deemed present if the 
95% confidence intervals for the interaction contrast ratios did not included the null value of 
zero.  
Based on this criterion, no interaction was found with BMI and weight gain, but some 
evidence of interaction was found with aspirin use in two polymorphisms (rs135542 and 
rs4253699) in analyses including all women. The magnitude of interaction was consistent 
across all six polymorphisms (with the exception of rs1800206); however, there was a 
suggestion of differing functionality between rs135542 and the other four SNPs. For 
rs135542, there appears to be a weak inverse association between NSAID use and breast 
cancer among common homozygotes. Non-users with the “at risk” allele show a weak 
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positive association while users with the “at risk” allele have a strong inverse association 
with breast cancer. Thus, the “at risk” allele and NSAID use may work synergistically to 
exacerbate the protective effect of NSAIDs for rs135542.  
For rs4253623, rs4253699, rs4253755 and rs4253760, the relationship between 
breast cancer and NSAID use is more clear. Among common homozygotes, NSAID use has 
a protective effect, but there is no association with NSAID use among those with the “at risk” 
allele. These results are consistent with NSAIDs operating through mechanisms involving 
PPARA in part.  
The third specific aim was to examine the association between genetic variations in 
PPARA and breast cancer survival in pre- and post-menopausal cases. To meet this aim, 
two different analytic techniques were conducted under the dominant inheritance models: 
(1) Cox proportional hazard models were performed, including time interactions when 
necessary, and (2) haplotypes were constructed and analyzed. Both all cause and breast 
cancer-specific mortality were explored. Like the case-control analysis, rs4253760 showed 
an increase in both all cause and breast cancer-specific mortality. This suggests that 
cardiovascular disease risk factors, which have been shown to be associated with PPARA, 
are not driving the poor prognosis found for rs4253760. The haplotype analyses did not 
further elucidate survival relationships. 
Lastly, the study aimed to assess interaction by polymorphic variation in PPARA with 
the association between obesity and weight gain and survival from breast cancer in pre- and 
post-menopausal women. This objective was underpowered due to the high survival rates 
found in this population (87.7% of cases were alive as of 2002) and the low minor allele 
frequencies (MAF) for several polymorphisms; therefore, this aim was exploratory only. The 
survival rates in LIBCSP are consistent with those found in Surveillance Epidemiology and 
End Results (SEER), which reported five year relative survival rate of 88.6% from 1996-
2003 [232]. 
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In addition to obesity and weight gain, additive and multiplicative interactions with 
several tumor and demographic characteristics were also examined, including patient age, 
stage, hormone receptor status and treatment. Stage acted an additive and multiplicative 
effect modifier for rs4253699 while the effect of rs4253755 was modified by radiation 
treatment. It is unclear whether these findings reflect a true association, or if instead they 
are due to biases associated with restricted power.  
8.2 STRENGTHS AND LIMITATIONS 
8.2.1 Tag SNP selection and genotyping 
Tag SNPs were selected using the PGA ldSelect Program [190] run for European 
Americans only because of the racial homogeneity of the LIBCSP population. Therefore, the 
fourteen tag SNPs identified to provide maximum coverage of PPARA are applicable only to 
Caucasians. The number of polymorphisms necessary to capture the gene for African 
Americans (AA) is much larger (45 SNPs) due to the greater diversity in their population 
history compared to Caucasians. In this study, both races were included in analyses since 
AAs were not substantial enough to influence results yet added additional statistical power. 
For example, Table 8.1 presents the observed MAFs for Caucasians, AAs and the 
combined group compared to the PGA individuals of European descent. As this table 
shows, the combined population frequencies reflect very little AA influence with the 
exception of rs4253760, where the increased frequency of common homozygotes drives up 
the MAF slightly in the combined group. 
The statistical analyses were limited to six of the fourteen SNPs. The eight other 
polymorphisms were purposely omitted because of the poor concordance between the 
blinded repeats and the replicates (kappa statistic < 0.90). Possible explanations for this low 
concordance include poor DNA quality, genotyping error and the location of the SNPs. Poor 
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DNA quality seems unlikely given the success of the Taqman assays in genotyping three of 
the SNPs. Genotyping error is a distinct possibility considering initial concerns with the laser 
intensity. Lastly, the location of the polymorphisms could have contributed to the low 
concordance. Five of the requested SNPs were found in repeat regions of the PPARA gene 
and, therefore, would have been difficult to genotype successfully.  
TABLE 8.1. Minor allele frequencies by race for LIBCSP versus PGA 
rs# LIBCSP 
Combined 
LIBCSP 
Caucasian 
PGA 
Caucasian 
LIBCSP 
AA 
PGA 
AA 
All cases 
rs135542 0.224 (n=1069) 0.226 (n=988) 0.205 0.240 (n=50) 0.348 
rs1800206 0.054 (n=1085) 0.054 (n=1004) 0.022 0.010 (n=48) 0.021 
rs4253623 0.123(n=1102) 0.123 (n=1018) 0.109 0.127 (n=51) 0.021 
rs4253699 0.220 (n=1092) 0.220 (n=1008) 0.182 0.294 (n=51) 0.312 
rs4253755 0.120 (n=1092) 0.124 (n=1009) 0.130 0.069 (n=51) 0.042 
rs4253760 0.186 (n=1061) 0.167 (n=982) 0.196 0.585 (n=47) 0.667 
Post-menopausal women 
rs135542 0.220 (n=662) 0.221 (n=621)  0.269 (n=26)  
rs1800206 0.052 (n=679) 0.053 (n=638)  0.020 (n=25)  
rs4253623 0.132 (n=688) 0.132 (n=646)  0.115 (n=26)  
rs4253699 0.217 (n=683) 0.218 (n=641)  0.288 (n=26)  
rs4253755 0.113 (n=679) 0.118 (n=638)  0.038 (n=26)  
rs4253760 0.168 (n=652) 0.153 (n=614)  0.565 (n=23)  
 
Whether inclusion of only six PPARA polymorphisms in the analyses is sufficient to 
represent variability within the gene is an important consideration. A comparison with the 
linkage disequilibrium (LD) from the HapMap version B36 shows that five of the analyzed 
SNPs capture three out of the four haplotype blocks (Figure 8.1) among individuals of 
European descent. The excluded haplotype block (Block 1) is less than one kilobase in 
length and only includes two polymorphisms; thus, its exclusion only minimally impacts gene 
coverage. rs4253699 is not included in HapMap, but its location would be between 
rs7364220 and rs4253701. Based on HapMap data, therefore, the six SNPs included in this 
study appear to adequately cover the majority of PPARA despite the loss of eight tag SNPs. 
By definition, tag SNPs should show minimal LD in the LIBCSP since they were 
selected to be maximally informative (r2 < 0.80) using PGA data (with the exception of 
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rs1800206, which was forced into the program because of its functionality). Any 
polymorphisms with an r2 greater than 0.80 would, therefore, reflect deviations from the PGA 
population and would create doubt on the applicability of using the PGA population as the 
reference population for tag SNP selection. LD in the LIBCSP is consistent with expected 
results with all polymorphisms showing low pair-wise correlation in both cases and controls. 
Therefore, the PGA population is an appropriate reference population for this study. 
Among controls, all polymorphisms were in Hardy-Weinberg Equilibrium (p>0.05). 
For the survival analyses, however, two SNPs (rs1800206 and rs4253760) showed 
deviations from HWE with p-values of 0.03 and 0.01 using a permuted version of the exact 
test, respectively, in the cases. These deviations will be present in regions of association 
and suggest that underlying evolutionary selection factors could be influencing the 
distribution of these genotypes in this population [195, 233].  
Lastly, approximately 71.2% and 71.5% of cases and controls respectively had DNA 
available for these analyses. Thus, it is possible our results may not be applicable to all 
women. However, in analyses in which we compared risk factors for breast cancer among 
all women in the study as compared with those among women who donated blood, similar 
results were found. Similarly, in a comparison of tumor characteristics and other clinical 
indicators for survival, little difference was noted between all cases and cases who donated 
blood. Thus, restricting analyses to those who donated blood does not appear to bias results 
but does influence the precision of the effect estimates. 
8.2.2 Recall bias 
Reported weight at age 50 and other past exposures may be subject to recall bias 
and non-differential misclassification since disease diagnosis has occurred before exposure 
ascertainment. Several studies have found a high degree of recall in weight over time [214-
216] although it has been suggested that underweight women may overestimate their past 
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weight while overweight women may underestimate their past weight [216]. Additionally, 
aspirin use may be subject to misclassification if subjects were taking the drug periodically 
or used more than one NSAID [234]. Misclassification in these exposures is unlikely to bias 
the interaction models, however, since misclassification will not differ by genotype status. 
Additionally, the main gene effect analyses will not be affected by recall or diagnostic bias 
since laboratory personnel were blinded to case-control status and participants were 
unaware of their PPARA genotype. Thus, recall bias will minimally impact the results of this 
dissertation. 
8.2.3 Study Power 
For the case-control analyses, study power was sufficient to detect an association for 
both the main gene effect and the interaction models. Power was also adequate for the 
common haplotypes but limited for the haplotypes that occurred in less than 5% of the 
population. Similarly, interaction models for the functional SNP, rs1800206, were also 
limited because of its low prevalence in this population. 
For the main gene effect survival analyses, study power was more than sufficient to 
detect an association. Study power was limited for the haplotype and effect modification 
survival analyses, however, and the hazard ratios for these analyses were extremely 
imprecise. Therefore, we consider the haplotype and interaction models in the survival 
analyses to be exploratory and it would be difficult to draw any conclusions based on these 
findings alone. Our results do suggest, however, that further investigation of PPARA in 
another larger cohort of breast cancer survivors is warranted.  
The power constraints in the interaction survival models are a function of three 
different factors: (1) the low MAFs for these polymorphisms, (2) high breast cancer survival 
rates, and (3) the limited availability of select clinical features from the follow-up interview. 
The MAFs for the six polymorphisms ranged from 5.4% to 22.4%. When these 
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polymorphisms are then stratified by characteristics that occur in less than 25% of the 
population, several small cell sizes result. This imbalance is further compounded by the high 
overall survival rates observed in this cohort and in SEER [232]. As mentioned earlier, 132 
cases were deceased in these analyses. When these cases are stratified by genotype and 
then by possible modifiers, cells for select variables, including treatment and stage, contain 
less than ten observations. Treatment data is only available for approximately 750 
genotyped cases of which only 56 were deceased. While all genotyped cases have stage 
information, only seven in situ cases were deceased. Consequently, the in situ stratum was 
severely imbalanced and estimates were very imprecise. In summary, based on these three 
factors, only 43% power is obtained when the modifier is found in 25% of the population for 
the even the most common polymorphism in this cohort.  
8.3 FUTURE DIRECTIONS 
This dissertation implicated rs4253760 in both breast cancer development and 
survival. Although this SNP is located in the fifth intron of the gene, it is highly correlated 
with ten other polymorphisms, none of which have known functionality. Therefore, the 
biological relevance of this particular polymorphism has not been established. The 
consistency of these results for both the survival and case-control analyses is very 
provocative and deserves further investigation. 
8.3.1 Replication 
This dissertation is the first to examine the associations between PPARA and breast 
cancer incidence and survival. While our use of semi-Bayesian techniques reduces the 
probability of false positives, further replication is needed to confirm our findings. 
Genotyping error and limited power (particularly for the survival analyses) could be 
responsible for these results. Therefore, it is important to replicate these associations in a 
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different cohort with a larger sample size to ensure our findings reflect a true biological 
relationship. Further, given the poor performance of mass spectrometry in this population, it 
may be important to use different genotyping methods to improve concordance with blinded 
replicates, including Illumina genotyping. Lastly, this study only investigated single 
nucleotide polymorphisms; however, insertions or deletions could also play a role in disease 
development and may be important to include in future analyses. 
8.3.2 Expansion to the PPAR family 
Other members of the PPAR family may be involved in breast cancer incidence and 
survival. In particular, among the three PPAR genes, research has focused primarily on 
PPAR-gamma (PPARG), which is involved in adipocyte differentiation. PPARG agonists 
have demonstrated strong anti-diabetic effects, suggesting it is involved in insulin regulation 
[149]. In a meta-analysis of 16 family-based studies that examined the association between 
a PPARG polymorphism that results in a proline to alanine substitution at codon 12 
(Pro12Ala) and Type 2 diabetes, a genotype relative risk of 0.79 (p<0.001, no confidence 
intervals provided) for the Ala allele was observed [235]. PPARG may also hinder estrogen 
biosynthesis in human breast tissue by inhibiting expression of the gene encoding 
aromatase [236] and have anti-inflammatory effects although this is remains controversial 
[149].  
Genetic variants of PPARG have been examined in association with thyroid, 
endometrial, prostate and colorectal cancers [237-242], but only one study has investigated 
its association with body mass and breast cancer incidence [243]. This case-control study 
was nested within the Nurses Health Study to examine the relationship between the 
Pro12Ala polymorphism, breast cancer and body weight in 725 cases and 953 controls. This 
polymorphism has been suggested to have a functional effect, leading to a decrease in DNA 
binding and transactivation activity. Weight gain since the age of 18 appeared to be the 
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most strongly associated with PPARG genotype, but no other weight gain intervals were 
presented. The authors report an odds ratio of 1.08 (95% CI: 0.85-1.38) for Ala allele 
carriers compared to non-carriers using conditional logistic regression and adjusting for 
matched factors (age, menopausal status, postmenopausal hormone use, date of blood 
draw, time of blood draw and fasting status).  
PPARG has also been implicated in breast cancer survival. In fact, a pilot study was 
recently published examining the impact of rosiglitazone, a drug therapy used in the 
treatment of diabetes that has been shown to target PPARG gene expression, in women 
with breast cancer [244]. Although the PPAR gamma agonist did not reduce tumor cell 
proliferation, the study highlights the interest in PPARG and breast cancer survival. Several 
other clinical trials have also been published examining PPAR gamma agonists in 
connection to prostate, breast and colorectal cancer. 
As with many functional SNPs, the Pro12Ala polymorphism is relatively rare with 
minor allele frequencies of 7.5% and 6.8% in the HapMap CEU and ED Seattle SNP 
populations respectively. Therefore, statistical power is a concern. Given the interest in this 
gene and the fact it has already been genotyped successfully in the Long Island population, 
however, investigating this SNP in connection to breast cancer incidence and survival is the 
natural follow-up to this dissertation. As a second component to this analysis, gene-gene 
interaction could also be explored, looking at the functional PPARA SNP (rs1800206, 
L162V) in combination with the PPARG Pro12Ala SNP. Sample size would definitely be an 
issue for this interaction, but it is an intriguing exploratory analysis to consider. 
Lastly, it would be interesting to explore all three PPAR genes (PPAR delta, gamma 
and alpha) together in a pathway-based multigenic approach. Recently, classification and 
regression tree (CART) analysis [245] has emerged as a tool for identifying individuals at 
high risk for disease development. This approach could be applied on a much larger scale to 
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include several other genes, such as leptin or insulin-like growth factor-1, on the 
inflammatory or insulin resistance pathways.  
8.3.3 Survival 
As discussed above, the major shortcoming of the survival analyses, particularly for 
the interaction models, was our limited study power. This limitation could perhaps be 
minimized by extending the follow-up time from five years to ten. Vital status for this 
dissertation was ascertained through December 31, 2002; however, additional follow-up 
could be undertaken through linkages with the National Death Index (NDI) to determine the 
long-term vital status of the cohort. The results of this additional follow-up time could 
potentially boost the statistical power of the survival analyses by increasing the number of 
deaths observed in the study. In fact, vital status information through the end of 2005 has 
already been requested from the NDI for this cohort, so that this direction could be explored.  
8.4 SUMMARY 
This study is the first to examine PPARA polymorphisms in connection to breast 
cancer incidence and survival. Interactions with BMI, NSAID use and post-menopausal 
weight gain were also explored. Our results suggest that PPARA does influence breast 
cancer development and prognosis. Replication in another cohort is warranted to confirm 
these findings. In particular, rs4253760 should be further investigated to better elucidate its 
role in disease development and progression. 
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FIGURE 8.1. PPARA linkage disequilibrium from HapMap version B36 in the CEU population 
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APPENDICES 
APPENDIX A: TABLE OF PPAR-ALPHA STUDIES 
 TABLE A.1. Table of epidemiologic literature on PPAR-alpha for all health outcomes 
Author 
(Year) 
Study 
Design 
Study Population SNPs Outcome(s) Unadjusted Association Adjusted Association Adjusted for 
confounders 
        
Shin MJ 
(2007) 
[177] 
trial 609 Caucasians 
and 335 African 
Americans who 
participated in the 
Cholesterol and 
Atherosclerosis 
Pharmacogenetics 
Study, simuvastatin 
trial 
 L162V 
 rs42537
28 
 apo-CIII 
(µg/mL) 
 Triglycerides 
(mg/dL) 
 LDL (mg/dL) 
 HDL (mg/dL) 
 MAF=1.5% in AAs and 
6.1% in Caucasians for 
L162V 
 TG: 120.9±6.7 CC 
139.7±13.2 GC/GG 
 LDL: 124.5±3.8 CC 
122.5±7.4 GC/GG 
 HDL: 55.0±1.5 CC 
59.6±2.9 GC/GG 
 apoCIII: 12.7±0.5 CC 
15.1±0.9 GC/GG 
 age 
 sex 
 BMI 
 Waist 
 Smoking 
 Alcohol 
 Exercise 
 Estrogen 
use 
 Hyprtension 
 Type II DM 
        
Uthurralt 
J (2007) 
[175] 
Cross-
section 
601 young 
Caucasian adults 
(mean age=24 
years) 
 L162V  Triglycerides 
 HDL 
 LDL 
 Fasting glucose 
 Fasting insulin 
 BMI 
 MAF for L162V = 7.5%  TG: 102.92±4.49 CC 
146.80±11.84 CG 
 HDL: 48.13±0.56 CC 
44.67±1.48 CG 
 LDL: 96 CC 
98 CG 
 BMI: 25.1 CC 
29.5 CG in men 
 Glu: 85.78±0.41 CC 
83.65±1.03 CG in 
women 
 age 
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 TABLE A.1. Table of epidemiologic literature on PPAR-alpha for all health outcomes 
Author 
(Year) 
Study 
Design 
Study Population SNPs Outcome(s) Unadjusted Association Adjusted Association Adjusted for 
confounders 
        
Manresa 
JM 
(2006) 
[178] 
Cross-
section 
1748 participants 
(910 women, 838 
men) between 
9/94-3/96 in Spain 
 L162V  HDL (mg/dL) 
 LDL (mg/dL) 
 Triglycerides 
(mg/dL) 
 BMI 
 Type II DM 
 MAF for L162V = 4.1% 
 Mean (SD) 
 HDL: 53.0 (15.1) CC 
49.0 (15.7) GC/GG 
 BMI: 26.4 (4.3) 
27.1 (4.6) 
 LDL: 150 (39) CC 
150 (43) GC/GG 
 TG: 93 (68, 127) CC 
93 (73, 128) 
GC/GG 
 DM: 144 (13.0%) CC 
12 (12.6%) GC/GG 
  
        
Tai ES 
(2006) 
[179] 
Trial 827 men from the 
Veterans Affairs 
HDL Intervention 
Trial, randomized 
to receive 
gemfibrozil (n=413, 
placebo; n=414, 
gemfibrozil) 
 L162V  LDL (mg/dL) 
 HDL (mg/dL) 
 Triglycerides 
(mg/dL) 
 BMI 
 Diabetes 
 apoAI (mg/dL) 
 apoB (mg/dL) 
 Combined CVD 
endpts (stroke, 
non-fatal MI, 
CHD death) 
 MAF for L162V = 6.8% 
 Mean (SD) 
 BMI: 29.1 (4.5) CC 
29.8 (5.0) GC/GG 
 LDL: 114 (22) CC 
113 (23) GC/GG 
 HDL: 31.8 (5.2) CC 
30.7 (4.9) GC/GG 
 apoAI: 107 (17) CC 
104 (16) GC/GG 
 apoB: 97 (20) CC 
96 (20) GC/GG 
 TG: 152 (86) CC 
159 (89) GC/GG 
 DM: 25% CC 
37% GC/GG 
 HR=1.63 (0.82, 3.24) for 
combined end points for 
V162 carriers vs. non-
carriers among individuals 
with no DM or insulin 
resistance 
 HR=0.40 (0.17, 0.92) for 
combined end points for 
V162 carriers vs. non-
carriers among individuals 
with DM or insulin 
resistance 
 Age 
 Hypertension 
 Smoking 
 BMI 
 Lipids 
 Tmt group 
 
        
  
144
 TABLE A.1. Table of epidemiologic literature on PPAR-alpha for all health outcomes 
Author 
(Year) 
Study 
Design 
Study Population SNPs Outcome(s) Unadjusted Association Adjusted Association Adjusted for 
confounders 
        
Doney 
AS 
(2005) 
[176] 
Cohort 1810 Caucasian 
subjects with Type 
II DM from the Go-
DARTS Study 
 L162V 
 G2528C 
 BMI 
 LDL (mmol/L) 
 HDL (mmol/L) 
 Triglycerides 
 Non-fatal MI 
 Age at 
diagnosis with 
Type II DM 
 MAF=6.9% L162V 
 BMI: 30.5 (30.2, 30.7) 
CC 
30.7 (30.0, 31.4) 
CG 
 LDL: 2.89 (2.84, 2.92) 
CC 
2.89 (2.78, 3.00) 
CG 
 HDL: 1.22 (1.20, 1.24) 
CC 
1.23 (1.20, 1.28) 
CG 
 Tri: 2.7 (2.6, 2.8) CC 
2.8 (2.6, 3.1) CG 
 HR=0.31 (0.10, 0.93) for 
non-fatal MI in V162 
carriers vs. non-carriers 
 Βinsulin = 2.6 (0.2, 5.1) for 
age at diagnosis with Type 
II DM in V162 carriers vs. 
non-carriers 
 
 Smoking 
 Gender 
 Age 
 Insulin tmt 
 Prevalent 
angina 
 Prevalent 
cerebro-
vascular 
disease 
 Prevalent MI 
        
Flavell 
DM 
(2005) 
[152] 
Cohort 912 Caucasian 
Type II diabetics, 
who are 
participating in the 
UDACS and EDSC 
studies in Great 
Britain. Study 
period not stated. 
 L162V 
 A/C 
Intron 1 
 G/C 
Intron 7 
 Age of Onset 
 Progression of 
DM2 
 Individual variants not 
associated with 
outcomes 
 12.5% of the participants 
were carriers of the 
V162 allele 
 age at dx: 52.7±0.5 CC 
54.7±1.2 GC/GG 
For C-L-C haplotype 
compared to A-L-G: 
 -5.86±2.57 (p=0.02) effect 
on age at dx 
 OR=3.75 (1.65, 8.56) for 
early age at dx 
 Family 
history of 
diabetes 
 Sex 
 Smoking 
        
Tai ES 
(2005) 
[161] 
Cohort 2106 men and 
women who 
participated in the 
Framingham 
Offspring Study 
and went to their 5th 
exam from 1992-
1995 
 L162V  Interaction 
between PUFA 
intake and 
L162V 
 LDL, HDL, 
Triglycerides 
 13.7% of men and 
13.1% of women were 
carriers of the V162 
allele 
 PPARA and PUFA intake 
interacted with plasma 
triglyceride levels 
(p=0.048) and apoC-III 
(p<0.01) 
 No interactions were 
found for LDL-C, HDL-C, 
or total cholesterol 
 Gender 
 Age 
 Family 
 BMI 
 Smoking 
 Alcohol 
consumption 
 Drug use 
 Energy 
 Total fat 
intake 
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 TABLE A.1. Table of epidemiologic literature on PPAR-alpha for all health outcomes 
Author 
(Year) 
Study 
Design 
Study Population SNPs Outcome(s) Unadjusted Association Adjusted Association Adjusted for 
confounders 
        
Chen S 
(2004) 
[153] 
Trial 372 participants in 
the LCAS trial and 
received 
fluvastatin. Study 
location and time 
period were not 
provided. 
 L162V 
 A/C 
Intron 1 
 Total 
cholesterol 
 HDL-C 
 LDL-C 
 Triglyceride 
 No associations found 
between PPARA and 
lipoprotein levels (data 
not presented) 
  
        
Foucher 
C (2004) 
[154] 
Trial  155 participants in 
DAIS, a 
multinational study, 
who were 
randomized to 
receive fenofibrate 
and had the SNPs 
for the genes of 
interest 
 L162V 
 G/C 
Intron 7 
 
 Reduction of 
triglyceride levels 
> 30% vs. ≤30% 
 
 92.9% vs. 91.4% of high 
vs. low responders to 
fenofibrate with the L/L 
allele (p>0.05) 
 84.7% vs. 68.8% of high 
vs. low responders with 
the G/G allele (p<0.05) 
 OR=3.19 (1.28-7.98), 
comparing Intron 7 G/G vs. 
G/C+C/C  
 No associations found with 
L162V (data not shown) 
 
 Baseline TG 
level 
 CEPT, 
apoE, LPL 
and LIPC 
SNPs 
 Gender 
 Age 
 BMI 
 Smoking 
 Baseline 
HbA1c 
        
Gouni-
Berthold 
I (2004) 
[163] 
Case-
control 
842 subjects 
recruited between 
1999 and 2002 in 
Cologne; 404 
subjects with DM-2 
were matched with 
438 non-diseased 
on sex and age.  
 L162V  Atherosclerosis 
 Lipoprotein 
levels 
 Obesity 
 9.41% vs. 11.42% with 
the V162 allele in cases 
vs. controls (p=0.34) 
 In DM patients: 
 BMI: 28.8±5.1 CC 
27.8±4.9 GC/GG 
 LDL: 140±46 CC 
135±44 GC/GG 
 HDL: 50±17 CC 
51±18 GC/GG 
 In non-DM controls: 
 BMI: 26.5±3.7 CC 
26.7±3.8 GC/GG 
 LDL: 171±69 CC 
175±51 GC/GG 
 HDL: 60±17 CC 
62±14 GC/GG 
 OR=0.49 (0.21-1.15) for 
atherosclerosis in V162 
carriers vs. non-carriers 
among patients with DM 
 OR=0.44 (0.18-1.11) for 
CHD in V162 carriers vs. 
non-carriers among 
patients with DM 
 OR=0.68 (0.20, 2.33) for 
atherosclerosis in V162 
carriers vs. non-carriers 
among healthy controls 
 OR=1.03 (0.12, 8.70) for 
CHD in V162 carriers vs. 
non-carriers among 
healthy controls 
 CHD family 
history 
 Age 
 LDL/HDL 
ratio 
 Hyprtension 
 BMI 
 Sex 
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 TABLE A.1. Table of epidemiologic literature on PPAR-alpha for all health outcomes 
Author 
(Year) 
Study 
Design 
Study Population SNPs Outcome(s) Unadjusted Association Adjusted Association Adjusted for 
confounders 
        
Robitaille 
J (2004) 
[164] 
Cross-
section 
632 men recruited 
through the 
Chicoutimi Hospital 
Lipid Clinic in 
Canada. Study 
period not 
specified. 
 L162V  Metabolic 
Syndrome 
 BMI 
 LDL (mmol/L) 
 HDL (mmol/L) 
 Triglycerides 
(mmol/L) 
 apoB (g/L) 
 fasting glucose 
(mmol/L) 
 Frequency of V162 
allele was similar in 
diseased (n=281) vs. not 
diseased (n=351) 
 10.6% of subjects were 
V162 allele carriers 
 BMI: 27.0±4.3 CC 
26.8±4.1 GC/GG 
 LDL: 3.84±1.01 CC 
3.72±0.99 GC/GG 
 HDL: 1.01±0.34 CC 
0.97±0.35 GC/GG 
 TG: 2.63±2.72 CC 
3.26±3.02 GC/GG 
 apoB: 1.15±0.25 CC 
1.20±0.25 GC/GG 
 glucose: 5.36±0.72 CC 
5.39±0.75 GC/GG 
 Carriers of V162 allele had 
higher triglyceride levels 
(p<0.0001) 
 V162 had higher freq 
among men with 
abdominal obesity, 
hypertriglyceridemia, and 
low HDL-C simultaneously 
 Age 
 BMI 
        
Bosse Y 
(2003) 
[165] 
Cohort 663 subjects 
enrolled in the 
Quebec Family 
Study (241 nuclear 
families). Time 
period not stated. 
 L162V  Fasting glucose 
(mmol/L) 
 Fasting insulin 
(pmol/L) 
 15% of the cohort are 
carriers of the V162 
allele 
 Geo mean (95% CI) 
 Glucose: 5.19 (5.06, 5.31) 
CC 
5.06 (4.86, 5.26) 
GC/GG 
 Insulin: 63.1 (56.2, 70.9) 
CC 
61.9 (50.2, 76.3) 
GC/GG 
 Age 
 Gender 
 BMI 
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 TABLE A.1. Table of epidemiologic literature on PPAR-alpha for all health outcomes 
Author 
(Year) 
Study 
Design 
Study Population SNPs Outcome(s) Unadjusted Association Adjusted Association Adjusted for 
confounders 
        
Bosse Y 
(2003) 
[167] 
Cohort 698 subjects 
enrolled in the 
Quebec Family 
Study (253 nuclear 
families). Time 
period not stated. 
 L162V  Obesity, BMI > 
30 vs. BMI ≤ 30 
 % body fat 
 BMI 
 Weight (kg) 
 15% of the cohort are 
carriers of the V162 
alleles 
 OR=1.46 (p=0.15; no CI) 
of obesity (BMI > 30 vs. 
BMI ≤ 30) in V162 
carriers vs. non-carriers 
 In women: 
 BMI: 28.1±8.6 CC 
25.9±6.3 GC/GG  
 Weight: 71.4±22.1 CC 
65.6±15.3 GC/GG 
 OR=1.77 (p=0.041, no CI) 
of obesity (BMI > 30 vs. 
BMI ≤ 30) in V162 carriers 
vs. non-carriers 
 Age 
 Gender 
 Alcohol 
consumption 
        
Brune S 
(2003) 
[155] 
Case-
control 
104 AD cases were 
recruited from the 
University of Bonn 
hospital; 123 
healthy controls 
were identified from 
the general 
population. Time 
period not stated. 
 L162V 
 G/C 
Intron 7 
 Alzheimer 
Disease 
 14% vs. 7% with the 
V162 allele in cases vs. 
controls (p=0.03) 
 17% vs. 19% with the 
Intron 7 C allele in cases 
vs. controls (p=0.82) 
 OR=2.24 (1.12-4.50) of 
AD, comparing presence 
vs. absence of V162 allele 
 Sex 
 Age 
        
Bosse Y 
(2002) 
[166] 
Trial  63 obese 
participants were 
randomized to 
receive placebo 
(n=31) or 
gemfibrozil (600 
mg) (n=32) in 
Quebec, Canada. 
Time period not 
stated.  
 L162V  Triglycerides 
(mmol/L) 
 LDL (mmol/L) 
 HDL (mmol/L) 
At baseline 
 17% V162 allele 
frequency in all subjects 
 TG: 2.66±0.80 CC 
2.34±0.59 GC/GG 
 LDL: 0.39±0.10 CC 
0.34±0.04 GC/GG 
 HDL: 0.23±0.05 CC 
0.21±0.03 GC/GG 
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Author 
(Year) 
Study 
Design 
Study Population SNPs Outcome(s) Unadjusted Association Adjusted Association Adjusted for 
confounders 
        
Brisson 
D (2002) 
[160] 
Cohort 292 
hypertriglyceridemi
c individuals who 
had underwent a 3-
month therapy with 
fenofibrate in 
Quebec, Canada. 
No time period 
given. 
 L162V  post-tmt TG>2.0 
mmol/l 
 Plasma TC/HDL-
C ratio > 5 
 27% of individuals in the 
cohort were carriers of 
the V162 allele 
 OR=1.02 (0.55-1.90) of 
residual hypertrigly for 
carriers vs. non-carriers 
 OR=1.19 (0.61-2.33) of 
TC/HDL-C>5 for carriers 
vs. non-carriers following 
fenofibrate treatment 
 Age 
 Gender 
 TC/HDL-C 
before tmt 
        
Eurlings 
P (2002) 
[157] 
Case-
control 
102 FCHL 
probands and 124 
spouses (controls) 
were recruited from 
two lipid clinics in 
the Netherlands. 
Study period not 
provided. 
 L162V 
 G/A 
Intron 2 
 G/C 
Intron 7 
 Familial 
combined 
hyperlipidemia 
 BMI 
 HDL (mmol/L) 
 Triglycerides 
(mmol/L) 
 apoB (g/L) 
 The V162 allele was 
present in 2% of cases 
and 4.8% of controls 
(p=0.10). No further 
analyses were 
conducted due to small 
numbers. 
 In FCHL patients: 
 BMI: 27.3±3.2 CC 
30.1±3.5 GC/GG 
 HDL: 0.91±0.25 CC 
1.14±0.30 GC/GG 
 TG: 4.35±8.27 CC 
1.74±0.27 GC/GG 
 apoB: 1.40±0.32 CC 
1.23±0.61 GC/GG 
 In healthy spouses: 
 BMI: 25.2±3.9 CC 
26.6±3.4 GC/GG 
 HDL: 1.23±0.38 CC 
1.12±0.42 GC/GG 
 TG: 1.31±0.59 CC 
1.47±0.73 GC/GG 
 apoB: 0.99±0.25 CC 
1.01±0.30 GC/GG 
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Author 
(Year) 
Study 
Design 
Study Population SNPs Outcome(s) Unadjusted Association Adjusted Association Adjusted for 
confounders 
        
Flavell D 
(2002) 
[158] 
Trial & 
Cohort 
 395 Finnish men 
who participated in 
LOCAT and were 
randomized to 
receive gemfibrozil 
to investigate its 
effect on 
atherosclerosis 
progression 
 3012 men who 
participated in the 
Second Northwick 
Park Heart Study 
in the United 
Kingdom (7 year 
study period) and 
examined risk of 
ischemic heart 
disease 
 L162V 
 G/C 
Intron 7 
 Plasma lipid 
concentrations 
 Atherosclerosis 
progression, 
measured as the 
change in 
average 
diameter of 
coronary 
segments 
(∆ADS) and 
change in 
minimum luminal 
diameter (∆MLD) 
 IHD risk 
 Triglyceride 
(mmol/L) 
 LDL (mmol/L) 
 HDL (mmol/L) 
 apoB 
 
 For LOCAT: freq of 
V162 = 2.8% and Intron 
7 C allele = 13.4% 
 For NPHS2, freq of 
V162 = 6.3% and C 
allele = 17.4% 
 No associations with 
lipid concentrations at 
baseline or following tmt 
with gemfibrozil 
 For ∆ADS, V162 carriers 
showed higher, positive 
diameter changes 
(p=0.022) while C allele 
carriers showed reduced 
diameter changes 
(p=0.095) 
 For ∆MLD, V162 were 
protective (p=0.064) 
while C allele carriers 
showed greater 
decreases in MLD 
(p=0.003) 
 In LOCAT 
 TG: 1.82±0.73 CC 
1.52±0.71 GC/GG 
 LDL: 3.42±0.60 CC 
3.41±0.54 GC/GG 
 HDL: 1.02±0.17 CC 
1.05±0.17 GC/GG 
 In NPHS2 
 TG: 1.80±0.98 CC 
1.79±0.91 GC/GG 
 HDL: 0.80±0.24 CC 
0.80±0.25 GC/GG 
 apoB: 0.88±0.28 CC 
0.84±0.28 GC/GG 
 HR=0.75 (0.45, 1.26) of 
IHD risk comparing V162 
allele carriers to non-
carriers 
 HR=1.83 (0.96, 3.51) of 
IHD risk comparing Intron 
7 C allele carriers vs. non-
carriers 
 Age 
 BMI 
 Cholesterol 
 Fibrinogen 
 Smoking 
 Systolic BP 
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Author 
(Year) 
Study 
Design 
Study Population SNPs Outcome(s) Unadjusted Association Adjusted Association Adjusted for 
confounders 
        
Jamshidi 
Y (2002) 
[159] 
Trial  A subset of 908 
participants in the 
LEADER trial in 
Great Britain were 
genotyped. 608 
received 
bezafibrate while 
300 were a random 
subset from the 
placebo group. No 
time period 
specified. 
 L162V 
 G/A 
Intron 2 
 G/C 
Intron 7 
 Triglycerides 
(mmol/L) 
 Decrease in TG 
 Decrease in 
Fibrinogen 
(among those 
who received 
active drug) 
 MAF for V162 = 7% 
 In DM patients—mean 
(SD) 
 TG: 2.63 (1.35) CC 
2.48 (1.07) GC/GG 
 In non-DM individuals 
 TG: 2.33 (1.14) CC 
2.55 (1.15) GC/GG 
 Decrease in TG among 
those who received 
bezafibrate: 0.58 (0.79) 
CC 
0.82 (0.80) GC/GG 
 Decrease in fibrinogen 
(g/L) among those who 
received bezafibrate: 
0.40 (0.61) CC 
0.40 (0.55)  
 
 In the diabetic group 
(n=158), Intron 7 C allele 
carriers had lower baseline 
TG levels than non-carriers 
(2.26 vs. 2.83, p=0.048) 
 No differences in baseline 
TG levels were evident 
between V162 allele 
carriers vs. non-carriers 
(2.48 vs. 2.63, p=0.77) 
 In the non-diabetic group 
(n=654), no differences in 
baseline TG levels were 
evident in Intron 7 C allele 
carriers vs. non-carriers 
(2.42 vs. 2.33, p=0.20) 
 V162 allele carriers were 
had higher TG levels (2.55 
vs. 2.33, p=0.022) 
 Age 
 BMI 
        
Nieters A 
(2002) 
[170] 
Nested 
CCS 
154 cases and 154 
controls nested 
within the EPIC-
Heidelberg cohort 
of 25,544 
participants. 
Participants were 
recruited in 1998. 
 L162V  Obesity, 
measured as 
BMI ≥ 35 kg/m2 
 OR=1.35, no CI 
presented 
 χ2 p=0.45 for freq of 
L162 homozy vs. V162 
carriers (11.1% in cases; 
8.0% in controls) 
 
 OR=1.45 (p=0.36, no CI 
presented) 
 
 Sports 
activity 
 Occ activity 
 Daily hours 
of TV 
 Energy 
intake 
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Tai ES 
(2002) 
[162] 
Cohort 2372 men and 
women who 
participated in the 
Framingham 
Offspring Study and 
went to their 5th 
exam from 1992-
1995 
 L162V  LDL (mg/dL) 
 HDL (mg/dL) 
 apoB (g/L) 
 V162 allele frequency in 
cohort was 6.9% 
 In women—mean (SD) 
 LDL:124 (1.07) CC 
128 (3.01) GC/GG 
 HDL: 58.5 (0.50) CC 
57.1 (1.18) GC/GG 
 apoB: 108 (0.95) CC 
112 (2.88) GC/GG 
 In men, the V162 allele 
was associated with higher 
levels of LDL (p<0.001), 
apoB (p<0.01) and apoC-
III (p<0.01) but no 
differences in triglyceride 
levels were noted (p=0.19) 
 In women, only apoB 
levels achieved statistical 
significance (p=0.03) 
although a trend of higher 
lipoprotein levels in 
carriers was evident. 
 Familial 
relationships 
 Age 
 BMI 
 Smoking 
 Drug use 
        
Evans D 
(2001) 
[168] 
Cross-
section 
 381 patients from 
a medical clinic in 
Hamburg, 
Germany 
 369 morbidly 
obese patients 
who are 
undergoing gastric 
banding surgery in 
Dinslaken 
 199 Blood Donors 
in Hamburg 
 L162V  Obese (BMI>30) 
 DM2 
 
 No significant 
differences in 
frequencies were noted 
for either obesity or DM2 
 7% vs. 6% V162 allele 
freq in obese vs. non-
obese individuals 
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Evans D 
(2001) 
[169] 
Cross-
section 
 370 morbidly 
obese patients 
who are 
undergoing gastric 
banding surgery in 
Dinslaken 
 199 Blood Donors 
in Hamburg 
 112 patients with 
mixed 
hyperlipoproteina
mia 
 76 patients with 
hypercholesterole
mia 
 154 patients with 
DM2 (all from 
Hamburg) 
 L162V  DM2 
 Morbid obesity 
 Glucose < 126 
mg/dl 
 The allele freq was 6% 
in the cohort combined 
 No difference in freq 
between DM2 patients 
and non-cases 
 In women with DM 
 BMI: 29±7 CC 
24±3 GC/GG 
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Vohl MC 
(2000) 
[174] 
Case-
control 
 121 Caucasians 
with DM2 were 
age and sex-
matched with non-
diseased controls 
in Quebec, 
Canada in 1998 
 193 healthy 
Caucasian men 
from Quebec were 
also investigated. 
No time period 
was specified. 
 L162V  BMI 
 Fasting glucose 
(mmol/L) 
 Fasting insulin 
(pmol/L) 
 LDL (mmol/L) 
 HDL (mmol/L) 
 Triglycerides 
(mmol/L) 
 apoB 
 In the second sample, 
the V162 allele 
frequency was 6.6%. 
 Sample 1—
DM&Controls 
 BMI: 28.9±4.1 CC 
28.8±4.5 GC/GG 
 Glucose: 5.89±1.61 CC 
5.73±1.11 GC/GG 
 Insulin: 134.5±115.7 CC 
133.2±100.4 
GC/GG 
 LDL: 4.17±1.18 CC 
4.55±1.19 GC/GG 
 HDL: 0.98±0.35 CC 
1.00±0.33 GC/GG 
 TG: 3.58±3.23 CC 
3.30±2.65 GC/GG 
 apoB: 1.19±0.26 CC 
1.28±0.27 GC/GG 
 Sample 2—DM 
 BMI: 29.9±4.3 CC 
29.1±2.9 GC/GG 
 Glucose: 5.41±0.56 CC 
5.33±0.33 GC/GG 
 Insulin: 109.9±83.7 CC 
85.8±42.5 GC/GG 
 LDL: 3.49±0.74 CC 
3.86±0.56 CG/GG 
 HDL: 0,93±0.20 CC 
0.91±0.17 GC/GG 
 TG: 2.17±1.16 CC 
1.98±0.80 GC/GG 
 apoB: 1.07±0.24 CC 
1.18±0.16 GC/GG 
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APPENDIX B: BREAST CANCER SURVIVAL AND OBESITY LITERATURE REVIEW 
 
TABLE B.1. Breast cancer survival and obesity literature (2003-Present) 
Author 
(Year) 
Study 
Population 
Follow-up Obesity timepoint Pre-menopausal 
Associations 
Post-menopausal 
Associations 
Adjusted for 
confounders* 
       
Cleveland R 
(2007) [112] 
1,508 cases in 
the Long Island 
Breast Cancer 
Study Project 
Mean follow-
up 66.7 
years 
BMI one year prior 
to diagnosis (BMI < 
24.9 (ref), 25.0-
29.9, ≥ 30) 
 HR=2.62 (1.26, 5.45)* 
for overall survival in 
women with a BMI ≥ 30 
compared to those with 
a BMI < 24.9 
 HR=1.63 (1.08, 2.45)* 
for overall survival in 
pre- and post- 
menopausal women 
with a BMI ≥ 30 
compared to those 
with a BMI < 24.9 
 Age 
 History of 
hypertension 
       
Majed B 
(2007) [114] 
Patients at Curie 
Institute 1981-99 
for a total of 
14,709 patients 
Maximum 
follow-up of 
20 years; 
median 
follow-up of 8 
years 
BMI at diagnosis 
(BMI < 24.9 (ref), 
25.0-30, ≥ 30) 
 HR=1.32 (1.22, 1.42)* for overall survival in pre- and 
post- menopausal women with a BMI between 25.0 
and 29.9 compared to those with a BMI < 24.9 
 HR=1.53 (1.37, 1.72)* for overall survival in pre- and 
post- menopausal women with a BMI ≥ 30 
compared to those with a BMI < 24.9 
 Age 
 Tumor dimension 
 Node involvement 
 Menopausal status 
 Year diagnosed 
 ER/PR status 
 Tumor extension 
 Scarf-Bloom 
Richardson Grade 
       
Reeves GK 
(2007) [115] 
1.2 million UK 
women recruited 
into the Million 
Women Study 
(1,179 pre-
menopausal, 
5,629 post-
menopausal) 
Median 7.0 
years follow-
up 
BMI at baseline 
(BMI < 22.5, 22.5-
24.9 (ref), 25.0-
27.4, 27.5-29, ≥ 30) 
 HR=0.91 (0.49, 1.70)* 
for overall survival in 
individuals with a BMI 
between 27.5 and 29.0 
compared to those with 
a BMI between 18.5 and 
24.9 
 HR=0.64 (0.34, 1.21)* 
for overall survival in 
individuals with a BMI ≥ 
30 compared to those 
with a BMI between 18.5 
and 24.9 
 HR=1.22 (0.99, 1.49)* 
for overall survival in 
individuals with a BMI 
between 27.5 and 
29.0 compared to 
those with a BMI 
between 18.5 and 
24.9 
 HR=1.49 (1.27, 1.75)* 
for overall survival in 
individuals with a BMI 
≥ 30 compared to 
those with a BMI 
between 18.5 and 
24.9 
 Age 
 Geographic region 
 SES 
 Reproductive history 
 Smoking 
 Alcohol 
 Physical activity 
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Follow-up Obesity timepoint Pre-menopausal 
Associations 
Post-menopausal 
Associations 
Adjusted for 
confounders* 
       
       
Abrahamson 
PE (2006) 
[113] 
1,254 women 
ages 20-54 
diagnosed with 
invasive breast 
cancer between 
1990-92 in 
Atlanta or New 
Jersey 
8-10 years of 
follow-up 
BMI at diagnosis 
(BMI <18.5, 18.5-
24.9 (ref), 25.0-
29.9, ≥ 30) 
 HR=1.38 (1.04, 1.83)* 
for overall survival in 
individuals with a BMI 
between 25.0 and 29.9 
compared to those with 
a BMI between 18.5 and 
24.9 
 HR=1.65 (1.23, 2.21)* 
for overall survival in 
individuals with a BMI ≥ 
30 versus those with a 
BMI between 18.5 and 
24.9 
  Income 
 Stage 
       
Kroenke CM 
(2005) [246] 
5,204 
participants 
(1062 pre-
menopausal, 
4073 post-
menopausal) in 
the Nurses 
Health Study 
who were 
diagnosed with 
non-metastatic 
breast cancer 
from 1996-2000 
Ranged from 
2-26 years 
(median: 9 
years) 
BMI at baseline 
--Height in 1976 
and weight 
reported closest but 
prior to diagnosis 
date 
 RR=2.02 (1.13-3.61)* for 
breast cancer death in 
individuals with BMI ≥ 30 
compared to BMI 21-22 
(ref) 
 RR=1.47 (0.94-2.32)* for 
breast cancer death in 
individuals with BMI 
between 25-29 
compared to BMI 21-22 
 RR=0.88 (0.61-1.28)* 
for breast cancer 
death in individuals 
with BMI ≥ 30 
compared to BMI 21-
22 (ref) 
 RR=0.99 (0.74-1.33)* 
for breast cancer 
death in individuals 
with BMI between 25-
29 compared to BMI 
21-22 
 
 Age 
 Oral Contraceptive 
Use 
 Birth index 
 Age @ meno 
 HRT use 
 Protein intake 
 Tumor size 
 Nodal status 
 Chemotherapy 
 Tamoxifen use 
       
Loi S (2005) 
[247] 
1,101 
participants (813 
pre-menopausal, 
288 post-
menopausal) in 
the ABCFS study 
who were 
diagnosed with 
incident, primary 
breast cancer 
and lived in 
Sydney or 
Ranged from 
0.2-10.8 
years 
(median: 5 
years) 
BMI 1 year prior to 
diagnosis 
 HR=1.50 (1.00-2.26)* of 
distant recurrence in 
obese (BMI>30) 
compared to non-obese 
(BMI ≤ 30) individuals 
 HR=1.71 (1.05-2.77)* of 
mortality from any cause 
in obese versus non-
obese individuals 
 HR=2.03 (0.99-4.21)* 
of distant recurrence 
in obese (BMI>30) 
compared to non-
obese (BMI ≤ 30) 
individuals 
 HR=0.84 (0.28-2.56)* 
of mortality from any 
cause in obese versus 
non-obese individuals 
 Age 
 Tumor grade 
 Nodal Status 
 Progesterone 
receptor status 
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(Year) 
Study 
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Follow-up Obesity timepoint Pre-menopausal 
Associations 
Post-menopausal 
Associations 
Adjusted for 
confounders* 
       
Melbourne 
Australia. 
       
Whiteman 
MK (2005) 
[248] 
3,924 
participants 
(2551 pre-
menopausal, 
1373 post-
menopausal) in 
the multicenter 
CASH study who 
were diagnosed 
with primary 
breast cancer 
from 12/1/80-
12/31/82 
Followed 
until 
12/31/97 
(median: 
14.6 years) 
Adult BMI 
--Usual weight as 
an adult 
 HR=1.38 (1.05-1.80)* of 
breast cancer mortality 
in individuals with a BMI 
≥ 30 compared to BMI < 
23 
 HR=1.27 (1.05-1.52)* of 
breast cancer mortality 
in individuals with a BMI 
between 25-30 
compared to BMI < 23 
 HR=1.32 (0.94-1.83)* 
of breast cancer 
mortality in individuals 
with a BMI ≥ 30 
compared to BMI < 23 
 HR=1.23 (0.97-1.57)* 
of breast cancer 
mortality in individuals 
with a BMI between 
25-30 compared to 
BMI < 23 
 Age @ diagnosis 
 Race 
 Radiation therapy 
 History of benign 
breast disease 
 Education 
 Cancer stage 
       
Berclaz G 
(2004) [249] 
6,370 patients 
(3494 pre-
menopausal, 
2876 post-
menopausal) 
who participated 
in the 
randomized 
clinical trials of 
the International 
breast cancer 
Study Group 
Median: ~14 
years 
Not stated (most 
likely BMI at 
diagnosis) 
 HR=1.16 (1.02-1.33)* of 
disease free survival in 
obese (BMI ≥ 30) versus 
normal weight (BMI < 
25) individuals 
 HR=1.06 (0.96-1.17)* of 
disease free survival in 
overweight (BMI 
between 25-30) versus 
normal weight (BMI< 25) 
individuals 
 HR=1.22 (1.05-1.42)* of 
overall survival in obese 
versus normal weight 
individuals 
 HR=1.11 (0.97-1.24)* of 
overall survival in 
overweight versus 
normal weight 
individuals 
 HR=1.06 (0.94-1.20)* 
of disease free 
survival in obese (BMI 
≥ 30) versus normal 
weight (BMI < 25) 
individuals 
 HR=1.04 (0.94-1.16)* 
of disease free 
survival in overweight 
(BMI between 25-30) 
versus normal weight 
(BMI< 25) individuals 
 HR=1.10 (0.96-1.26)* 
of overall survival in 
obese versus normal 
weight individuals 
 HR=1.06 (0.94-1.19)* 
of overall survival in 
overweight versus 
normal weight 
individuals 
 Nodal status 
 Tumor size 
 Vessel invasion 
 ER status 
 Progesterone 
receptor status 
 Tumor grade 
 Treatment Regimens 
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(Year) 
Study 
Population 
Follow-up Obesity timepoint Pre-menopausal 
Associations 
Post-menopausal 
Associations 
Adjusted for 
confounders* 
       
Enger SM 
(2004) [121] 
1,376 patients 
who were 
diagnosed with 
invasive breast 
cancer from 
1/1/88 through 
12/31/95 at the 
Kaiser 
Permanente 
Hospital in San 
Diego 
Median: 6.8 
years 
Weight at diagnosis  HR=1.60 (0.99-2.56) of breast cancer mortality in 
individuals who weigh over 175 lbs compared to 
those who weigh under 133 lbs.  
 HR=1.41 (0.86-2.29) of breast cancer mortality in 
individuals weighing between 151-174 lbs 
compared to those who weigh < 133 lbs. 
 Linear trend of death from breast cancer was 
evident among individuals with early stage disease 
with higher weight increasing the risk of death 
(p=0.03). 
 Age 
 Grade 
 Stage 
 Tumor size 
 Lymph node status 
 ER status 
       
Enger SM 
(2004) [250] 
717 pre-
menopausal 
breast cancer 
patients who 
were diagnosed 
between 7/1/83 
and 12/31/89 in 
Los Angeles 
County 
Ranged from 
0.3-15.1 
years 
(median:10.4 
years) 
BMI and weight 
one year prior to 
diagnosis 
--weight change 
from age 18 to one 
year prior to 
diagnosis 
 HR=0.76 (0.53-1.07)* of 
breast cancer death in 
women with BMI ≥ 24.9 
compared to BMI < 20.4 
 HR=0.86 (0.60-1.23)* of 
breast cancer death in 
women who weighed 
68.2 kg or greater 
compared to those who 
weighed less than 54.1 
kg 
 HR=0.93 (0.61-1.42)* of 
breast cancer death in 
women who gained 10 
kg or more compared to 
women who gained no 
weight. 
  Age 
 Stage at diagnosis 
 Physical activity 
 Height (weight model 
only) 
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(Year) 
Study 
Population 
Follow-up Obesity timepoint Pre-menopausal 
Associations 
Post-menopausal 
Associations 
Adjusted for 
confounders* 
       
Borugian MJ 
(2003) [251] 
603 women (229 
pre-menopausal, 
357 post-
menopausal) 
who were 
diagnosed with 
breast cancer in 
Vancouver 
between 7/1991 
and 12/1992 
Followed for 
up to 10 
years 
Waist-to-hip ratio at 
time of diagnosis 
 RR=1.2 (0.4-3.4)* of 
breast cancer mortality 
in women in the 4th WHR 
quartile (WHR>0.848) 
compared to women in 
the lowest quartile 
(WHR<0.756) 
 RR=0.6 (0.2-1.8)* of 
breast cancer mortality 
in women in the third 
WHR quartile (WHR 
0.801-0.848) compared 
to women in the lowest 
quartile (WHR<0.756) 
 RR=3.3 (1.1-10.4)* of 
breast cancer 
mortality in women in 
the 4th WHR quartile 
(WHR>0.848) 
compared to women 
in the lowest quartile 
(WHR<0.756) 
 RR=2.3 (0.7-7.1)* of 
breast cancer 
mortality in women in 
the third WHR quartile 
(WHR 0.801-0.848) 
compared to women 
in the lowest quartile 
(WHR<0.756) 
 Age 
 BMI 
 Family history of 
breast cancer 
 ER status 
 Stage at diagnosis 
 Systemic treatment 
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APPENDIX C: COMPARISON OF TNM STAGING EDITIONS [252] 
 
TABLE C.1. Comparison of TNM Staging Editions [252] 
TNM 5th Edition TNM 6th EDITION 
Tis 
• Carcinoma in situ, includes intraductal 
carcinoma, lobular carcinoma in situ, or 
Paget's disease of the nipple with no tumor 
Tis – carcinoma in situ 
• Tis (DCIS) 
• Tis (LCIS) 
• Tis (Paget’s) 
 
N2 
• Metastasis to ipsilateral axillary lymph 
node(s) fixed to one another or to other 
structures 
N2 
• Metastasis in ipsilateral axillary lymph 
nodes fixed or matted, or in clinically 
apparent* ipsilateral internal mammary 
nodes in the absence of clinically evident 
axillary lymph node metastasis 
N2a – excluded N2a 
• Metastasis in ipsilateral axillary lymph 
nodes fixed to one another (matted) or to 
other structures 
N2b – excluded N2b 
• Metastasis only in clinically apparent* 
ipsilateral internal mammary nodes in the 
absence of clinically evident axillary lymph 
node metastasis 
N3 
• Metastasis to ipsilateral internal mammary 
node(s) 
N3 
• Metastasis in ipsilateral infraclavicular 
lymph node(s), with or without axillary 
lymph node involvement, or in clinically 
apparent* ipsilateral internal mammary 
lymph nodes in the presence of clinically 
evident axillary lymph node metastasis; or 
metastasis in ipsilateral supraclavicular 
lymph node(s), with or without axillary or 
internal mammary lymph node involvement 
N3a – excluded N3a 
• Metastasis in ipsilateral infraclavicular 
lymph node(s) 
N3b – excluded N3b 
• Metastasis in ipsilateral internal mammary 
lymph node(s) and axillary lymph node(s) 
N3c – excluded N3c 
• Metastasis in ipsilateral supraclavicular 
lymph node(s) 
M1 
• Distant metastasis, includes metastasis to 
ipsilateral supraclavicular lymph node(s) 
M1 
• Distant metastasis 
Overall classification Overall classification 
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TNM 5th Edition TNM 6th EDITION 
Stage 0              Tis   N0   M0 
Stage I               T1   N0   M0 
Stage IIA            T0   N1   M0    
                           T1   N1   M0    
                           T2   N0   M0 
Stage IIB            T2   N1   M0    
                           T3   N0   M0 
Stage IIIA           T0   N2   M0    
                           T1   N2   M0    
                           T2   N2   M0    
                           T3   N1   M0    
                           T3   N2   M0 
Stage IIIB           T4   Any N   M0  
                           Any T   N3   M0 
Stage IV             Any T   Any N   M1 
Stage 0              Tis   N0   M0 
Stage I               T1   N0   M0 
Stage IIA            T0   N1   M0    
                           T1   N1   M0    
                           T2   N0   M0 
Stage IIB            T2   N1   M0    
                           T3   N0   M0 
Stage IIIA           T0   N2   M0    
                           T1   N2   M0    
                           T2   N2   M0    
                           T3   N1   M0    
                           T3   N2   M0 
Stage IIIB           T4   N0   M0    
                           T4   N1   M0    
                           T4   N2   M0 
Stage IIIC           Any T   N3   M0 
Stage IV             Any T   Any N   M1 
* Clinically apparent is defined as detected by imaging studies (excluding 
lymphoscintigraphy) or by clinical examination or grossly visible pathologically. 
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APPENDIX D: METHODS AND DATA ANALYSIS TABLES 
 
TABLE D.1. Variables and variable definitions included in case-control and survival analyses 
Analysis  Variable  
CCS Survival Topic Name Labels and Values 
  Body Size   
 X  BMI20H20 BMI at age 20 using height at age 20 
X X  BMI50H20 BMI at age 50 using height at age 20 
X X  BMI50HRF BMI at age 50 using height at reference 
X X  WTCH20CAT Weight change from age 20 to reference 
age. 
0= if weight loss is within 3.00 kg 
(reference) 
1=  if –44.91 to –3.01 kg weight loss 
2= if 3.01 to 7.71 kg weight gain 
3= if 7.72 to 8.15 kg weight gain 
4= if 8.16 to 14.96 kg weight gain 
5=  if 14.97 to 87.09 kg weight gain  
X X  WTCH20 Continuous weight change from age 20 to 
reference age.   
X X  WTCH50_CAT Weight change from age 50 to reference.  
0= if no change in weight (reference) 
1=  if –68.04 to –0.04 kg weight loss 
2= if 0.01 to 2.71 kg weight gain 
3= if 2.72 to 4.98 kg weight gain 
4= if 4.99 to 11.33 kg weight gain  
5=  if 11.34 to 62.14 kg weight gain 
X X  WTCH50 Continuous weight change from age 50 to 
reference.   
 Reproductive   
X   AGEFB Age at first live birth 
 X  MENPSTAT Menopausal status (derived from data on 
last menstrual period, 
oophorectomies/hysterectomies and other 
surgical information, pregnancy status, 
lactation status, and HRT use) 
1 =  Premenopausal 
2 =  Postmenopausal 
 Demographic   
X X  RACE Self-identified race 
1 = White 
2 =  Black 
3 =  Other (Asian, Native American, 
etc.) 
X   RELIGION Religion in which subject was raised 
1 =  None 
2 =  Protestant 
3 =  Catholic 
4 =  Jewish 
5 = Other 
 Medical 
history / 
Treatment 
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Analysis  Variable  
CCS Survival Topic Name Labels and Values 
X   ASPNEW Aspirin usage 
0=non-users 
1=users 
 X  ERPRSTAT Combined estrogen receptor and 
progesterone receptor status among 
cases 
0= ER-/PR- 
1= ER-/PR+ 
2=  ER+/PR- 
3=  ER+/PR+ 
 X  CHEMO_INT Chemotherapy at F/U based on interview 
data 
1=yes 
2= no 
X   FAMHX1 mother, sister, or daughter with breast 
cancer 
0 = No FamHx of BrCa in Mother, 
Sister, or Daughter 
1 = FamHx of BrCa in Mother, Sister, 
or Daughter 
 X  HT_INT Hormone Therapy at F/U based on 
interview data 
1=yes 
2= no 
 X  RAD_INT Radiation Therapy at F/U based on 
interview data 
1=yes 
2= no 
 X  STAGE stage of breast cancer 
0 = Control 
1 = In situ 
2 = Invasive 
 Matched 
variables 
  
X X  AGEGRP Five-year diagnosis age group for subject 
1 =  20-24  
2 =  25-29  
3 =  30-34  
4 =  35-39  
5 =  40-44  
6 =  45-49  
7 =  50-54  
8 =  55-59  
9 =  60-64  
10 =  65-69  
11 =  70-74  
12 =  75-79  
13 =  80-84  
14 =  85-89  
15 =  90-94  
16 =  95-100 
 Outcome   
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Analysis  Variable  
CCS Survival Topic Name Labels and Values 
X   CASECONT Case/control status 
1 = Case 
2 = Control 
 X  DUR Time-to-event variable 
 X  NDI_2002 Vital status (based on all cause mortality) 
for all 1508 LIBCSP cases 
1 = deceased 
0 = alive 
 X  NDI_BRCA Indicator variable for breast cancer 
related death 
0=alive 
1=BRCA-related death 
9=other causes of death 
 X  NDI_PRIMARY Vital status determined from the primary 
cause of death listed on the NDI records 
0=alive 
1= BRCA death 
2=Lung CA death 
3=Other CA death 
4=CVD death 
5=Other cause of death 
 X  NDI_UNDER Vital status determined from the 
underlying cause of death listed on the 
NDI records 
0=alive 
1= BRCA death 
2=Lung CA death 
3=Other CA death 
4=CVD death 
5=Other cause of death 
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TABLE D.2. ORs across levels for select covariates with adjusted OR and test for homogeneity for 
rs135542 (AA vs. AG+GG) in post-menopausal women 
Covariate 
 
Stratum-specific 
OR (95% CI) 
Mantel-Haenszel 
OR (95% CI) 
Χ2 Breslow-Day test for 
homogeneity of the OR 
(df), p-value 
BMI at age 50 (kg/m2)    
 < 18.50 1.07 (0.50, 2.31) 
 18.50-24.99 1.01 (0.75, 1.36) 
 25.00-29.99 0.76 (0.50, 1.16) 
 ≥ 30.00 1.18 (0.60, 2.29) 
0.95 (0.77, 1.19) 1.69 (3), 0.64 
BMI at age 50 (kg/m2)    
 < 25.00 1.03 (0.78, 1.36) 
 ≥ 25.00 0.86 (0.61, 1.23) 
0.96 (0.77, 1.20) 0.60 (1), 0.44 
BMI at reference 
(kg/m2)    
 < 18.50 1.14 (0.30, 4.37) 
 18.50-24.99 0.80 (0.57, 1.22) 
 25.00-29.99 0.83 (0.56, 1.23) 
 ≥ 30.00 1.48 (0.95, 2.32) 
0.95 (0.76, 1.18) 5.39 (3), 0.15 
BMI at reference 
(kg/m2)    
 < 25.00 0.82 (0.59, 1.14) 
 ≥ 25.00 1.07 (0.80, 1.43) 
0.95 (0.76, 1.18) 1.42 (1), 0.23 
Weight change from 50 
to reference date (6 
levels) 
   
 no change 0.80 (0.48, 1.34) 
 -68.04 to -0.04 kg 0.65 (0.38, 1.13) 
 0.01 to 2.71 kg 0.61 (0.33, 1.14) 
 2.72 to 4.98 kg  1.11 (0.62, 1.37) 
 4.99 to 11.33 kg 1.23 (0.70, 2.16) 
 11.34 to 62.14 kg  1.54 (0.86, 2.74) 
0.93 (0.74, 1.17) 7.97 (5), 0.16 
Weight gain from 50 to 
reference date (3 
levels) 
   
 No change or loss 0.73 (0.50, 1.05) 
 0.01-4.98 kg 0.86 (0.56, 1.30) 
 ≥ 4.99 kg 1.37 (0.91, 2.04) 
0.94 (0.75, 1.18) 5.38 (2), 0.07 
Physical activity 
(hrs/wk)    
 0 1.09 (0.72, 1.65) 
 < 0.69 0.95 (0.60, 1.51) 
 0.7-2.6 0.92 (0.57, 1.50) 
 ≥ 2.7 0.75 (0.46, 1.20) 
0.93 (0.74, 1.17) 1.43 (3), 0.70 
Jewish Ethnicity    
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 Jewish 1.30 (0.72, 2.36) 
 Non-Jewish 0.92 (0.73, 1.17) 
0.97 (0.78, 1.21) 1.11 (1), 0.29 
Race    
 White 0.96 (0.76, 1.20) 
 Non-white 1.10 (0.44, 2.73) 
0.96 (0.77, 1.20) 0.08 (1), 0.77 
Aspirin Use    
 Aspirin user 1.42 (0.90, 2.26) 
 Non-user 0.88 (0.68, 1.14) 
0.99 (0.79, 1.24) 3.14 (1), 0.08 
Diabetes Diagnosis    
 Yes 1.20 (0.59, 2.46) 
 No 0.93 (0.74, 1.18) 
0.96 (0.77, 1.19) 0.43 (1), 0.51 
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TABLE D.3. ORs across levels for select covariates with adjusted OR and test for homogeneity for 
rs1800206 (CC vs. CG+GG) in post-menopausal women 
Covariate 
 
Stratum-specific OR 
(95% CI) 
Mantel-Haenszel 
OR (95% CI) 
Χ2 Breslow-Day test for 
homogeneity of the OR 
(df), p-value 
BMI at age 50 (kg/m2)    
 < 18.50 1.21 (0.31, 4.81) 
 18.50-24.99 1.13 (0.71, 1.81) 
 25.00-29.99 0.87 (0.44, 1.72) 
 ≥ 30.00 0.93 (0.35, 2.48) 
1.04 (0.73, 1.47) 0.48 (3), 0.92 
BMI at age 50 (kg/m2)    
 < 25.00 1.15 (0.74, 1.79) 
 ≥ 25.00 0.89 (0.51, 1.56) 
1.04 (0.74, 1.47) 0.49 (1), 0.48 
BMI at reference 
(kg/m2)    
 < 18.50 --- 
 18.50-24.99 0.81 (0.45, 1.46) 
 25.00-29.99 1.37 (0.78, 2.40) 
 ≥ 30.00 1.00 (0.48, 2.09) 
1.03 (0.72, 1.45) 3.15 (3), 0.37 
BMI at reference 
(kg/m2)    
 < 25.00 0.77 (0.43, 1.36) 
 ≥ 25.00 1.21 (0.77, 1.88) 
1.02 (0.72, 1.44) 1.49 (1), 0.22 
Weight change from 
50 to reference date 
(6 levels) 
   
 no change 0.66 (0.27, 1.66) 
 -68.04 to -0.04 kg 1.44 (0.57, 3.64) 
 0.01 to 2.71 kg 0.63 (0.27, 1.48) 
 2.72 to 4.98 kg  2.59 (0.63, 10.68) 
 4.99 to 11.33 kg 0.80 (0.39, 1.65) 
 11.34 to 62.14 kg  1.68 (0.62, 4.54) 
0.99 (0.69, 1.43) 5.81 (5), 0.33 
Weight gain from 50 
to reference date (3 
levels) 
   
 No change or loss 0.97 (0.51, 1.84) 
 0.01-4.98 kg 0.97 (0.48, 1.95) 
 ≥ 4.99 kg 1.02 (0.58, 1.81) 
0.99 (0.69, 1.43) 0.02 (2), 0.99 
Physical activity 
(hrs/wk)    
 0 1.61 (0.81, 3.22) 
 < 0.69 0.70 (0.30, 1.61) 
 0.7-2.6 1.38 (0.65, 2.93) 
 ≥ 2.7 0.63 (0.31, 1.26) 
1.01 (0.71, 1.45) 5.05 (3), 0.17 
Jewish Ethnicity    
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 Jewish 2.24 (0.74, 6.79) 
 Non-Jewish 0.95 (0.66, 1.37) 
1.04 (0.73, 1.47) 2.16 (1), 0.14 
Race    
 White 1.04 (0.73, 1.49) 
 Non-white 1.03 (0.19, 5.42) 
1.04 (0.74, 1.47) 0.00 (1), 0.99 
Aspirin Use    
 Aspirin user 0.97 (0.47, 1.99) 
 Non-user 1.18 (0.77, 1.80) 
1.12 (0.78, 1.61) 0.22 (1), 0.64 
Diabetes Diagnosis    
 Yes 1.33 (0.36, 4.96) 
 No 1.01 (0.70, 1.45) 
1.03 (0.73, 1.46) 0.16 (1), 0.69 
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TABLE D.4. ORs across levels for select covariates with adjusted OR and test for homogeneity for 
rs4253623 (AA vs. AG+GG) in post-menopausal women 
Covariate 
 
Stratum-specific OR 
(95% CI) 
Mantel-Haenszel 
OR (95% CI) 
Χ2 Breslow-Day test for 
homogeneity of the OR 
(df), p-value 
BMI at age 50 (kg/m2)    
 < 18.50 1.28 (0.56, 2.94) 
 18.50-24.99 0.88 (0.63, 1.24) 
 25.00-29.99 0.86 (0.52, 1.41) 
 ≥ 30.00 1.11 (0.54, 2.28) 
0.93 (0.72, 1.20) 0.98 (3), 0.81 
BMI at age 50 (kg/m2)    
 < 25.00 0.92 (0.67, 1.26) 
 ≥ 25.00 0.93 (0.61, 1.40) 
0.92 (0.72, 1.19) 0.00 (1), 0.98 
BMI at reference 
(kg/m2)    
 < 18.50 1.78 (0.33, 9.48) 
 18.50-24.99 0.93 (0.62, 1.38) 
 25.00-29.99 0.89 (0.58, 1.38) 
 ≥ 30.00 0.85 (0.52, 1.40) 
0.91 (0.71, 1.17) 0.71 (3), 0.87 
BMI at reference 
(kg/m2)    
 < 25.00 0.96 (0.65, 1.42) 
 ≥ 25.00 0.88 (0.63, 1.22) 
0.91 (0.71, 1.17) 0.12 (1), 0.73 
Weight change from 
50 to reference date 
(6 levels) 
   
 no change 0.71 (0.38, 1.32) 
 -68.04 to -0.04 kg 1.32 (0.72, 2.44) 
 0.01 to 2.71 kg 1.14 (0.60, 2.15) 
 2.72 to 4.98 kg  0.66 (0.33, 1.37) 
 4.99 to 11.33 kg 0.70 (0.38, 1.28) 
 11.34 to 62.14 kg  1.06 (0.53, 2.10) 
0.90 (0.70, 1.17) 4.20 (5), 0.52 
Weight gain from 50 
to reference date (3 
levels) 
   
 No change or loss 0.97 (0.63, 1.50) 
 0.01-4.98 kg 0.90 (0.56, 1.45) 
 ≥ 4.99 kg 0.83 (0.53, 1.31) 
0.90 (0.70, 1.17) 0.24 (2), 0.89 
Physical activity 
(hrs/wk)    
 0 1.04 (0.66, 1.66) 
 < 0.69 0.92 (0.57, 1.50) 
 0.7-2.6 1.20 (0.66, 2.19) 
 ≥ 2.7 0.82 (0.48, 1.42) 
0.98 (0.76, 1.27) 0.95 (3), 0.81 
Jewish Ethnicity    
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 Jewish 0.71 (0.37, 1.39) 
 Non-Jewish 0.96 (0.73, 1.26) 
0.92 (0.72, 1.18) 0.66 (1), 0.42 
Race    
 White 0.94 (0.73, 1.22) 
 Non-white 0.68 (0.24, 1.92) 
0.92 (0.72, 1.19) 0.35 (1), 0.55 
Aspirin Use    
 Aspirin user 1.24 (0.76, 2.03) 
 Non-user 0.84 (0.62, 1.14) 
0.94 (0.72, 1.21) 1.72 (2), 0.19 
Diabetes Diagnosis    
 Yes 0.62 (0.29, 1.33) 
 No 0.97 (0.74, 1.26) 
0.92 (0.72, 1.19) 1.19 (1), 0.28 
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TABLE D.5. ORs across levels for select covariates with adjusted OR and test for homogeneity for 
rs4253699 (TT vs. CT+TT) in post-menopausal women 
Covariate 
 
Stratum-specific OR 
(95% CI) 
Mantel-Haenszel 
OR (95% CI) 
Χ2 Breslow-Day test for 
homogeneity of the OR 
(df), p-value 
BMI at age 50 (kg/m2)    
 < 18.50 0.75 (0.33, 1.69) 
 18.50-24.99 1.20 (0.89, 1.62) 
 25.00-29.99 0.95 (0.63, 1.42) 
 ≥ 30.00 1.39 (0.72, 2.70) 
1.10 (0.89, 1.37) 2.21 (3), 0.53 
BMI at age 50 (kg/m2)    
 < 25.00 1.14 (0.86, 1.51) 
 ≥ 25.00 1.05 (0.75, 1.49) 
1.10 (0.89, 1.37) 0.12 (1), 0.73 
BMI at reference 
(kg/m2)    
 < 18.50 1.63 (0.39, 6.82) 
 18.50-24.99 1.09 (0.77, 1.53) 
 25.00-29.99 0.99 (0.68, 1.45) 
 ≥ 30.00 1.24 (0.80, 1.94) 
1.10 (0.88, 1.37) 0.89 (3), 0.83 
BMI at reference 
(kg/m2)    
 < 25.00 1.11 (0.80, 1.55) 
 ≥ 25.00 1.09 (0.81, 1.45) 
1.10 (0.88, 1.36) 0.01 (1), 0.92 
Weight change from 
50 to reference date 
(6 levels) 
   
 no change 0.89 (0.54, 1.48) 
 -68.04 to -0.04 kg 1.01 (0.58, 1.76) 
 0.01 to 2.71 kg 0.85 (0.48, 1.50) 
 2.72 to 4.98 kg  1.31 (0.73, 2.34) 
 4.99 to 11.33 kg 1.38 (0.80, 2.40) 
 11.34 to 62.14 kg  1.67 (0.93, 2.99) 
1.13 (0.90, 1.42) 4.44 (5), 0.49 
Weight gain from 50 
to reference date (3 
levels) 
   
 No change or loss 0.94 (0.65, 1.37) 
 0.01-4.98 kg 1.05 (0.70, 1.58) 
 ≥ 4.99 kg 1.51 (1.01, 2.26) 
1.14 (0.91, 1.42) 3.07 (2), 0.22 
Physical activity 
(hrs/wk)    
 0 1.64 (1.09, 2.46) 
 < 0.69 0.75 (0.47, 1.19) 
 0.7-2.6 1.18 (0.73, 1.91) 
 ≥ 2.7 0.82 (0.51, 1.32) 
1.08 (0.86, 1.35) 7.88 (3), 0.05 
Jewish Ethnicity    
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 Jewish 0.97 (0.57, 1.67) 
 Non-Jewish 1.14 (0.90, 1.44) 
1.11 (0.89, 1.38) 0.26 (1), 0.61 
Race    
 White 1.10 (0.88, 1.38) 
 Non-white 1.08 (0.44, 2.65) 
1.10 (0.89, 1.37) 0.00 (1), 0.96 
Aspirin Use    
 Aspirin user 1.56 (1.00, 2.45) 
 Non-user 0.93 (0.72, 1.21) 
1.06 (0.85, 1.32) 3.84 (1), 0.05 
Diabetes Diagnosis    
 Yes 1.05 (0.51, 2.13) 
 No 1.11 (0.88, 1.40) 
1.11 (0.89, 1.37) 0.02 (1), 0.88 
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TABLE D.6. ORs across levels for select covariates with adjusted OR and test for homogeneity for 
rs4253755 (GG vs. AG+AA) in post-menopausal women 
Covariate 
 
Stratum-specific OR 
(95% CI) 
Mantel-Haenszel 
OR (95% CI) 
Χ2 Breslow-Day test for 
homogeneity of the OR 
(df), p-value 
BMI at age 50 (kg/m2)    
 < 18.50 1.50 (0.63, 3.56) 
 18.50-24.99 1.19 (0.84, 1.69) 
 25.00-29.99 1.23 (0.75, 2.02) 
 ≥ 30.00 0.75 (0.36, 1.58) 
1.16 (0.90, 1.50) 1.73 (3), 0.63 
BMI at age 50 (kg/m2)    
 < 25.00 1.22 (0.88, 1.68) 
 ≥ 25.00 1.06 (0.70, 1.59) 
1.15 (0.90, 1.49) 0.29 (1), 0.59 
BMI at reference 
(kg/m2)    
 < 18.50 2.42 (0.48, 12.30) 
 18.50-24.99 1.16 (0.79, 1.73) 
 25.00-29.99 1.19 (0.75, 1.89) 
 ≥ 30.00 1.02 (0.61, 1.68) 
1.15 (0.89, 1.49) 1.09 (3), 0.78 
BMI at reference 
(kg/m2)    
 < 25.00 1.21 (0.83, 1.78) 
 ≥ 25.00 1.11 (0.79, 1.57) 
1.16 (0.90, 1.49) 0.11 (1), 0.74 
Weight change from 
50 to reference date 
(6 levels) 
   
 no change 1.25 (0.67, 2.35) 
 -68.04 to -0.04 kg 1.47 (0.77, 2.79) 
 0.01 to 2.71 kg 0.74 (0.38, 1.45) 
 2.72 to 4.98 kg  1.32 (0.68, 2.59) 
 4.99 to 11.33 kg 1.21 (0.65, 2.28) 
 11.34 to 62.14 kg  1.03 (0.51, 2.07) 
1.15 (0.88, 1.51) 2.58 (5), 0.76 
Weight gain from 50 
to reference date (3 
levels) 
   
 No change or loss 1.35 (0.87, 2.12) 
 0.01-4.98 kg 0.99 (0.62, 1.59) 
 ≥ 4.99 kg 1.12 (0.70, 1.78) 
1.15 (0.88, 1.50) 0.92 (2), 0.63 
Physical activity 
(hrs/wk)    
 0 1.34 (0.83, 2.16) 
 < 0.69 0.57 (0.33, 0.98) 
 0.7-2.6 1.42 (0.80, 2.54) 
 ≥ 2.7 1.15 (0.67, 1.97) 
1.06 (0.82, 1.38) 7.12 3, 0.07 
Jewish Ethnicity    
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 Jewish 1.16 (0.58, 2.35) 
 Non-Jewish 1.15 (0.88, 1.51) 
1.15 (0.89, 1.49) 0.00 (1), 0.98 
Race    
 White 1.15 (0.89, 1.49) 
 Non-white 1.03 (0.19, 5.42) 
1.15 (0.89, 1.48) 0.02 (1), 0.90 
Aspirin Use    
 Aspirin user 1.46 (0.88, 2.45) 
 Non-user 1.02 (0.75, 1.39) 
1.12 (0.86, 1.46) 1.39 (1), 0.24 
Diabetes Diagnosis    
 Yes 0.94 (0.40, 2.19) 
 No 1.18 (0.90, 1.54) 
1.15 (0.89, 1.49) 0.25 (1), 0.62 
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TABLE D.7. ORs across levels for select covariates with adjusted OR and test for homogeneity for 
rs4253760 (TT vs. GT+GG) in post-menopausal women 
Covariate 
 
Stratum-specific OR 
(95% CI) 
Mantel-Haenszel 
OR (95% CI) 
Χ2 Breslow-Day test for 
homogeneity of the OR 
(df), p-value 
BMI at age 50 (kg/m2)    
 < 18.50 1.34 (0.58, 3.09) 
 18.50-24.99 1.27 (0.93, 1.75) 
 25.00-29.99 1.21 (0.78, 1.87) 
 ≥ 30.00 1.04 (0.53, 2.04) 
1.23 (0.98, 1.55) 0.34 (3), 0.95 
BMI at age 50 (kg/m2)    
 < 25.00 1.29 (0.96, 1.73) 
 ≥ 25.00 1.15 (0.80, 1.66) 
1.23 (0.98, 1.55) 0.21 (1), 0.65 
BMI at reference 
(kg/m2)    
 < 18.50 0.72 (0.16, 3.20) 
 18.50-24.99 1.26 (0.88, 1.81) 
 25.00-29.99 1.46 (0.97, 2.19) 
 ≥ 30.00 0.97 (0.61, 1.55) 
1.22 (0.97, 1.54) 2.16 (3), 0.54 
BMI at reference 
(kg/m2)    
 < 25.00 1.22 (0.86, 1.74) 
 ≥ 25.00 1.22 (0.90, 1.66) 
1.22 (0.97, 1.54) 0.00 (1), 0.99 
Weight change from 
50 to reference date 
(6 levels) 
   
 no change 1.38 (0.81, 2.34) 
 -68.04 to -0.04 kg 1.29 (0.73, 2.29) 
 0.01 to 2.71 kg 0.78 (0.42, 1.43) 
 2.72 to 4.98 kg  1.45 (0.76, 2.76) 
 4.99 to 11.33 kg 1.34 (0.75, 2.38) 
 11.34 to 62.14 kg  1.20 (0.65, 2.24) 
1.22 (0.96, 1.55) 2.71 (5), 0.74 
Weight gain from 50 
to reference date (3 
levels) 
   
 No change or loss 1.34 (0.91, 1.97) 
 0.01-4.98 kg 1.05 (0.68, 1.63) 
 ≥ 4.99 kg 1.27 (0.83, 1.93) 
1.22 (0.96, 1.56) 0.68 (2), 0.71 
Physical activity 
(hrs/wk)    
 0 1.39 (0.90, 2.15) 
 < 0.69 0.95 (0.59, 1.55) 
 0.7-2.6 1.07 (0.64, 1.79) 
 ≥ 2.7 1.40 (0.85, 2.29) 
1.20 (0.94, 1.52) 1.89 (3), 0.60 
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Jewish Ethnicity    
 Jewish 1.56 (0.82, 2.97) 
 Non-Jewish 1.19 (0.93, 1.53) 
1.23 (0.98, 1.55) 0.60 (1), 0.44 
Race    
 White 1.27 (0.99, 1.61) 
 Non-white 0.87 (0.34, 2.19) 
1.24 (0.98, 1.56) 0.60 (1), 0.44 
Aspirin Use    
 Aspirin user 1.29 (0.81, 2.04) 
 Non-user 1.22 (0.92, 1.61) 
1.24 (0.97, 1.57) 0.04 (1), 0.85 
Diabetes Diagnosis    
 Yes 1.49 (0.70, 3.16) 
 No 1.21 (0.95, 1.54) 
1.23 (0.98, 1.55) 0.27 (1), 0.60 
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TABLE D.8. Model building procedure for SNP rs135542 (AA vs. AG+GG) in post-menopausal 
women, ∆W interaction & BMI 
 Full Model Model 2 Model 3 Model 4 Model 5 Model 6 
 β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 1,196 1,196 1,196 1,198 1,239 1,239 
Main 
Exposure: 
rs135542 
0.2788 
(0.1964) 
0.0810 
(0.1205) 
0.0828 
(0.1200) 
0.0850 
(0.1199) 
0.0933 
(0.1176) 
0.0901 
(0.1174) 
INTERCEPT -1.4217 
(0.3619) 
-1.3530 
(0.3554) 
-1.3606 
(0.3520) 
-1.3823 
(0.3489) 
-1.3192 
(0.3427) 
-1.1875 
(0.3329) 
WTCH_1 0.00910 
(0.1873) 
-0.0270 
(0.1439) 
-0.0274 
(0.1438) 
-0.0269 
(0.1436) 
-0.0390 
(0.1414) 
-0.0291 
(0.1411) 
WTCH_2 0.4699 
(0.2038) 
0.2541 
(0.1661) 
0.2556 
(0.1658) 
0.2486 
(0.1653) 
0.2671 
(0.1616) 
0.4055 
(0.1395) 
RACE_DIC -0.0427 
(0.2550) 
-0.0580 
(0.2545) 
-0.0540 
(0.2532) REMOVED --- --- 
JEWISH -0.0150 
(0.1636) 
-0.0253 
(0.1632) REMOVED --- --- --- 
FAMHX1 0.1122 
(0.1582) 
0.1097 
(0.1579) 
0.1090 
(0.1578) 
0.1173 
(0.1575) 
REMOVED --- 
BMI50 0.1600 
(0.0885) 
0.1597 
(0.0883) 
0.1598 
(0.0883) 
0.1613 
(0.0876) 
0.1451 
(0.0856) REMOVED 
AGEGRP 0.1141 
(0.0350) 
0.1160 
(0.0349) 
0.1162 
(0.0349) 
0.1184 
(0.0347) 
0.1165 
(0.0340) 
0.1100 
(0.0337) 
Interactions:       
WTCH1SNP1 -0.0799 
(0.2919) REMOVED --- --- --- --- 
WTCH2SNP1 -0.5416 
(0.2883) REMOVED --- --- --- --- 
-2 log L 1624.204 1628.158 1628.182 1630.803 1688.051 1690.924 
Notes  
Evaluate 
EMM with 
the 
likelihood 
ratio test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Removed 
FAMHX1 
Removed 
BMI50 
Test of 
interaction term  
χ2 (2): 
1624.204– 
1628.158= 
3.954; 
p=0.14 
--- --- --- --- 
Change in 
estimate   
|0.0810-
0.0828| = 
0.0018 
|0.0810- 
0.0850| = 
0.0040 
|0.0810- 
0.0933| = 
0.0123 
|0.0810 - 
0.0901| = 
0.0091 
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Compare to:  Full Model Model 2 Model 2 Model 2 Model 2 
Conclusion:  
Interaction 
term is not 
contributing 
to the 
model and 
will be 
removed. 
Change in 
estimate < 
0.10. 
Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Family 
history is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. BMI 
is not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.9. Model building procedure for SNP rs135542 (AA vs. AG+GG) in post-menopausal 
women, BMI interaction 
 Full Model Model 2 Model 3 Model 4 Model 5 Model 6 
 β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 1,211 1,211 1,211 1,211 1,253 1,331 
Main 
Exposure: 
rs135542 
0.1697 
(0.1802) 
0.0437 
(0.1201) 
0.1694 
(0.1793) 
0.1706 
(0.1791) 
0.1981 
(0.1765) 
0.2199 
(0.1704) 
INTERCEPT -1.3218 
(0.3175) 
-1.2462 
(0.3114) 
-1.3209 
(0.3125) 
-1.3282 
(0.3102) 
-1.3547 
(0.3061) 
-1.3479 
(0.2964) 
BMIREF_1 0.2607 
(0.1745) 
0.2784 
(0.1358) 
0.2606 
(0.1744) 
0.2605 
(0.1744) 
0.2446 
(0.1727) 
0.2445 
(0.1671) 
BMIREF_2 0.6447 
(0.1966) 
0.3958 
(0.1490) 
0.6445 
(0.1961) 
0.6511 
(0.1958) 
0.6296 
(0.1913) 
0.6903 
(0.1839) 
RACE_DIC -0.0349 
(0.2666) 
-0.0467 
(0.2654) 
-0.0353 
(0.2654) REMOVED --- --- 
JEWISH 0.00254 
(0.1622) 
-0.0146 
(0.1616) REMOVED --- --- --- 
FAMHX1 0.1287 
(0.1567) 
0.1178 
(0.1562) 
0.1288 
(0.1566) 
0.1358 
(0.1563) 
REMOVED  
ASPNEW -0.3698 
(0.1352) 
-0.3825 
(0.1348) 
-0.3698 
(0.1351) 
-0.3712 
(0.1351) 
-0.3555 
(0.1326) REMOVED 
AGEGRP 0.1258 
(0.0310) 
0.1244 
(0.0310) 
0.1257 
(0.0310) 
0.1262 
(0.0309) 
0.1339 
(0.0303) 
0.1150 
(0.0292) 
Interactions:       
BMI1SNP1 0.0706 
(0.2786) REMOVED 
0.0706 
(0.2786) 
0.0696 
(0.2784) 
0.00421 
(0.2728) 
0.0182 
(0.2639) 
BMI2SNP1 -0.5954 
(0.3009) REMOVED 
-0.5951 
(0.3005) 
-0.6046 
(0.3002) 
-0.5935 
(0.2946) 
-0.6016 
(0.2848) 
-2 log L 1640.226 1645.351 1640.226 1641.041 1697.881 1813.388 
Notes  
Evaluate 
EMM with 
the 
likelihood 
ratio test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Removed 
FAMHX1 
Removed 
ASPNEW 
Test of 
interaction 
term 
 
χ2 (2): = 
1645.351-
1640.226=5
.125; p=0.08 
--- --- --- --- 
Change in 
estimate   
|0.1697-
0.1694| = 
0.0003 
|0.1697- 
0.1706| = 
0.0009 
|0.1697- 
0.1981| = 
0.0284 
|0.1697- 
0.2199| = 
0.0502 
Compare to:  Full Model Full Model Full Model Full Model Full Model 
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Conclusion:  
Interaction 
term is 
contributing 
to the 
model and 
will be kept 
in the 
model. 
Results 
should be 
presented 
as 
stratified. 
Change in 
estimate < 
0.10. 
Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Family 
history is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Aspirin use 
is not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.10. Model building procedure for SNP rs135542 (AA vs. AG+GG) in post-menopausal 
women, NSAID interaction 
 Full Model Model 2 Model 3 Model 4 Model 5 Model 6 
 β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 1,126 1,126 1,127 1,127 1,164 1,253 
Main 
Exposure: 
rs135542 
0.2193 
(0.1439) 
0.0585 
(0.1249) 
0.2154 
(0.1439) 
0.2195 
(0.1433) 
0.2508 
(0.1412) 
0.1768 
(0.1347) 
INTERCEPT -1.4200 
(0.3629) 
-1.3022 
(0.3581) 
-1.4194 
(0.3584) 
-1.4344 
(0.3559) 
-1.4286 
(0.3518) 
-1.1935 
(0.2965) 
WTCH_1 0.0151 
(0.1485) 
0.00478 
(0.1481) 
0.0200 
(0.1484) 
0.0187 
(0.1483) 
0.00556 
(0.1465) REMOVED 
WTCH_2 0.4042 
(0.1496) 
0.4012 
(0.1492) 
0.4030 
(0.1496) 
0.4070 
(0.1491) 
0.4013 
(0.1460) REMOVED 
RACE_DIC -0.00012 
(0.2714) 
0.0299 
(0.2711) REMOVED --- --- --- 
JEWISH -0.0551 
(0.1697) 
-0.0468 
(0.1694) 
-0.0586 
(0.1688) REMOVED --- --- 
FAMHX1 0.1184 
(0.1631) 
0.1223 
(0.1629) 
0.1286 
(0.1627) 
0.1261 
(0.1626) 
REMOVED --- 
ASPNEW -0.1955 
(0.1755) 
-0.4354 
(0.1407) 
-0.1995 
(0.1754) 
-0.1990 
(0.1754) 
-0.1543 
(0.1729) 
-0.1667 
(0.1651) 
AGEGRP 0.1410 
(0.0364) 
0.1356 
(0.0362) 
0.1411 
(0.0362) 
0.1414 
(0.0362) 
0.1448 
(0.0357) 
0.1364 
(0.0302) 
Interactions       
ASPSNP1 -0.6634 
(0.2933) REMOVED 
-0.6599 
(0.2929) 
-0.6582 
(0.2929) 
-0.7470 
(0.2871) 
-0.5505 
(0.2736) 
-2 log L 1518.470 1523.644 1519.729 1519.849 1568.494 1706.293 
Notes  
Evaluate 
EMM with 
the 
likelihood 
ratio test* 
Removed 
RACE_DIC 
Removed 
JEWISH 
Removed 
FAMHX1 
Removed 
WTCH_1, 
WTCH_2 
Test of 
interaction 
term 
 
χ2 (1): = 
1523.644-
1518.470=5.
174; p=0.02 
--- --- --- --- 
Change in 
estimate   
|0.2193-
0.2154| = 
0.0039 
|0.2193- 
0.2195| = 
0.0002 
|0.2193- 
0.2508| = 
0.0315 
|0.2193- 
0.1768| = 
0.0425 
Compare to:  Full Model Full Model Full Model Full Model Full Model 
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Conclusion:  
Interaction 
term is 
contributing 
to the 
model and 
will be kept. 
Results 
should be 
presented 
as 
stratified. 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Family 
history is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Weight 
change is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.11. Summary of odds ratios for rs135542 stratified by three effect modifiers 
Exposure Status Genotypes Controls (N) 
Cases 
(N) 
Stratum OR 
(95% CI) 
Adjusted OR 
(95% CI)* 
AA 149 114 1.00 1.00 No change 
or loss 
AG+AA 94 99 1.38 (0.95, 2.00) 
1.40 
(0.96, 2.04) 
AA 123 101 1.00 1.05 (0.73, 1.51) 0.01-4.98 
AG+AA 75 72 1.17 (0.77, 1.77) 
1.23 
(0.82, 1.85) 
AA 98 156 1.00 1.92 (1.34, 2.74) 
Weight 
gain from 
age 50 
(kg) 
≥ 4.99 
AG+AA 73 85 0.73 (0.49, 1.09) 
1.47 
(0.99, 2.19) 
AA 187 143 1.00 1.00 
< 24.99 
AG+AA 127 119 1.23 (0.88, 1.71) 
1.25 
(0.89, 1.74) 
AA 131 133 1.00 1.28 (0.92, 1.77) 25.00-
29.99 
AG+AA 73 89 1.20 (0.81, 1.78) 
1.62 
(1.11, 2.37) 
AA 79 119 1.00 1.99 (1.39, 2.86) 
BMI at 
reference 
(kg/m2) 
≥ 30.00 
AG+AA 65 66 0.67 (0.43, 1.05) 
1.36 
(0.91, 2.05) 
AA 256 279 1.00 1.00 
Non-user 
AG+AA 177 219 1.14 (0.87, 1.47) 
1.19 
(0.92, 1.55) 
AA 106 102 1.00 0.85 (0.61, 1.17) 
Aspirin 
use 
User 
AG+AA 68 46 0.70 (0.44, 1.12) 
0.58 
(0.38, 0.88) 
*Adjusted for age 
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TABLE D.12. Model building procedure for SNP rs1800206 (CC vs. CG+GG) in post-menopausal 
women, Jewish interaction 
 Full Model Model 2 Model 3 Model 4 Model 5 Model 6 
 β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 1,316 1,316 1,317 1,317 1,362 1,362 
Main 
Exposure: 
rs1800206 
-0.1048 
(0.1927) 
-0.0171 
(0.1821) 
-0.0188 
(0.1820) 
-0.0174 
(0.1818) 
0.0386 
(0.1785) 
0.0624 
(0.1778) 
INTERCEPT -1.1147 
(0.2924) 
-1.1214 
(0.2920) 
-1.1220 
(0.2892) 
-1.1281 
(0.2863) 
-1.1362 
(0.2809) 
-0.9833 
(0.2744) 
BMIREF_DIC 0.3375 
(0.1126) 
0.3348 
(0.1125) 
0.3370 
(0.1124) 
0.3379 
(0.1122) 
0.3153 
(0.1103) REMOVED 
RACE_DIC 0.00342 
(0.2437) 
0.00558 
(0.2436) REMOVED --- --- --- 
JEWISH -0.0816 
(0.1608) 
-0.0213 
(0.1549) 
-0.0233 
(0.1541) REMOVED --- --- 
FAMHX1 0.1185 
(0.1499) 
0.1202 
(0.1497) 
0.1278 
(0.1494) 
0.1271 
(0.1493) 
REMOVED --- 
AGEGRP 0.0972 
(0.0295) 
0.0970 
(0.0295) 
0.0970 
(0.0294) 
0.0972 
(0.0294) 
0.1026 
(0.0287) 
0.1050 
(0.0286) 
Interactions:       
JEWSNP2 0.8447 
(0.6123) REMOVED --- --- --- --- 
-2 log L 1800.186 1802.167 1803.269 1803.292 1866.184 1874.379 
Notes  
Evaluate 
EMM with 
the 
likelihood 
ratio test* 
Removed 
RACE_DIC 
Removed 
JEWISH 
Removed 
FAMHX1 
Removed 
BMIREF_D
IC 
Test of 
interaction 
term 
 
χ2 (1): = 
1802.167-
1800.186=1
.981; p=0.16 
--- --- --- --- 
Change in 
estimate   
|-0.0171--
0.0188| = 
0.0017 
|-0.0171--
0.0174| = 
0.0003 
|-0.0171- 
0.0386| = 
0.0557 
|-0.0171- 
0.0624| = 
0.0795 
Compare to:  Full Model Model 2 Model 2 Model 2 Model 2 
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Conclusion:  
Interaction 
term is not 
contributing 
to the model 
(p>0.10) 
and can be 
removed. 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Family 
history is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. BMI is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.13. Model building procedure for SNP rs1800206 (CC vs. CG+GG) in post-menopausal 
women, PA interaction 
 Full Model Model 2 Model 3 Model 4 Model 5 Model 6 
 β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 1,233 1,233 1,233 1,234 1,275 1,362 
Main 
Exposure: 
rs1800206 
0.4547 
(0.3616) 
-0.0127 
(0.1885) 
-0.0101 
(0.1882) 
-0.0130 
(0.1881) 
0.0318 
(0.1852) 
0.0624 
(0.1778) 
INTERCEPT -0.9554 
(0.3192) 
-0.9002 
(0.3164) 
-0.9087 
(0.3142) 
-0.8924 
(0.3116) 
-0.9491 
(0.3078) 
-0.9833 
(0.2744) 
PA_1 0.1252 
(0.1622) 
0.0552 
(0.1553) 
0.0535 
(0.1551) 
0.0480 
(0.1550) 
0.0927 
(0.1527) REMOVED 
PA_2 -0.1608 
(0.1716) 
-0.1605 
(0.1619) 
-0.1612 
(0.1619) 
-0.1657 
(0.1618) 
-0.1346 
(0.1592) REMOVED 
PA_3 -0.1502 
(0.1692) 
-0.2679 
(0.1592) 
-0.2688 
(0.1591) 
-0.2752 
(0.1590) 
-0.2799 
(0.1567) REMOVED 
RACE_DIC 0.0810 
(0.2535) 
0.0777 
(0.2531) 
0.0833 
(0.2519) REMOVED --- --- 
JEWISH -0.0304 
(0.1608) 
-0.0365 
(0.1605) REMOVED --- --- --- 
FAMHX1 0.1275 
(0.1545) 
0.1123 
(0.1540) 
0.1111 
(0.1539) 
0.1178 
(0.1535) 
REMOVED --- 
AGEGRP 0.1025 
(0.0307) 
0.1017 
(0.0306) 
0.1020 
(0.0306) 
0.1013 
(0.0305) 
0.1090 
(0.0300) 
0.1050 
(0.0286) 
Interactions:       
PA1SNP2 -0.8180 
(0.5702) REMOVED --- --- --- --- 
PA2SNP2 -0.0895 
(0.5281) REMOVED --- --- --- --- 
PA3SNP2 -1.0248 
(0.5136) REMOVED --- --- --- --- 
-2 log L 1685.107 1690.851 1690.903 1692.180   
Notes  
Evaluate 
EMM with 
the 
likelihood 
ratio test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Removed 
FAMHX1 
Removed 
PA_1, 
PA_2, 
PA_3 
Test of 
interaction 
term 
 
χ2 (3): = 
1690.851-
1685.107=5
.744; p=0.12 
--- --- --- --- 
Change in 
estimate   
|-0.0127--
0.0101| = 
0.0026 
|-0.0127--
0.0130| = 
0.0003 
|-0.0127-
0.0318| = 
0.0445 
|-0.0127--
0.0624| = 
0.0751 
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Compare to:  Full Model Model 2 Model 2 Model 2 Model 2 
Conclusion:  
Interaction 
term is not 
contributing 
to the 
model 
(p>0.10) 
and can be 
removed. 
Change in 
estimate < 
0.10. 
Jewish is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Family 
history is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. PA is 
not a 
confounder 
and is 
removed 
from the 
model 
 
  187
 
TABLE D.14. Model building procedure for SNP rs4253623 (AA vs. AG+GG) in post-menopausal 
women, NSAID interaction 
 Full Model Model 2 Model 3 Model 4 Model 5 Model 6 
 β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 1253 1253 1253 1254 1295 1377 
Main 
Exposure: 
rs4253623 
-0.1747 
(0.1583) 
-0.0734 
(0.1350) 
-0.0729 
(0.1350) 
-0.0741 
(0.1349) 
-0.0532 
(0.1330) 
-0.0716 
(0.1281) 
INTERCEPT -0.9549 
(0.2936) 
-0.9813 
(0.2927) 
-0.9895 
(0.2895) 
-0.9801 
(0.2871) 
-1.0153 
(0.2828) 
-0.9837 
(0.2740) 
ASPNEW -0.4644 
(0.1511) 
-0.3737 
(0.1313) 
-0.3734 
(0.1313) 
-0.3761 
(0.1313) 
-0.3606 
(0.1291) REMOVED 
RACE_DIC 0.0642 
(0.2551) 
0.0648 
(0.2549) 
0.0694 
(0.2538) REMOVED REMOVED REMOVED 
JEWISH -0.0258 
(0.1586) 
-0.0295 
(0.1585) REMOVED REMOVED REMOVED REMOVED 
FAMHX1 0.1076 
(0.1549) 
0.1161 
(0.1547) 
0.1151 
(0.1546) 
0.1220 
(0.1542) 
REMOVED REMOVED 
AGEGRP 0.1187 
(0.0304) 
0.1190 
(0.0304) 
0.1193 
(0.0303) 
0.1188 
(0.0302) 
0.1262 
(0.0297) 
0.1071 
(0.0285) 
Interactions:       
ASPSNP3 
0.3702 
(0.3024) REMOVED REMOVED REMOVED REMOVED REMOVED 
-2 log L 1711.883 1713.379 1713.414 1714.576 1770.055 1894.097 
Notes  
Evaluate 
EMM with 
the 
likelihood 
ratio test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Removed 
FAMHX1 
Removed 
ASPNEW 
Test of 
interaction 
term 
 
χ2 (1): = 
1713.379-
1711.883=1
.496; p=0.22 
--- --- --- --- 
Change in 
estimate   
|-0.0734 
--0.0729| = 
0.0005 
|-0.0734--
0.0741| = 
0.0007 
|-0.0734- -
0.0532| = 
0.0202 
|-0.0734- -
0.0716| = 
0.0018 
Compare to:  Full Model Model 2 Model 2 Model 2 Model 2 
  188
Conclusion:  
Interaction 
term is not 
contributing 
to the 
model 
(p>0.10) 
and can be 
removed. 
Change in 
estimate < 
0.10. 
Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Family 
history is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Aspirin is 
not a 
confounder 
and is 
removed 
from the 
model 
 
 
 
TABLE D.15. ORs, ICRs and multiplicative p-values for rs4253623 by aspirin use 
Exposure Status Genotypes Controls (N) 
Cases 
(N) 
ORadjusted 
(95% CI)* 
ICR 
(95% CI) 
P-
value† 
AA 339 403 1.00   Non-
User 
AG+GG 108 108 0.86 (0.63, 1.16)   
AA 140 113 0.64 (0.48, 0.85)   
Aspirin 
Use 
User 
AG+GG 42 42 0.79 (0.50, 1.25) 
0.96 
(-0.91, 2.82) 0.22 
*adjusted for age 
†multiplicative p-value 
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TABLE D.16. Model building procedure for SNP rs4253699 (TT vs. CT+CC) in post-menopausal 
women, PA interaction 
 Full Model Model 2 Model 3 Model 4 Model 5 Model 6 
 β (SE) β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 1239 1239 1239 1240 1281 1370 
Main Exposure: 
rs4253699 
0.4709 
(0.2135) 
0.0889 
(0.1182) 
0.0891 
(0.1180) 
0.0919 
(0.1179) 
0.0685 
(0.1160) 
0.0954 
(0.1115) 
INTERCEPT -1.1443 
(0.3237) 
-1.0222 
(0.3170) 
-1.0210 
(0.3149) 
-1.0104 
(0.3123) 
-1.0479 
(0.3085) 
-1.0703 
(0.2753) 
PA_1 0.3334 
(0.1960) 
0.0716 
(0.1552) 
0.0718 
(0.1550) 
0.0671 
(0.1550) 
0.1099 
(0.1527) REMOVED 
PA_2 0.00480 
(0.2051) 
-0.1213 
(0.1607) 
-0.1212 
(0.1607) 
-0.1257 
(0.1606) 
-0.0970 
(0.1581) REMOVED 
PA_3 -0.0506 
(0.2053) 
-0.2945 
(0.1595) 
-0.2944 
(0.1595) 
-0.3003 
(0.1593) 
-0.3019 
(0.1570) REMOVED 
RACE_DIC 0.0642 
(0.2524) 
0.0580 
(0.2515) 
0.0572 
(0.2503) REMOVED REMOVED REMOVED 
JEWISH -0.0198 
(0.1603) 
0.00538 
(0.1595) REMOVED REMOVED REMOVED REMOVED 
FAMHX1 0.1105 
(0.1545) 
0.1075 
(0.1542) 
0.1076 
(0.1541) 
0.1146 
(0.1537) 
REMOVED REMOVED 
AGEGRP 0.1073 
(0.0305) 
0.1098 
(0.0305) 
0.1097 
(0.0305) 
0.1092 
(0.0304) 
0.1163 
(0.0299) 
0.1111 
(0.0285) 
Interactions:       
PA1SNP4 -0.7006 
(0.3223) REMOVED REMOVED REMOVED REMOVED REMOVED 
PA2SNP4 -0.3260 
(0.3294) REMOVED REMOVED REMOVED REMOVED REMOVED 
PA3SNP4 -0.6200 
(0.3275) REMOVED REMOVED REMOVED REMOVED REMOVED 
-2 log L 1690.326 1696.261 1696.262 1697.439 1752.145 1882.945 
Notes  
Evaluate 
EMM with 
the 
likelihood 
ratio test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Removed 
FAMHX1 
Removed 
PA_1, 
PA_2, 
PA_3 
Test of 
interaction term  
χ2 (3): = 
1696.261-
1690.326=5
.935; 
p=0.11 
--- --- --- --- 
Change in 
estimate   
|0.0889-
0.0891| = 
0.0002 
|0.0889-
0.0919| = 
0.003 
|0.0889- 
0.0685| = 
0.0204 
|0.0889- 
0.0954| = 
0.0065 
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Compare to:  Full Model Model 2 Model 2 Model 2 Model 2 
Conclusion:  
Interaction 
term is not 
contributin
g to the 
model 
(p>0.10) 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Jewish is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Family 
history is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. PA is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.17. Model building procedure for SNP rs4253699 (TT vs. CT+CC) in post-menopausal 
women, NSAID interaction 
 Full Model Model 2 Model 3 Model 4 Model 5 
 β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 1247 1247 1247 1248 1288 
Main 
Exposure: 
rs4253699 
-0.0372 
(0.1358) 
0.0764 
(0.1178) 
-0.0378 
(0.1357) 
-0.0332 
(0.1356) 
-0.0738 
(0.1334) 
INTERCEPT -1.0044 
(0.2960) 
-1.0628 
(0.2939) 
-1.0085 
(0.2931) 
-1.0050 
(0.2907) 
-1.0152 
(0.2867) 
ASPNEW -0.5631 
(0.1664) 
-0.3959 
(0.1321) 
-0.5629 
(0.1664) 
-0.5632 
(0.1664) 
-0.5521 
(0.1635) 
RACE_DIC 0.0421 
(0.2576) 
0.0289 
(0.2570) 
0.0445 
(0.2564) REMOVED REMOVED 
JEWISH -0.0156 
(0.1590) 
-0.0182 
(0.1589) REMOVED REMOVED REMOVED 
FAMHX1 0.1355 
(0.1543) 
0.1369 
(0.1542) 
0.1349 
(0.1542) 
0.1423 
(0.1539) 
REMOVED 
AGEGRP 0.1220 
(0.0305) 
0.1236 
(0.0305) 
0.1222 
(0.0304) 
0.1220 
(0.0304) 
0.1290 
(0.0298) 
Interactions:      
ASPSNP4 0.4546 
(0.2721) REMOVED 
0.4549 
(0.2720) 
0.4487 
(0.2719) 
0.4687 
(0.2673) 
-2 log L 1699.775 1702.574 1699.785 1700.908 1755.090 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Removed 
FAMHX1 
Test of 
interaction 
term 
 
χ2 (1): = 
1702.574-
1699.775=2.799; 
p=0.09
--- --- --- 
Change in 
estimate   
|-0.0372--
0.0378| = 
0.0006 
|-0.0372--
0.0332| = 
0.004 
|-0.0372- -
0.0738| = 
0.0366 
Compare to:  Full Model Full Model Full Model Full Model 
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Conclusion:  
Interaction term 
is contributing 
to the model 
(p<0.10) and 
will be kept in 
the model. 
Results will be 
stratified. 
Change in 
estimate < 
0.10. Jewish 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Family 
history is 
not a 
confounder 
and is 
removed 
from the 
model 
 
 
TABLE D.18. ORs, ICRs and multiplicative p-values for rs4253699 by physical activity level and 
aspirin use 
Exposure Status Genotypes Controls (N) 
Cases 
(N) 
ORadjusted 
(95% CI)* 
ICR 
(95% CI) P-value† 
TT 124 113 1.00   
0 
CT+CC 63 94 1.61 (1.07, 2.43)   
TT 89 117 1.48 (1.01, 2.16)   
< 0.69 
CT+CC 56 55 1.12 (0.71, 1.77) 
-1.62 
(-2.89, -0.36)  
TT 91 80 1.03 (0.69, 1.53)   
0.7-2.6 
CT+CC 54 56 1.20 (0.76, 1.90) 
-0.92 
(-2.21, 0.37)  
TT 93 79 0.97 (0.65, 1.45)   
Physical 
Activity 
(hrs/wk) 
≥ 2.7 
CT+CC 69 48 0.79 (0.50, 1.24) 
-1.08 
(-2.23, 0.06) 0.06 
TT 261 310 1.00   
Non-
User 
CT+CC 182 201 0.93 (0.72, 1.21)   
TT 125 90 0.58 (0.42, 0.79)   
Aspirin 
Use 
User 
CT+CC 56 63 0.85 (0.57, 1.28) 
1.09 
(-0.83, 3.01) 0.08 
*adjusted for age 
†multiplicative p-value 
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TABLE D.19. Model building procedure for SNP rs4253755 (GG vs. AG+AA) in post-menopausal 
women, PA interaction 
 Full Model Model 2 Model 3 Model 4 Model 5 
 β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 1,242 1,242 1,242 1,243 1,285 
Main 
Exposure: 
rs4253755 
0.2551 
(0.2531) 
0.0913 
(0.1396) 
0.2552 
(0.2531) 
0.2684 
(0.2516) 
0.2431 
(0.2462) 
INTERCEPT -0.9480 
(0.3165) 
-0.9351 
(0.3143) 
-0.9497 
(0.3143) 
-0.9367 
(0.3114) 
-0.9825 
(0.3078) 
PA_1 0.1976 
(0.1748) 
0.0169 
(0.1545) 
0.1973 
(0.1746) 
0.1962 
(0.1746) 
0.2243 
(0.1722) 
PA_2 -0.2238 
(0.1804) 
-0.1823 
(0.1608) 
-0.2238 
(0.1804) 
-0.2242 
(0.1804) 
-0.1843 
(0.1777) 
PA_3 -0.3585 
(0.1823) 
-0.3526 
(0.1597) 
-0.3586 
(0.1823) 
-0.3613 
(0.1821) 
-0.3362 
(0.1798) 
RACE_DIC 0.0783 
(0.2552) 
0.0800 
(0.2543) 
0.0794 
(0.2539) REMOVED --- 
JEWISH -0.00704 
(0.1594) 
0.00152 
(0.1589) REMOVED --- --- 
FAMHX1 0.0876 
(0.1549) 
0.0816 
(0.1544) 
0.0874 
(0.1549) 
0.0933 
(0.1546) 
REMOVED 
AGEGRP 0.1062 
(0.0305) 
0.1084 
(0.0304) 
0.1063 
(0.0305) 
0.1054 
(0.0304) 
0.1129 
(0.0299) 
Interactions:      
PA1SNP3 -0.8364 
(0.3783) REMOVED 
-0.8361 
(0.3782) 
-0.8536 
(0.3776) 
-0.7958 
(0.3700) 
PA2SNP3 0.2061 
(0.3970) REMOVED 
0.2061 
(0.3970) 
0.1891 
(0.3964) 
0.1253 
(0.3867) 
PA3SNP3 -0.00054 
(0.3794) REMOVED 
-0.00039 
(0.3793) 
-0.0162 
(0.3787) 
-0.1371 
(0.3701) 
-2 log L 1691.449 1699.463 1691.451 1692.522 1749.938 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Removed 
FAMHX1 
Test of 
interaction 
term 
 
χ2 (3): = 
1699.463-
1691.449=8.014; 
p=0.05
--- --- --- 
Change in 
estimate   
|0.2551-
0.2552| = 
0.0001 
|0.2551-
0.2684| = 
0.0133 
|0.2551- 
0.2431| = 
0.0120 
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Compare to:  Full Model Full Model Full Model Full Model 
Conclusion:  
Interaction term 
is contributing 
to the model 
and will be 
kept. Results 
should be 
presented as 
stratified.. 
Change in 
estimate < 
0.10. Jewish 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. 
Family 
history is 
not a 
confounder 
and is 
removed 
from the 
model 
 
 
TABLE D.20. Summary of odds ratios for rs4253755 stratified by PA 
Exposure Status Genotypes Controls (N) 
Cases 
(N) 
Stratum OR 
(95% CI) 
Adjusted OR 
(95% CI)* 
AA 147 162 1.00 1.00 
0 
AG+AA 53 36 1.34 (0.83, 2.16) 
1.28 
(0.79, 2.07) 
AA 107 144 1.00 1.25 (0.89, 1.75) < 0.69 
AG+AA 39 30 0.57 (0.33, 0.98) 
0.72 
(0.42, 1.22) 
AA 123 93 1.00 0.83 (0.59, 1.18) 0.7-2.6 
AG+AA 38 33 1.42 (0.80, 2.54) 
1.20 
(0.68, 2.12) 
AA 119 103 1.00 0.71 (0.50, 1.02) 
Physical 
Activity 
(hrs/wk) 
≥ 2.7 
AG+AA 26 32 1.15 (0.67, 1.97) 
0.79 
(0.47, 1.34) 
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TABLE D.21. Model building procedure for SNP rs4253760 (TT vs. GT+GG) in 
post-menopausal women, no interactions 
 Full Model Model 2 Model 3 Model 4 
 β (SE) β (SE) β (SE) β (SE) 
Sample Size 1,282 1,283 1,284 1,330 
Main 
Exposure: 
rs4253760 
0.1891 
(0.1221) 
0.1957 
(0.1206) 
0.1918 
(0.1202) 
0.2056 
(0.1178) 
INTERCEPT -1.0274 
(0.2890) 
-1.0247 
(0.2868) 
-1.0211 
(0.2841) 
-1.0330 
(0.2789) 
RACE_DIC 0.0340 
(0.2507) REMOVED --- --- 
JEWISH 0.0335 
(0.1558) 
0.0304 
(0.1552) REMOVED --- 
FAMHX1 0.0872 
(0.1522) 
0.0944 
(0.1519) 
0.0929 
(0.1518) REMOVED 
AGEGRP 0.1032 
(0.0298) 
0.1030 
(0.0297) 
0.1034 
(0.0296) 
0.1076 
(0.0290) 
Interactions:     
-2 log L 1761.540 1762.675 1763.988 1826.088 
Notes  Removed RACE_DIC 
Removed 
JEWISH 
Removed 
FAMHX1 
Test of 
interaction 
term 
--- --- --- --- 
Change in 
estimate  
|0.1891-0.1957| 
= 0.0066 
|0.1891-
0.1918| = 
0.0027 
|0.1891- 
0.2056| = 
0.0165 
Compare to:  Full Model Full Model Full Model 
Conclusion:  
Change in 
estimate < 
0.10. Race is 
not a 
confounder and 
is removed 
from the model 
Change in 
estimate < 
0.10. Jewish 
is not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Family 
history is not 
a confounder 
and is 
removed 
from the 
model 
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TABLE D.22. Haplotypes, frequencies and Odds Ratios by menopausal status for six PPARA SNPs 
Haplotype 
Number* 
rs135542 rs1800206 rs4253623 rs4253699 rs4253755 rs4253760 Control 
Freq 
Case 
Freq 
OR 
(95% CI)† 
All women          
1 A C A C A G 0.06 0.06 0.99 (0.58, 1.70) 
2 A C A C A T 0.02 0.03 1.68 (0.73, 3.88) 
3 A C A C G G 0.02 0.02 0.98 (0.33, 2.89) 
4 A C A C G T 0.05 0.05 0.79 (0.41, 1.52) 
5 A C A T A G 0.03 0.03 1.07 (0.47, 2.44) 
6 A C A T G G 0.03 0.03 1.60 (0.74, 3.44) 
7 A C A T G T 0.41 0.40 0.98 (0.79, 1.22) 
8 A C G T G T 0.10 0.10 1.09 (0.72, 1.63) 
9 A G A C G G 0.01 0.02 2.49 (0.90, 6.86) 
10 A G A C G T 0.01 0.01 1.18 (0.32, 4.42) 
11 G C A C G T 0.01 0.01 1.37 (0.29, 6.55) 
12 G C A T G T 0.18 0.18 1.03 (0.74, 1.42) 
          
Post-menopausal women only        
1 A C A C A G 0.06 0.05 1.01 (0.49, 2.09) 
2 A C A C A T 0.02 0.03 2.03 (0.71, 5.82) 
3 A C A C G G 0.02 0.01 0.97 (0.23, 4.18) 
4 A C A C G T 0.06 0.05 0.89 (0.40, 1.99) 
5 A C A T A G 0.03 0.03 1.64 (0.61, 4.46) 
6 A C A T G G 0.02 0.04 2.83 (0.93, 8.65) 
7 A C A T G T 0.42 0.39 0.92 (0.70, 1.20) 
8 A C G C G T 0.01 0.01 0.77 (0.12, 4.91) 
9 A C G T G T 0.10 0.10 0.97 (0.59, 1.59) 
10 A G A C G G 0.01 0.03 5.02 (1.45, 17.39) 
11 A G A T G G 0.01 0.01 0.47 (0.08, 2.83) 
12 G C A C G T 0.01 0.01 0.42 (0.05, 3.55) 
13 G C A T G G 0.01 0.01 1.07 (0.13, 8.67) 
14 G C A T G T 0.17 0.18 1.19 (0.79, 1.80) 
*haplotypes with frequency ≥ 0.01 
†adjusted for age, frequency matched variable 
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FIGURE D.1. Kaplan-Meier curves for rs135542 (AA vs. AG+GG) for overall survival 
 
 
FIGURE D.2. Kaplan-Meier curve for rs1800206 (CC vs. CG+GG) for overall survival 
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FIGURE D.3. Kaplan-Meier curves for rs4253623 (AA vs. AG+GG) for overall survival 
 
 
FIGURE D.4. Kaplan-Meier curve for rs4253699 (TT vs. CT+CC) for overall survival 
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FIGURE D.5. Kaplan-Meier curve for rs4253755 (GG vs. AG+AA) for overall survival 
 
 
FIGURE D.6. Kaplan-Meier curve for rs4253760 (TT vs. GT+GG ) for overall survival 
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TABLE D.23. Model building procedure for SNP rs135542 (AA vs. AG+GG), 
looking at overall survival with continuous interaction term 
 Full Model Model 2 Model 3 Model 4 
 β (SE) β (SE) β (SE) β (SE) 
Sample Size 1010 1010 1011 1013 
Main 
Exposure: 
rs135542 
-0.24419 
(0.43248) 
-0.22084 
(0.18959) 
-0.18859 
(0.18866) 
-0.19903 
(0.18854) 
JEWISH -0.40175 
(0.27825) 
-0.40183 
(0.27825) REMOVED --- 
RACE_DIC 0.52756 
(0.31793) 
0.52756 
(0.31793) 
0.58208 
(0.31631) REMOVED 
Interactions:     
SNP1_DUR 0.0000202 
(0.0003356) REMOVED --- --- 
-2 log L 1659.942 1659.946 1662.497 1665.901 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Test of 
interaction 
term 
 
χ2 (1): 
1659.946– 
1659.942= 
0.004; p=0.95
--- --- 
Change in 
estimate   
|-0.22084--
0.18859| = 
0.0323 
|-0.22084- -
0.19903| = 
0.0218 
Compare to:  Full Model Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.24. Model building procedure for SNP rs1800206 (CC vs. CG+GG), 
looking at overall survival with continuous time interaction term 
 Full Model Model 2 Model 3 Model 4 
 β (SE) β (SE) β (SE) β (SE) 
Sample Size 1032 1032 1033 1034 
Main 
Exposure: 
rs1800206 
0.15791 
(0.69445) 
-0.28570 
(0.32995) 
-0.29635 
(0.32985) 
-0.27023 
(0.32966) 
JEWISH -0.55079 
(0.29430) 
-0.55031 
(0.29430) 
-0.58661 
(0.29314) REMOVED 
RACE_DIC 0.56211 
(0.30492) 
0.56025 
(0.30490) REMOVED --- 
Interactions:     
SNP2_DUR -0.0004162 
(0.0006035) REMOVED --- --- 
-2 log L 1702.728 1703.216 1706.424 1711.347 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
RACE_DIC 
Removed 
JEWISH 
Test of 
interaction 
term 
 
χ2 (1): 
1703.216– 
1702.728=0.488; 
p=0.48
--- --- 
Change in 
estimate   
|-0.28570--
0.29635| = 
0.0107 
|-0.28570- -
0.27023| = 
0.0155 
Compare to:  Full Model Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Race is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.25. Model building procedure for SNP rs4253623 (AA vs. AG+GG), 
looking at overall survival with continuous interaction term 
 Full Model Model 2 Model 3 Model 4 
 β (SE) β (SE) β (SE) β (SE) 
Sample Size 1,043 1,043 1,044 1,046 
Main 
Exposure: 
rs4253623 
0.11838 
(0.47793) 
-0.03073 
(0.21483) 
-0.00347 
(0.21454) 
-0.00277 
(0.21453) 
JEWISH -0.55396 
(0.29459) 
-0.55430 
(0.29458) REMOVED REMOVED 
RACE_DIC 0.54084 
(0.30487) 
0.54045 
(0.30486) 
0.60686 
(0.30364) REMOVED 
Interactions:     
SNP3_DUR -0.0001324 
(0.0003828) REMOVED REMOVED REMOVED 
-2 log L 1706.738 1706.858 1711.172 1715.084 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Test of 
interaction 
term 
 
χ2 (1): 
1706.738– 
1706.858= 0.12; 
p=0.73
--- --- 
Change in 
estimate   
|-0.03073--
0.00347| = 
0.02726 
|-0.03073-- 
0.00277| = 
0.0296 
Compare to:  Full Model Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.26. Model building procedure for SNP rs4253699 (TT vs. CT+CC), 
looking at overall survival with continuous interaction term 
 Full Model Model 2 Model 3 Model 4 
 β (SE) β (SE) β (SE) β (SE) 
Sample Size 1,038 1,038 1,039 1,040 
Main 
Exposure: 
rs4253699 
0.17208 
(0.40302) 
0.04990 
(0.18048) 
0.04900 
(0.18047) 
0.04902 
(0.18046) 
JEWISH -0.49808 
(0.28453) 
-0.49764 
(0.28452) REMOVED REMOVED 
RACE_DIC 0.58091 
(0.30466) 
0.58060 
(0.30465) 
0.64145 
(0.30339) REMOVED 
Interactions:     
SNP4_DUR -0.0001083 
(0.0003202) REMOVED REMOVED REMOVED 
-2 log L 1732.883 1732.998 1736.701  
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Test of 
interaction 
term 
 
χ2 (1): 
1732.883– 
1732.998= 
0.115; p=0.73
--- --- 
Change in 
estimate   
|0.04990-
0.04900| = 
0.009 
|0.04990-
0.04902| = 
0.0008 
Compare to:  Full Model Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.27. Model building procedure for SNP rs4253755 (GG vs. AG+AA), 
looking at overall survival with continuous time interaction term 
 Full Model Model 2 Model 3 Model 4 
 β (SE) β (SE) β (SE) β (SE) 
Sample Size 1047 1047 1048 1050 
Main 
Exposure: 
rs4253755 
0.45333 
(0.44432) 
0.10377 
(0.20539) 
0.11206 
(0.20534) 
0.07699 
(0.20387) 
JEWISH -0.34978 
(0.26833) 
-0.34957 
(0.26832) REMOVED --- 
RACE_DIC 0.46547 
(0.31890) 
0.46856 
(0.31894) 
0.51489 
(0.31755) REMOVED 
Interactions:     
SNP5_DUR -0.0003158 
(0.0003641) REMOVED --- --- 
-2 log L 1764.960 1765.722 1767.806 1770.639 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
RACE_DIC 
Test of 
interaction 
term 
 
χ2 (1): 
1764.960– 
1765.722=0.762; 
p=0.38
--- --- 
Change in 
estimate   
|0.10377-
0.11206| = 
0.0083 
|0.10377- 
0.07699| = 
0.0268 
Compare to:  Full Model Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.28. Model building procedure for SNP rs4253760 (TT vs. GT+GG), 
looking at overall survival with continuous time interaction term 
 Full Model Model 2 Model 3 Model 4 
 β (SE) β (SE) β (SE) β (SE) 
Sample Size 1017 1017 1018 1020 
Main 
Exposure: 
rs4253760 
0.76088 
(0.41558) 
0.04700 
(0.19100) 
0.79878 
(0.41410) 
0.81284 
(0.41404) 
JEWISH -0.38738 
(0.27671) 
-0.38712 
(0.27669) 
-0.41388 
(0.27558) REMOVED 
RACE_DIC 0.44255 
(0.32260) 
0.44358 
(0.32255) REMOVED --- 
Interactions:     
SNP6_DUR -0.0006499 
(0.0003442) REMOVED 
-0.0006512 
(0.0003443) 
-0.0006510 
(0.0003443) 
-2 log L 1686.081 1689.785 1688.057 1691.044 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
RACE_DIC 
Removed 
JEWISH 
Test of 
interaction 
term 
 
χ2 (1): 
1686.081– 
1689.785=3.704; 
p=0.05
--- --- 
Change in 
estimate   
|0.76088-
0.79878| = 
0.0379 
|0.76088- 
0.81284| = 
0.05196 
Compare to:  Full Model Full Model Full Model 
Conclusion:  
Interaction term 
is contributing 
to the model 
and will be 
kept. 
Change in 
estimate < 
0.10. Race is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
rs135542         
AA 85 6 1.00 1.00   < 45  
AG+GG 53 7 1.82 
(0.61, 
5.41) 
1.84  
(0.62, 
5.47) 
  
AA 136 16 1.00 1.66  
(0.65, 
4.24) 
  45-54  
AG+GG 104 10 0.83 
(0.38, 
1.83) 
1.37  
(0.50, 
3.77) 
-1.13  
(-3.60, 
1.35) 
 
AA 124 11 1.00 1.27  
(0.47, 
3.43) 
  55-64  
AG+GG 106 11 1.16 
(0.50, 
2.67) 
1.46  
(0.54, 
3.95) 
-0.65  
(-2.86, 
1.57) 
0.48 
AA 179 45 1.00 3.31  
(1.41, 
7.75) 
  
Age at 
diagnosis 
(years) 
≥ 65  
AG+GG 104 16 0.65 
(0.37, 
1.14) 
2.14  
(0.84, 
5.48) 
-2.00  
(-5.11, 
1.11) 
 
AA 175 16 1.00 1.00   Pre-
menopausal AG+GG 117 14 1.28 
(0.62, 
2.62) 
1.26  
(0.63, 
2.54) 
  
AA 335 60 1.00 1.85  
(1.09, 
3.13) 
  
Menopausal 
Status 
Post-
menopausal 
AG+GG 244 30 0.71 
(0.46, 
1.10) 
1.31  
(0.73, 
2.35) 
-0.80 
(-2.05, 
0.45) 
0.17 
AA 106 4 1.00 1.00   In-situ 
AG+GG 60 3 1.32 
(0.30, 
5.92) 
1.33  
(0.30, 
5.94) 
  
AA 418 74 1.00 4.45  
(1.63, 
12.18) 
  
Stage 
Invasive 
AG+GG 307 41 0.77 
(0.53, 
1.13) 
3.44  
(1.23, 
9.59) 
-1.35 
(-4.46, 
1.77) 
0.50 
AA 71 25 1.00 1.00   ER- 
AG+GG 53 11 0.64 
(0.32, 
1.31) 
0.64  
(0.31, 
1.29) 
  
ER status 
ER+ AA 268 34 1.00 0.38  
(0.23, 
0.64) 
  
  207
TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
  AG+GG 173 16 0.75 
(0.41, 
1.36) 
0.29  
(0.15, 
0.54) 
0.27 
(-0.24, 
0.78) 
0.72 
AA 101 31 1.00 1.00   PR- 
AG+GG 70 18 0.85 
(0.48, 
1.53) 
0.85  
(0.48, 
1.52) 
  
AA 238 28 1.00 0.41  
(0.24, 
0.68) 
  
PR status 
PR+ 
AG+GG 156 9 0.52 
(0.24, 
1.09) 
0.21  
(0.10, 
0.44) 
-0.05  
(-0.62, 
0.53) 
0.30 
AA 244 17 1.00 1.00   No 
AG+GG 180 5 0.41 
(0.15, 
1.11) 
0.41  
(0.15, 
1.11) 
  
AA 136 19 1.00 1.95  
(1.01, 
3.75) 
  
Received 
chemotherapy 
Yes 
AG+GG 108 13 0.87 
(0.43, 
1.76) 
1.70  
(0.83, 
3.50) 
0.34  
(-1.02, 
1.70) 
0.21 
AA 149 14 1.00 1.00   No 
AG+GG 121 6 0.55 
(0.21, 
1.42) 
0.54  
(0.21, 
1.42) 
  
AA 232 22 1.00 1.02  
(0.52, 
1.99) 
  
Received 
radiation 
Yes 
AG+GG 168 12 0.76 
(0.38, 
1.54) 
0.78  
(0.36, 
1.68) 
0.21  
(-0.64, 
1.07) 
0.58 
AA 144 13 1.00 1.00   No 
AG+GG 117 7 0.67 
(0.27, 
1.69) 
0.67  
(0.27, 
1.68) 
  
AA 236 19 1.00 0.88  
(0.43, 
1.78) 
  
Received 
hormone 
therapy 
Yes 
AG+GG 169 11 0.82 
(0.39, 
1.73) 
0.72  
(0.32, 
1.61) 
0.17  
(-0.71, 
1.06) 
0.73 
AA 380 54 1.00 1.00   No 
AG+GG 300 35 0.84 
(0.55, 
1.28) 
0.83  
(0.55, 
1.28) 
  
NSAID Use 
Yes AA 127 20 1.00 1.10  
(0.66, 
1.84) 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
  AG+GG 54 8 0.95 
(0.42, 
2.15) 
1.04  
(0.50, 
2.19) 
0.11  
(-0.84, 
1.05) 
0.79 
AA 41 7 1.00 1.00   No change 
or loss AG+GG 37 6 0.97 
(0.33, 
2.89) 
0.96  
(0.32, 
2.87) 
  
AA 126 17 1.00 0.84  
(0.35, 
2.05) 
  3.01-8.15 
AG+GG 95 10 0.78 
(0.36, 
1.71) 
0.66  
(0.25, 
1.74) 
-0.15  
(-1.43, 
1.14) 
 
AA 161 33 1.00 1.22  
(0.54, 
2.76) 
 0.75 
Weight gain 
from age 20 
(kg)* 
≥ 8.16 
AG+GG 106 13 0.64 
(0.34, 
1.21) 
0.78  
(0.31, 
1.95) 
-0.40  
(-1.83, 
1.02) 
 
AA 239 26 1.00 1.00   < 25.00 
AG+GG 177 18 0.93 
(0.51, 
1.70) 
0.93  
(0.51, 
1.70) 
  
AA 166 24 1.00 1.30  
(0.75, 
2.26) 
  25.00-29.99 
AG+GG 119 12 0.72 
(0.36, 
1.44) 
0.93  
(0.47, 
1.85) 
-0.30  
(-1.29, 
0.70) 
 
AA 119 28 1.00 2.02  
(1.19, 
3.45) 
 0.98 
BMI at 
reference 
(kg/m2) 
≥ 30.00 
AG+GG 71 14 0.88 
(0.46, 
1.66) 
1.76  
(0.92, 
3.37) 
-0.19  
(-1.54, 
1.15) 
 
rs1800206         
CC 123 9 1.00 1.00   < 45  
CG+GG 16 2 1.67 
(0.36, 
7.75) 
1.72  
(0.37, 
7.96) 
  
CC 229 27 1.00 1.60  
(0.75, 
3.39) 
  45-54  
CG+GG 22 2 0.81 
(0.19, 
3.39) 
1.29  
(0.28, 
5.98) 
-1.03  
(-4.34, 
2.29) 
 
CC 207 20 1.00 1.33  
(0.60, 
2.91) 
  
Age at 
diagnosis 
(years) 
55-64  
CG+GG 27 1 0.40 
(0.05, 
2.96) 
0.52  
(0.07, 
4.13) 
-1.52  
(-4.65, 
1.61) 
0.90 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
CC 253 59 1.00 2.98  
(1.48, 
6.01) 
   ≥ 65  
CG+GG 32 5 0.73 
(0.29, 
1.82) 
2.17  
(0.73, 
6.47) 
-1.53  
(-5.08, 
2.02) 
 
CC 271 26 1.00 1.00   Pre-
menopausal CG+GG 27 4 1.53 
(0.53, 
4.39) 
1.48  
(0.52, 
4.21) 
  
CC 524 86 1.00 1.60  
(1.05, 
2.44) 
  
Menopausal 
Status 
Post-
menopausal 
CG+GG 67 6 0.58 
(0.25, 
1.32) 
0.93  
(0.38, 
2.23) 
-1.15  
(-2.99, 
0.68) 
0.17 
CC 147 7 1.00 1.00   In-situ 
CG+GG 25 0 --- ---   
CC 665 108 1.00 3.25  
(1.51, 
6.99) 
  
Stage 
Invasive 
CG+GG 72 10 0.90 
(0.47, 
1.72) 
2.92  
(1.11, 
7.67) 
0.67  
(-1.26, 
2.60) 
0.17 
CC 114 29 1.00 1.00   ER- 
CG+GG 12 7 2.07 
(0.91, 
4.73) 
2.15  
(0.94, 
4.91) 
  
CC 404 49 1.00 0.50  
(0.31, 
0.78) 
  
ER status 
ER+ 
CG+GG 49 2 0.37 
(0.09, 
1.50) 
0.18  
(0.04, 
0.76) 
-1.46  
(-3.31, 
0.39) 
0.02 
CC 154 44 1.00 1.00   PR- 
CG+GG 19 7 1.28 
(0.58, 
2.85) 
1.29  
(0.58, 
2.86) 
  
CC 364 34 1.00 0.35  
(0.22, 
0.55) 
  
PR status 
PR+ 
CG+GG 42 2 0.55 
(0.13, 
2.30) 
0.19  
(0.05, 
0.79) 
-0.44  
(-1.53, 
0.64) 
0.28 
CC 393 20 1.00 1.00   No 
CG+GG 38 2 1.09 
(0.25, 
4.65) 
1.08  
(0.25, 
4.64) 
  
Received 
chemotherapy 
Yes CC 215 30 1.00 2.63  
(1.50, 
4.64) 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
  CG+GG 37 4 0.81 
(0.28, 
2.29) 
2.14  
(0.73, 
6.27) 
-0.58  
(-3.41, 
2.26) 
0.76 
CC 246 19 1.00 1.00   No 
CG+GG 29 2 0.96 
(0.21, 
3.93) 
0.92  
(0.22, 
3.97) 
  
CC 364 31 1.00 1.10  
(0.62, 
1.94) 
  
Received 
radiation 
Yes 
CG+GG 46 4 1.08 
(0.38, 
3.07) 
1.18  
(0.40, 
3.46) 
0.15  
(-1.65, 
1.96) 
0.87 
CC 238 18 1.00 1.00   No 
CG+GG 28 3 1.41 
(0.42, 
4.79) 
1.45  
(0.43, 
4.93) 
  
CC 368 29 1.00 1.02  
(0.57, 
1.84) 
  
Received 
hormone 
therapy 
Yes 
CG+GG 47 3 0.87 
(0.26, 
2.85) 
0.87  
(0.26, 
2.97) 
-0.60  
(-2.69, 
1.49) 
0.54 
CC 616 83 1.00 1.00   No 
CG+GG 75 7 0.74 
(0.34, 
1.59) 
0.74  
(0.34, 
1.59) 
  
CC 168 27 1.00 1.19  
(0.77, 
1.83) 
  
NSAID Use 
Yes 
CG+GG 18 3 1.03 
(0.31, 
3.39) 
1.22  
(0.38, 
3.86) 
0.30  
(-1.26, 
1.85) 
0.65 
CC 74 12 1.00 1.00   No change 
or loss CG+GG 4 1 1.69 
(0.22, 
13.05) 
1.66  
(0.22, 
12.88) 
  
CC 200 26 1.00 0.86  
(0.43, 
1.72) 
  3.01-8.15 
CG+GG 28 3 0.86 
(0.26, 
2.84) 
0.72  
(0.20, 
2.58) 
-0.79  
(-4.34, 
2.75) 
 
CC 240 44 1.00 1.17  
(0.61, 
2.23) 
 0.45 
Weight gain 
from age 20 
(kg)* 
≥ 8.16 
CG+GG 34 2 0.34 
(0.08, 
1.41) 
0.41  
(0.09, 
1.82) 
-1.43  
(-5.04, 
2.19) 
 
CC 391 41 1.00 1.00   BMI at 
reference 
(kg/m2) 
< 25.00 
CG+GG 36 3 0.82 
(0.25, 
2.65) 
0.82  
(0.25, 
2.63) 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
CC 249 35 1.00 1.32  
(0.84, 
2.07) 
  25.00-29.99 
CG+GG 41 4 0.73 
(0.26, 
2.04) 
0.96  
(0.34, 
2.67) 
-0.18  
(-1.61, 
1.26) 
 
CC 172 39 1.00 2.04  
(1.32, 
3.16) 
 0.99 
 
≥ 30.00 
CG+GG 20 3 0.74 
(0.23, 
2.38) 
1.49  
(0.46, 
4.80) 
-0.37  
(-2.43, 
1.70) 
 
rs4253623         
AA 113 10 1.00 1.00   < 45  
AG+GG 27 4 1.65 
(0.52, 
5.27) 
1.63  
(0.51, 
5.20) 
  
AA 197 22 1.00 1.27  
(0.60, 
2.68) 
  45-54  
AG+GG 56 7 1.10 
(0.47, 
2.58) 
1.39  
(0.53, 
3.64) 
-0.51  
(-2.70, 
1.67) 
 
AA 182 15 1.00 0.94  
(0.42, 
2.09) 
  55-64  
AG+GG 55 5 1.10 
(0.40, 
3.03) 
1.05  
(0.36, 
3.06) 
-0.52  
(-2.65, 
1.60) 
0.75 
AA 222 50 1.00 2.41  
(1.22, 
4.74) 
  
Age at 
diagnosis 
(years) 
≥ 65  
AG+GG 69 12 0.79 
(0.42, 
1.49) 
1.91  
(0.83, 
4.42) 
-1.13  
(-3.56, 
1.30) 
 
AA 235 24 1.00 1.00   Pre-
menopausal AG+GG 65 8 1.18 
(0.53, 
2.63) 
1.14  
(0.52, 
2.51) 
  
AA 461 72 1.00 1.44  
(0.93, 
2.25) 
  
Menopausal 
Status 
Post-
menopausal 
AG+GG 138 18 0.85 
(0.51, 
1.43) 
1.23  
(0.68, 
2.23) 
-0.36  
(-1.50, 
0.79) 
0.51 
AA 135 6 1.00 1.00   In-situ 
AG+GG 42 1 0.54 
(0.07, 
4.50) 
0.54  
(0.07, 
4.48) 
  
Stage 
Invasive AA 579 91 1.00 3.38  
(1.48, 
7.73) 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
  AG+GG 165 27 1.04 
(0.68, 
1.60) 
3.52  
(1.45, 
8.52) 
0.60  
(-1.27, 
2.46) 
0.52 
AA 98 27 1.00 1.00   ER- 
AG+GG 30 8 0.97 
(0.44, 
2.13) 
0.96  
(0.44, 
2.12) 
  
AA 343 41 1.00 0.45  
(0.28, 
0.74) 
  
ER status 
ER+ 
AG+GG 112 12 0.89 
(0.47, 
1.70) 
0.41  
(0.21, 
0.80) 
-0.01  
(-0.83, 
0.80) 
0.89 
AA 133 40 1.00 1.00   PR- 
AG+GG 42 10 0.84 
(0.42, 
1.67) 
0.83  
(0.42, 
1.67) 
  
AA 308 28 1.00 0.33  
(0.20, 
0.54) 
  
PR status 
PR+ 
AG+GG 100 10 1.07 
(0.52, 
2.20) 
0.35  
(0.18, 
0.71) 
0.19  
(-0.44, 
0.82) 
0.62 
AA 332 16 1.00 1.00   No 
AG+GG 106 5 0.97 
(0.36, 
2.65) 
0.97  
(0.36, 
2.66) 
  
AA 198 24 1.00 2.43  
(1.29, 
4.58) 
  
Received 
chemotherapy 
Yes 
AG+GG 54 11 1.62 
(0.79, 
3.31) 
3.94  
(1.83, 
8.49) 
1.53  
(-1.15, 
4.21) 
0.41 
AA 205 16 1.00 1.00   No 
AG+GG 68 5 0.94 
(0.34, 
2.56) 
0.94  
(0.34, 
2.56) 
  
AA 327 24 1.00 0.94  
(0.50, 
1.77) 
  
Received 
radiation 
Yes 
AG+GG 92 11 1.61 
(0.79, 
3.29) 
1.50  
(0.70, 
3.24) 
0.63  
(-0.66, 
1.91) 
0.39 
AA 211 15 1.00 1.00   No 
AG+GG 58 5 1.21 
(0.44, 
3.33) 
1.22  
(0.44, 
3.35) 
  
AA 318 23 1.00 1.00  
(0.52, 
1.92) 
  
Received 
hormone 
therapy 
Yes 
AG+GG 101 9 1.22 
(0.57, 
2.65) 
1.22  
(0.54, 
2.79) 
0.00  
(-1.48, 
1.49) 
>0.99 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
AA 551 73 1.00 1.00   No 
AG+GG 146 17 0.89 
(0.53, 
1.51) 
0.89  
(0.53, 
1.51) 
  
AA 137 21 1.00 1.15  
(0.71, 
1.88) 
  
NSAID Use 
Yes 
AG+GG 52 10 1.21 
(0.57, 
2.57) 
1.40  
(0.72, 
2.72) 
0.36  
(-0.74, 
1.45) 
0.51 
AA 63 10 1.00 1.00   No change 
or loss AG+GG 16 3 1.29 
(0.36, 
4.70) 
1.30  
(0.35, 
4.75) 
  
AA 184 24 1.00 0.89  
(0.42, 
1.90) 
  3.01-8.15 
AG+GG 51 4 0.62 
(0.21, 
1.78) 
0.55  
(0.17, 
1.78) 
-0.64  
(-2.55, 
1.27) 
 
AA 206 34 1.00 1.10  
(0.54, 
2.25) 
 >0.99 
Weight gain 
from age 20 
(kg)* 
≥ 8.16 
AG+GG 67 11 1.00 
(0.51, 
1.98) 
1.10  
(0.46, 
2.60) 
-0.30  
(-2.15, 
1.54) 
 
AA 339 31 1.00 1.00   < 25.00 
AG+GG 94 13 1.51 
(0.79, 
2.88) 
1.50  
(0.79, 
2.87) 
  
AA 228 32 1.00 1.52  
(0.93, 
2.49) 
  25.00-29.99 
AG+GG 69 7 0.71 
(0.32, 
1.62) 
1.09  
(0.48, 
2.47) 
-0.94  
(-2.37, 
0.50) 
 
AA 147 34 1.00 2.37  
(1.46, 
3.85) 
 0.45 
BMI at 
reference 
(kg/m2) 
≥ 30.00 
AG+GG 44 8 0.82 
(0.38, 
1.77) 
1.94  
(0.89, 
4.21) 
-0.93  
(-2.82, 
0.95) 
 
rs4253699         
TT 83 8 1.00 1.00   < 45  
CT+CC 58 6 1.07 
(0.37, 
3.07) 
1.08  
(0.37, 
3.11) 
  
TT 152 19 1.00 1.30  
(0.57, 
2.96) 
  
Age at 
diagnosis 
(years) 
45-54  
CT+CC 96 10 0.84 
(0.39, 
1.82) 
1.10  
(0.43, 
2.78) 
-0.28  
(-1.81, 
1.25) 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
TT 151 12 1.00 0.84  
(0.34, 
2.06) 
  55-64  
CT+CC 83 8 1.21 
(0.49, 
2.95) 
1.02  
(0.38, 
2.71) 
0.09  
(-1.27, 
1.46) 
>0.99 
TT 163 36 1.00 2.18  
(1.01, 
4.69) 
  
 
≥ 65  
CT+CC 127 28 1.01 
(0.62, 
1.65) 
2.20  
(1.00, 
4.83) 
-0.06  
(-1.63, 
1.51) 
 
TT 178 21 1.00 1.00   Pre-
menopausal CT+CC 120 11 0.80 
(0.38, 
1.65) 
0.77  
(0.38, 
1.57) 
  
TT 360 51 1.00 1.16  
(0.71, 
1.88) 
  
Menopausal 
Status 
Post-
menopausal 
CT+CC 235 41 1.22 
(0.81, 
1.84) 
1.41  
(0.85, 
2.34) 
0.49  
(-0.24, 
1.22) 
0.31 
TT 114 7 1.00 1.00   In-situ 
CT+CC 60 0 --- ---   
TT 435 68 1.00 2.45  
(1.13, 
5.34) 
  
Stage 
Invasive 
CT+CC 304 52 1.10 
(0.76, 
1.57) 
2.69  
(1.22, 
5.92) 
1.23  
(0.28, 
2.18) 
0.01 
TT 82 19 1.00 1.00   ER- 
CT+CC 45 18 1.59 
(0.83, 
3.03) 
1.63  
(0.85, 
3.10) 
  
TT 270 31 1.00 0.51  
(0.29, 
0.90) 
  
ER status 
ER+ 
CT+CC 182 22 1.05 
(0.61, 
1.82) 
0.54  
(0.29, 
0.99) 
-0.60  
(-1.68, 
0.48) 
0.31 
TT 112 29 1.00 1.00   PR- 
CT+CC 61 23 1.38 
(0.80, 
2.39) 
1.39  
(0.80, 
2.41) 
  
TT 240 21 1.00 0.36  
(0.20, 
0.63) 
  
PR status 
PR+ 
CT+CC 166 17 1.17 
(0.62, 
2.22) 
0.42  
(0.23, 
0.76) 
-0.33  
(-1.12, 
0.46) 
0.69 
Received No TT 275 13 1.00 1.00   
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
 CT+CC 164 9 1.17 
(0.50, 
2.74) 
1.17  
(0.50, 
2.73) 
  
TT 138 20 1.00 2.93  
(1.46, 
5.88) 
  
chemotherapy 
Yes 
CT+CC 114 14 0.86 
(0.44, 
1.71) 
2.54  
(1.19, 
5.40) 
-0.56  
(-2.73, 
1.61) 
0.59 
TT 170 10 1.00 1.00   No 
CT+CC 105 11 1.76 
(0.75, 
4.13) 
1.76  
(0.75, 
4.15) 
  
TT 244 23 1.00 1.58  
(0.75, 
3.31) 
  
Received 
radiation 
Yes 
CT+CC 174 12 0.75 
(0.37, 
1.51) 
1.18  
(0.51, 
2.73) 
-1.16  
(-3.09, 
0.77) 
0.13 
TT 165 11 1.00 1.00   No 
CT+CC 104 10 1.42 
(0.61, 
3.35) 
1.44  
(0.61, 
3.38) 
  
TT 246 19 1.00 1.13  
(0.54, 
2.37) 
  
Received 
hormone 
therapy 
Yes 
CT+CC 174 12 0.91 
(0.44, 
1.88) 
1.03  
(0.45, 
2.33) 
-0.54  
(-2.02, 
0.95) 
0.43 
TT 422 57 1.00 1.00   No 
CT+CC 271 35 0.97 
(0.63, 
1.47) 
0.96  
(0.63, 
1.47) 
  
TT 109 17 1.00 1.14  
(0.66, 
1.96) 
  
NSAID Use 
Yes 
CT+CC 78 13 1.07 
(0.52, 
2.21) 
1.22  
(0.67, 
2.23) 
0.12  
(-0.83, 
1.06) 
0.81 
TT 44 9 1.00 1.00   No change 
or loss CT+CC 34 4 0.63 
(0.19, 
2.05) 
0.60  
(0.19, 
1.97) 
  
TT 144 13 1.00 0.49  
(0.21, 
1.15) 
  3.01-8.15 
CT+CC 89 15 1.83 
(0.87, 
3.84) 
0.88  
(0.39, 
2.03) 
0.79  
(-0.01, 
1.59) 
 
Weight gain 
from age 20 
(kg)* 
≥ 8.16 TT 164 29 1.00 0.92  
(0.43, 
1.94) 
 >0.99 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
  CT+CC 108 18 0.93 
(0.52, 
1.68) 
0.86  
(0.39, 
1.93) 
0.34  
(-0.56, 
1.24) 
 
TT 260 28 1.00 1.00   < 25.00 
CT+CC 170 18 0.99 
(0.55, 
1.78) 
0.99  
(0.55, 
1.78) 
  
TT 174 24 1.00 1.26  
(0.73, 
2.17) 
  25.00-29.99 
CT+CC 119 14 0.87 
(0.45, 
1.69) 
1.10  
(0.58, 
2.08) 
-0.15  
(-1.14, 
0.84) 
 
TT 115 23 1.00 1.77  
(1.02, 
3.08) 
 0.80 
BMI at 
reference 
(kg/m2) 
≥ 30.00 
CT+CC 75 20 1.30 
(0.72, 
2.37) 
2.32  
(1.31, 
4.12) 
0.56  
(-0.78, 
1.90) 
 
rs4253755         
< 45  GG 108 11 1.00 1.00   
 AG+AA 32 3 0.91 
(0.25, 
3.25) 
0.90  
(0.25, 
3.23) 
  
45-54  GG 195 21 1.00 1.06  
(0.51, 
2.20) 
  
 AG+AA 57 7 1.13 
(0.48, 
2.66) 
1.20  
(0.47, 
3.10) 
0.24  
(-1.26, 
1.74) 
 
55-64  GG 180 19 1.00 1.04  
(0.49, 
2.18) 
  
 AG+AA 54 2 0.37 
(0.09, 
1.57) 
0.38  
(0.08, 
1.71) 
-0.56  
(-2.11, 
0.98) 
0.92 
≥ 65  GG 223 46 1.00 1.93  
(1.00, 
3.72) 
  
Age at 
diagnosis 
(years) 
 AG+AA 72 20 1.32 
(0.78, 
2.23) 
2.55  
(1.22, 
5.31) 
0.72  
(-0.90, 
2.34) 
 
GG 226 27 1.00 1.00   Pre-
menopausal AG+AA 72 5 0.60 
(0.23, 
1.55) 
0.60  
(0.23, 
1.56) 
  
GG 464 68 1.00 1.23  
(0.80, 
1.90) 
  
Menopausal 
Status 
Post-
menopausal 
AG+AA 138 27 1.31 
(0.84, 
2.05) 
1.62  
(0.96, 
2.73) 
0.78  
(-0.08, 
1.65) 
0.12 
Stage In-situ GG 136 5 1.00 1.00   
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
 AG+AA 38 2 1.45 
(0.28, 
7.45) 
1.43  
(0.28, 
7.35) 
  
Invasive GG 570 92 1.00 4.18  
(1.70, 
10.29) 
  
 
 AG+AA 177 30 1.05 
(0.70, 
1.58) 
4.38  
(1.70, 
11.30) 
-0.22  
(-3.09, 
2.65) 
0.73 
ER- GG 107 31 1.00 1.00   
 AG+AA 23 7 1.03 
(0.45, 
2.33) 
1.03  
(0.45, 
2.34) 
  
ER+ GG 349 40 1.00 0.42  
(0.26, 
0.67) 
  
ER status 
 AG+AA 109 13 1.05 
(0.56, 
1.96) 
0.44  
(0.23, 
0.83) 
-0.01  
(-0.90, 
0.87) 
>0.99 
PR- GG 145 45 1.00 1.00   
 AG+AA 34 9 0.86 
(0.42, 
1.77) 
0.87  
(0.42, 
1.77) 
  
PR+ GG 311 26 1.00 0.29  
(0.18, 
0.48) 
  
PR status 
 AG+AA 98 11 1.33 
(0.66, 
2.70) 
0.39  
(0.20, 
0.76) 
0.23  
(-0.43, 
0.89) 
0.40 
No GG 323 15 1.00 1.00   
 AG+AA 108 7 1.39 
(0.57, 
3.42) 
1.39  
(0.57, 
3.42) 
  
Yes GG 201 33 1.00 3.36  
(1.83, 
6.19) 
  
Received 
chemotherapy 
 AG+AA 54 3 0.36 
(0.11, 
1.17) 
1.20  
(0.35, 
4.14) 
-2.56  
(-5.29, 
0.17) 
0.06 
No GG 211 13 1.00 1.00   
 AG+AA 63 8 2.00 
(0.83, 
4.84) 
1.99  
(0.83, 
4.81) 
  
Yes GG 314 35 1.00 1.76 
(0.93, 
3.33) 
  
Received 
radiation 
 AG+AA 100 2 0.19 
(0.05, 
0.79) 
0.33  
(0.08, 
1.48) 
-2.42  
(-4.85, 
0.01) 
<0.01 
No GG 205 15 1.00 1.00   Received 
hormone 
therapy  AG+AA 58 5 1.18 (0.43, 
3.24) 
1.17  
(0.42, 
3.21) 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
Yes GG 317 30 1.00 1.25  
(0.67, 
2.33) 
   
 AG+AA 104 4 0.42 
(0.15, 
1.19) 
0.53  
(0.18, 
1.59) 
-0.89  
(-2.45, 
0.67) 
0.17 
GG 539 71 1.00 1.00   No 
AG+AA 159 21 1.00 
(0.62, 
1.63) 
1.00  
(0.62, 
1.63) 
  
GG 141 23 1.00 1.22  
(0.76, 
1.95) 
  
NSAID Use 
Yes 
AG+AA 47 9 1.17 
(0.54, 
2.53) 
1.43  
(0.71, 
2.85) 
0.21  
(-0.95, 
1.36) 
0.74 
GG 63 9 1.00 1.00   No change 
or loss AG+AA 18 5 1.79 
(0.60, 
5.33) 
1.80  
(0.60, 
5.36) 
  
3.01-8.15 GG 180 18 1.00 0.73  
(0.33, 
1.64) 
  
 AG+AA 52 11 2.06 
(0.97, 
4.35) 
1.51  
(0.62, 
3.66) 
-0.02  
(-1.98, 
1.94) 
 
≥ 8.16 GG 210 40 1.00 1.34  
(0.65, 
2.78) 
 0.14 
Weight gain 
from age 20 
(kg)* 
 AG+AA 66 8 0.64 
(0.30, 
1.37) 
0.88  
(0.34, 
2.28) 
-1.26  
(-3.55, 
1.02) 
 
< 25.00 GG 333 31 1.00 1.00   
 AG+AA 100 15 1.57 
(0.85, 
2.91) 
1.57  
(0.85, 
2.91) 
  
25.00-29.99 GG 228 33 1.00 1.52  
(0.93, 
2.48) 
  
 AG+AA 67 7 0.75 
(0.33, 
1.68) 
1.13  
(0.50, 
2.56) 
-0.96  
(-2.41, 
0.48) 
 
≥ 30.00 GG 145 33 1.00 2.30  
(1.41, 
3.76) 
 0.49 
BMI at 
reference 
(kg/m2) 
 AG+AA 48 10 0.91 
(0.45, 
1.84) 
2.11  
(1.04, 
4.31) 
-0.76  
(-2.59, 
1.07) 
 
rs4253760         
< 45 TT 91 8 1.00 1.00   Age at 
diagnosis 
(years)  GT+GG 43 5 1.29 (0.42, 
3.96) 
1.29  
(0.42, 
3.94) 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
45-54  TT 169 17 1.00 1.13  
(0.49, 
2.62) 
  
 GT+GG 78 10 1.31 
(0.60, 
2.86) 
1.48  
(0.58, 
3.75) 
0.06  
(-1.62, 
1.75) 
 
55-64 TT 159 15 1.00 1.07  
(0.46, 
2.53) 
  
 GT+GG 72 5 0.75 
(0.27, 
2.07) 
0.81  
(0.26, 
2.47) 
-0.56  
(-2.35, 
1.24) 
0.96 
≥ 65 TT 176 40 1.00 2.41  
(1.13, 
5.15) 
  
 
 GT+GG 108 24 1.01 
(0.61, 
1.67) 
2.42  
(1.09, 
5.39) 
-0.28  
(-2.17, 
1.61) 
 
TT 199 21 1.00 1.00   Pre-
menopausal GT+GG 90 9 0.97 
(0.44, 
2.11) 
0.96  
(0.45, 
2.08) 
  
TT 383 58 1.00 1.41  
(0.87, 
2.29) 
  
Menopausal 
Status 
Post-
menopausal 
GT+GG 203 34 1.12 
(0.73, 
1.71) 
1.58  
(0.93, 
2.69) 
0.21  
(-0.75, 
1.17) 
0.73 
TT 111 5 1.00 1.00   In-situ 
GT+GG 60 2 0.75 
(0.15, 
3.88) 
0.74  
(0.14, 
3.83) 
  
TT 484 75 1.00 3.27  
(1.32, 
8.08) 
  
Stage 
Invasive 
GT+GG 241 42 1.14 
(0.78, 
1.67) 
3.73  
(1.48, 
9.44) 
0.72  
(-0.99, 
2.44) 
0.61 
ER- TT 83 20 1.00 1.00   
 GT+GG 43 17 1.57 
(0.82, 
3.00) 
1.59  
(0.83, 
3.03) 
  
ER+ TT 304 35 1.00 0.50  
(0.29, 
0.86) 
  
ER status 
 GT+GG 141 16 1.57 
(0.82, 
3.00) 
0.50  
(0.26, 
0.97) 
-0.58  
(-1.65, 
0.49) 
0.32 
PR- TT 114 32 1.00 1.00   PR status 
 GT+GG 59 19 1.17 
(0.66, 
2.06) 
1.17  
(0.66, 
2.06) 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
PR+ TT 273 23 1.00 0.33  
(0.19, 
0.56) 
   
 GT+GG 125 14 1.35 
(0.69, 
2.62) 
0.44  
(0.23, 
0.82) 
-0.06  
(-0.75, 
0.64) 
0.75 
No TT 287 14 1.00 1.00   
 GT+GG 134 8 1.25 
(0.53, 
2.99) 
1.25  
(0.52, 
2.97) 
  
Yes TT 160 26 1.00 3.16  
(1.65, 
6.05) 
  
Received 
chemotherapy 
 GT+GG 83 7 0.55 
(0.24, 
1.28) 
1.74  
(0.70, 
4.32) 
-1.66  
(-4.08, 
0.75) 
0.18 
No TT 181 12 1.00 1.00   
 GT+GG 82 8 1.48 
(0.60, 
3.61) 
1.46  
(0.60, 
3.58) 
  
Yes TT 267 28 1.00 1.55  
(0.79, 
3.04) 
  
Received 
radiation 
 GT+GG 136 7 0.52 
(0.23, 
1.19) 
0.80  
(0.32, 
2.04) 
-1.21  
(-3.02, 
0.60) 
0.09 
No TT 170 12 1.00 1.00   
 GT+GG 90 7 1.11 
(0.44, 
2.82) 
1.10  
(0.43, 
2.80) 
  
Yes TT 275 26 1.00 1.29  
(0.65, 
2.56) 
  
Received 
hormone 
therapy 
 GT+GG 127 6 0.53 
(0.22, 
1.28) 
0.68  
(0.26, 
1.82) 
-0.71  
(-2.18, 
0.75) 
0.26 
TT 463 59 1.00 1.00   No 
GT+GG 219 29 1.06 
(0.68, 
1.65) 
1.06  
(0.68, 
1.65) 
  
TT 115 19 1.00 1.27  
(0.76, 
2.14) 
  
NSAID Use 
Yes 
GT+GG 65 12 1.14 
(0.55, 
2.35) 
1.45  
(0.78, 
2.69) 
0.12  
(-0.98, 
1.21) 
0.87 
TT 55 9 1.00 1.00   No change 
or loss GT+GG 24 4 1.02 
(0.31, 
3.30) 
0.99  
(0.31, 
3.24) 
  
Weight gain 
from age 20 
(kg)* 
3.01-8.15 TT 143 16 1.00 0.72  
(0.32, 
1.64) 
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TABLE D.29. Stratified and common referent hazard ratios and interaction contrast ratios and 
multiplicative p-values for select characteristics 
Characteristic Status Genotype Alive 
(N) 
Dead 
(N) 
Stratum 
HR 
(95% CI) 
Referent 
HR 
(95% CI) 
ICR 
(95% CI) 
P- 
Value† 
 GT+GG 80 12 1.35 
(0.64, 
2.86) 
0.97  
(0.41, 
2.30) 
0.25  
(-1.02, 
1.52) 
 
≥ 8.16 TT 175 33 1.00 1.16  
(0.56, 
2.44) 
 0.88 
 
 GT+GG 96 15 0.84 
(0.46, 
1.55) 
1.00  
(0.43, 
2.28) 
-0.16  
(-1.56, 
1.23) 
 
< 25.00 TT 285 29 1.00 1.00   
 GT+GG 136 14 1.02 
(0.54, 
1.93) 
1.02  
(0.54, 
1.93) 
  
25.00-29.99 TT 186 25 1.00 1.29  
(0.75, 
2.20) 
  
 GT+GG 102 15 1.13 
(0.60, 
2.14) 
1.45  
(0.78, 
2.70) 
0.14  
(-0.94, 
1.23) 
 
≥ 30.00 TT 124 26 1.00 1.94  
(1.14, 
3.30) 
 0.96 
BMI at 
reference 
(kg/m2) 
 GT+GG 63 15 1.14 
(0.61, 
2.16) 
2.23  
(1.20, 
4.17) 
0.27  
(-1.21, 
1.75) 
 
*weight gain models are adjusted for BMI at age 20 
†multiplicative p-value, calculated using likelihood ratio tests to compare models with interaction term(s) to those 
without 
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TABLE D.30. Distribution of select survival covariates by genotyping information 
  All Cases Alive Dead 
Variable NT (%)* NG (%)* NT (%) NG (%) NT (%) NG (%) 
 1508 1073 1310 941 198 132 
Age       
 < 45 years old 220 (15) 160 (15) 196 (15) 146 (16) 24 (12) 14 (11) 
 45-54 years old 397 (26) 285 (27) 359 (27) 256 (27) 38 (19) 29 (22) 
 55-64 years old 372 (25) 264 (25) 336 (26) 241 (26) 36 (18) 23 (17) 
 ≥ 65 years old 519 (34) 364 (34) 419 (32) 298 (32) 100 (51) 66 (50) 
ER/PR status       
 ER-/PR- 212 (14) 138 (13) 160 (12) 103 (11) 52 (26) 35 (27) 
 ER-/PR+ 52 (3) 33 (3) 44 (3) 29 (3) 8 (4) 4 (3) 
 ER+/PR- 143 (9) 99 (9) 115 (9) 79 (8) 28 (14) 20 (15) 
 ER+/PR+ 583 (39) 421 (39) 522 (40) 387 (41) 61 (31) 34 (26) 
 Missing 518 (34) 382 (36) 469 (36) 343 (36) 49 (25) 39 (30) 
Stage       
 In situ 235 (16) 185 (17) 22 (17) 178 (19) 10 (5) 7 (5) 
 Invasive 1273 (84) 888 (83) 1085 (83) 763 (81) 188 (95) 125 
(95) 
Tumor Size       
 ≤ 2 cm 466 (31) 352 (33) 444 (34) 336 (36) 22 (11) 16 (12) 
 2-5 cm 102 (7) 79 (7) 94 (7) 74 (8) 8 (4) 5 (4) 
 >5 cm 11 (1) 6 (1) 10 (1) 5 (1) 1 (1) 1 (1) 
 Missing 929 (62) 636 (59) 762 (58) 526 (56) 167 (84) 110 
(83) 
Nodal involvement       
 No positive nodes 462 (31) 355 (33) 440 (34) 337 (36) 23 (12) 18 (14) 
 Positive ipsilateral 
nodes or positive 
regional nodes 
134 (9) 98 (9) 125 (10) 93 (10) 9 (5) 5 (4) 
 Positive distant nodes 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
 Missing 911 (60) 620 (58) 745 (57) 511 (54) 166 (84) 109 
(83) 
Chemotherapy at follow-up       
 Yes 423 (28) 296 (28) 372 (28) 259 (28) 51 (26) 37 (28) 
 No 599 (40) 469 (44) 565 (43) 446 (47) 34 (17) 23 (17) 
 Missing 486 (32) 308 (29) 373 (28) 236 (25) 113 (57) 72 (55) 
Hormone Therapy at follow-
up 
      
 Yes 616 (41) 463 (43) 567 (43) 429 (46) 49 (25) 34 (26) 
 No 393 (26) 295 (27) 365 (28) 274 (29) 28 (14) 21 (16) 
 Missing 499 (33) 315 (29) 378 (29) 238 (25) 121 (61) 77 (58) 
Radiation Therapy at follow-
up 
      
 Yes 625 (41) 463 (43) 575 (44) 425 (45) 50 (25) 38 (29) 
 No 401 (27) 304 (28) 365 (28) 282 (30) 36 (18) 22 (17) 
 Missing 482 (32) 306 (29) 370 (28) 234 (25) 112 (57) 72 (55) 
BMI at reference (kg/m2)       
 < 24.99 700 (46) 490 (46) 623 (48) 442 (47) 77 (39) 48 (36) 
 25.00-29.99 476 (32) 341 (32) 416 (32) 301 (32) 60 (30) 40 (30) 
 ≥ 30.00 332 (22) 242 (23) 271 (21) 198 (21) 61 (32) 44 (33) 
Weight gain from age 20 (kg)       
 Maintenance or loss 139 (9) 96 (9) 117 (9) 82 (9) 22 (11) 14 (11) 
  223
 3.01-8.15 gain 382 (25) 266 (25) 338 (26) 236 (25) 44 (22) 30 (23) 
 ≥ 8.16 gain 465 (31) 329 (31) 390 (30) 280 (30) 75 (38) 49 (37) 
 Missing 522 (35) 382 (36) 465 (36) 343 (36) 57 (29) 39 (30) 
*NT = all cases, NG=cases for whom genotyping data is available 
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TABLE D.31. Model building procedure for SNP rs135542 (AA vs. AG+GG), breast cancer 
specific mortality with continuous time interaction term 
 Full Model Model 2 Model 3 Model 4 Model 5 
 β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 939 939 940 970 972 
Main 
Exposure: 
rs135542 
-0.27543 
(0.51975) 
0.19764 
(0.23170) 
0.21298 
(0.23029) 
0.13841 
(0.22375) 
0.12633 
(0.22361) 
FAMHX 0.36668 
(0.27154) 
0.36679 
(0.27155) 
0.36127 
(0.27127) REMOVED REMOVED 
JEWISH -0.16823 
(0.33039) 
-0.16972 
(0.33040) REMOVED REMOVED REMOVED 
RACE_DIC 0.71142 
(0.40158) 
0.71031 
(0.40158) 
0.73617 
(0.39903) 
0.70723 
(0.37265) REMOVED 
Interactions:      
SNP1_DUR 0.0004421 
(0.0004326) REMOVED REMOVED REMOVED REMOVED 
-2 log L 1024.382 1025.439 1025.845 1100.060 1103.398 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
FAMHX 
Removed 
RACE_DIC 
Test of 
interaction 
term 
 
χ2 (1): 
1024.382–
1025.439= 
1.057; p=0.30
--- --- --- 
Change in 
estimate   
|0.19764-
0.21298| = 
0.0153 
|0.19764- 
0.13841| = 
0.05923 
|0.19764- 
0.12633| = 
0.07131 
Compare to:  Full Model Model 2 Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Fam 
history is not 
a confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.32. Model building procedure for SNP rs1800206 (CC vs. CG+GG), breast cancer 
specific mortality with continuous time interaction term 
 Full Model Model 2 Model 3 Model 4 Model 5 
 β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 962 962 991 992 993 
Main 
Exposure: 
rs135542 
0.47436 
(0.78157) 
-0.01875 
(0.37327) 
-0.10467 
(0.37205) 
-0.08129 
(0.37182) 
-0.09386 
(0.37173) 
FAMHX 0.34479 
(0.27027) 
0.34340 
(0.27025) REMOVED REMOVED REMOVED 
JEWISH -0.46077 
(0.35674) 
-0.45996 
(0.35674) 
-0.50418 
(0.35500) REMOVED REMOVED 
RACE_DIC 0.73319 
(0.37739) 
0.73023 
(0.37736) 
0.68922 
(0.35490) 
0.75766 
(0.35284) REMOVED 
Interactions:      
SNP2_DUR -0.0004962 
(0.0007306) REMOVED REMOVED REMOVED REMOVED 
-2 log L 1066.969 1067.451 1140.507 1142.961 1146.928 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
FAMHX 
Removed 
JEWISH 
Removed 
RACE_DIC 
Test of 
interaction 
term 
 
χ2 (1): 
1067.451–
1066.969= 
0.482; p=0.49
--- --- --- 
Change in 
estimate   
|-0.01875--
0.10467| = 
0.08592 
|-0.01875- -
0.08129| = 
0.06254 
|-0.01875- -
0.09386| = 
0.07511 
Compare to:  Full Model Model 2 Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Fam 
history is not 
a confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.33. Model building procedure for SNP rs4253623 (AA vs. AG+GG), breast cancer 
specific mortality with continuous time interaction term 
 Full Model Model 2 Model 3 Model 4 Model 5 
 β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 972 972 973 1003 1005 
Main 
Exposure: 
rs135542 
0.16276 
(0.60127) 
-0.08152 
(0.27405) 
-0.06111 
(0.27379) 
0.00433 
(0.26080) 
0.00644 
(0.26080) 
FAMHX 0.36710 
(0.27029) 
0.36782 
(0.27030) 
0.34958 
(0.27007) REMOVED REMOVED 
JEWISH -0.47746 
(0.35688) 
-0.47814 
(0.35687) REMOVED REMOVED REMOVED 
RACE_DIC 0.70352 
(0.37732) 
0.70341 
(0.37733) 
0.76741 
(0.37549) 
0.73462 
(0.35275) REMOVED 
Interactions:      
SNP3_DUR -0.0002315 
(0.0005164) REMOVED REMOVED REMOVED REMOVED 
-2 log L 1068.739 1068.942 1071.107 1145.133 1149.062 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
FAMHX 
Removed 
RACE_DIC 
Test of 
interaction 
term 
 
χ2 (1): 
1068.739–
1068.942= 
0.203; p=0.65
--- --- --- 
Change in 
estimate   
|-0.08152--
0.06111| = 
0.02041 
|-0.08152- 
0.00433| = 
0.08585 
|-0.08152- 
0.00644| = 
0.087961 
Compare to:  Full Model Model 2 Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Family 
history is not 
a confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.34. Model building procedure for SNP rs4253699 (TT vs. CT+CC), breast cancer 
specific mortality with continuous time interaction term 
 Full Model Model 2 Model 3 Model 4 Model 5 
 β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 968 968 969 998 999 
Main 
Exposure: 
rs135542 
0.01237 
(0.49998) 
0.04439 
(0.22618) 
0.04491 
(0.22616) 
0.03811 
(0.21951) 
0.03812 
(0.21950) 
FAMHX 0.36929 
(0.26431) 
0.36952 
(0.26430) 
0.35475 
(0.26404) REMOVED REMOVED 
JEWISH -0.39154 
(0.34020) 
-0.39170 
(0.34019) REMOVED REMOVED REMOVED 
RACE_DIC 0.74518 
(0.37693) 
0.74544 
(0.37692) 
0.80005 
(0.37493) 
0.76219 
(0.35226) REMOVED 
Interactions:      
SNP4_DUR 0.0000299 
(0.0004167) REMOVED REMOVED REMOVED REMOVED 
-2 log L 1095.610 1095.615 1097.216 1171.229 1175.252 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
FAMHX 
Removed 
RACE_DIC 
Test of 
interaction 
term 
 
χ2 (1): 
1095.615–
1095.610= 
0.005; p=0.94
--- --- --- 
Change in 
estimate   
|0.04439-
0.04491| = 
0.00052 
|0.04439- 
0.03811| = 
0.00628 
|0.04439- 
0.03812| = 
0.006271 
Compare to:  Full Model Model 2 Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Family 
history is not 
a confounder 
and is 
removed 
from the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.35. Model building procedure for SNP rs4253755 (GG vs. AG+AA), breast cancer 
specific mortality with continuous time interaction term 
 Full Model Model 2 Model 3 Model 4 Model 5 
 β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 974 974 975 1005 977 
Main 
Exposure: 
rs4253755 
-0.35848 
(0.63062) 
-0.29349 
(0.28837) 
-0.28580 
(0.28828) 
-0.09506 
(0.26701) 
-0.32441 
(0.28651) 
FAMHX 0.32536 
(0.26927) 
0.32559 
(0.26926) 
0.31578 
(0.26901) REMOVED 
0.28404 
(0.26772) 
JEWISH -0.27586 
(0.32665) 
-0.27597 
(0.32664) REMOVED REMOVED REMOVED 
RACE_DIC 0.51131 
(0.40219) 
0.51126 
(0.40218) 
0.55271 
(0.40000) 
0.57711 
(0.37397) REMOVED 
Interactions:      
SNP4_DUR 0.0000610 
(0.0005238) REMOVED REMOVED REMOVED REMOVED 
-2 log L 1098.460 1098.473 1099.395 1174.094 1101.388 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
JEWISH 
Removed 
FAMHX 
Removed 
RACE_DIC 
Test of 
interaction 
term 
 
χ2 (1): 
1098.473–
1098.460= 
0.013; p=0.91
--- --- --- 
Change in 
estimate   
|-0.29349--
0.28580| = 
0.00769 
|-0.29349- -
0.09506| = 
0.19843 
|-0.29349- -
0.32441| = 
0.03092 
Compare to:  Full Model Model 2 Model 2 Model 2 
Conclusion:  
Interaction term 
is not 
contributing to 
the model and 
will be 
removed. 
Change in 
estimate < 
0.10. Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
Change in 
estimate > 
0.10. Family 
history is a 
confounder 
and will 
remain in the 
model 
Change in 
estimate < 
0.10. Race 
is not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.36. Model building procedure for SNP rs4253760 (TT vs. GT+GG), breast cancer 
specific mortality with continuous time interaction term 
 Full Model Model 2 Model 3 Model 4 Model 5 
 β (SE) β (SE) β (SE) β (SE) β (SE) 
Sample Size 945 945 975 946 948 
Main 
Exposure: 
rs4253760 
0.67005 
(0.54552) 
-0.28124 
(0.25736) 
0.84292 
(0.52474) 
0.72983 
(0.54340) 
0.74355 
(0.54327) 
FAMHX 0.24078 
(0.28239) 
0.23796 
(0.28241) REMOVED 
0.20292 
(0.28130) 
0.18903 
(0.28100) 
JEWISH -0.33446 
(0.34136) 
-0.33259 
(0.34135) 
-0.37835 
(0.33952) 
-0.37253 
(0.33964) REMOVED 
RACE_DIC 0.65411 
(0.40792) 
0.65438 
(0.40781) 
0.61834 
(0.38177) REMOVED REMOVED 
Interactions:      
SNP4_DUR -0.0009544 
(0.0005104) REMOVED 
-0.00102 
(0.0004849) 
-0.0009557 
(0.0005107) 
-0.0009543 
(0.0005106) 
-2 log L 1035.496 1039.340 1107.41 1037.870 1039.520 
Notes  
Evaluate EMM 
with the 
likelihood ratio 
test* 
Removed 
FAMHX 
Removed 
RACE_DIC 
Removed 
JEWISH 
Test of 
interaction 
term 
 
χ2 (1): 
1039.340–
1035.496= 
3.844; p=0.05
--- --- --- 
Change in 
estimate   
|0.67005-
0.84292| = 
0.17287 
|0.67005- 
0.72983| = 
0.05978 
|0.67005- 
0.74355| = 
0.07355 
Compare to:  Full Model Full Model Full Model Full Model 
Conclusion:  
Interaction term 
is contributing 
to the model 
and will remain 
in the model. 
Change in 
estimate 
>0.10. Family 
history is a 
confounder 
and will 
remain in the 
model 
Change in 
estimate > 
0.10. Race is 
not a 
confounder 
and is 
removed in 
the model 
Change in 
estimate < 
0.10. 
Jewish 
ethnicity is 
not a 
confounder 
and is 
removed 
from the 
model 
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TABLE D.37. Hazard ratios and frequencies by vital status for six SNPs in relation to all-cause (n=132) and breast cancer specific mortality 
(n=88) mortality among a cohort of women with breast cancer (n = 1073) 
 Overall Mortality Breast Cancer-Specific Mortality 
 N† MST* Log Rank HR HR† N† MST* Log Rank HR HR‡ 
Genotype  (days) P-value (95% CI) (95% CI)  (days) P-value (95% CI) (95% CI) 
rs135542           
 AA 78/602 2044.9 0.29 1.00  45/569 2086.3 0.57 1.00  
 AG+GG 44/411 2101.9  0.82 
(0.57, 1.19) 
 36/403 2120.3  1.14 
(0.73, 1.76) 
 
rs1800206           
 CC 115/927 2080.8 0.41 1.00  76/888 2118.2 0.80 1.00  
 CG+GG 10/107 1634.3  0.76 
(0.40, 1.46) 
 8/105 1616.7  0.91 
(0.44, 1.89) 
 
rs4263623           
 AA 97/811 2087.0 0.99 1.00  65/779 2120.2 0.98 1.00  
 AG+GG 28/235 1981.5  1.00 
(0.66, 1.52) 
 19/226 1953.3  1.01 
(0.60, 1.68) 
 
rs4253699           
 TT 75/624 2086.4 0.79 1.00  51/600 2118.9 0.86 1.00  
 CT+CC 52/416 2025.7  1.05 
(0.74, 1.50) 
 35/399 2061.9  1.04 
(0.68, 1.60) 
 
rs4253755           
 GG 97/803 2087.1 0.71 1.00  68/774 2114.9 0.60 1.00  
 AG+AA 32/247 1930.0  1.08 
(0.72, 1.61) 
 18/233 1900.3  0.87 
(0.52, 1.47) 
 
rs4253760           
 TT 80/675 2095.1 0.60 1.00 1.00 57/652 2122.8 0.62 1.00 1.00 
 GT+GG 44/345 1923.8  1.10 
(0.76, 1.59) 
2.25 
(1.00, 5.08) 
25/326 1887.3  0.89 
(0.55, 1.42) 
2.50 
(0.90, 6.96) 
        *The mean survival time will be underestimated because largest survival time is censored. 
        †Sample size for cases/cohort 
        ‡Adjusted for a continuous time interaction. 
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TABLE D.38. Hazard ratios and frequencies by vital status for haplotypes in relation to all-cause (n=132) and breast cancer specific mortality 
(n=88) mortality among a cohort of women with breast cancer (n = 1073) 
       Overall Mortality Breast Cancer Mortality 
Haplotype 
Number* 
rs135542 rs1800206 rs4253623 rs4253699 rs4253755 rs4253760 Alive 
Freq 
Dead 
Freq 
HR 
(95% CI) 
Alive 
Freq 
Dead 
Freq 
HR 
(95% CI) 
1 A C A C A G 0.06 0.07 1.01 
(0.36, 2.86) 
0.06 0.06 0.83 
(0.21, 
3.29) 
2 A C A C A T 0.03 0.03 0.93 
(0.21, 4.14) 
0.03 0.03 1.11 
(0.19, 
6.50) 
3 A C A C G G 0.02 0.00 0.31 
(0.03, 3.76) 
0.02 0.00 0.09 
(0.00, 
6.27) 
4 A C A C G T 0.05 0.08 2.11 
(0.67, 6.58) 
0.05 0.07 1.50 
(0.30, 
7.39) 
5 A C A T A G 0.03 0.03 0.90 
(0.18, 4.53) 
0.03 0.02 0.40 
(0.03, 
4.59) 
6 A C A T G G 0.03 0.06 1.77 
(0.57, 5.46) 
0.03 0.03 1.09 
(0.20, 
5.91) 
7 A C A T G T 0.40 0.38 0.79 
(0.51, 1.23) 
0.40 0.38 0.83 
(0.48, 
1.44) 
8 A C G T G T 0.10 0.12 0.98 
(0.45, 2.10) 
0.10 0.12 0.96 
(0.37, 
2.50) 
9 A G A C G G 0.02 0.02 0.77 
(0.11, 5.21) 
0.02 0.03 1.15 
(0.12, 
10.76) 
10 A G A C G T 0.01 0.00 0.19 
(0.01, 7.21) 
0.01 0.00 0.44 
(0.01, 
15.91) 
11 G C A C G T 0.01 0.01 0.12 
(0.00, 6.45) 
0.01 0.01 0.53 
(0.01, 
27.13) 
12 G C A T G T 0.18 0.17 0.69 
(0.35, 1.36) 
0.18 0.21 1.11 
(0.52, 
2.36) 
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*haplotypes with frequency ≥ 0.01 
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TABLE D.39. Hazard ratios and frequencies for all cause mortality by vital status for six SNPs in all cases verus 
invasive cases only 
 All Cases Invasive Cases Only 
 N HR HR* N HR HR* 
Genotype Cases/Cohort (95% CI) (95% CI) Cases/Cohort (95% CI) (95% CI) 
rs135542       
 AA 78/602 1.00 1.00 74/492 1.00 1.00 
 AG+GG 44/411 0.82  
(0.57, 1.19) 
0.80 
(0.34, 1.86) 
41/348 0.77 
(0.53, 1.13) 
0.66 
(0.28, 1.59) 
rs1800206       
 CC 115/927 1.00 1.00 108/773 1.00 1.00 
 CG+GG 10/107 0.76  
(0.40, 1.46) 
1.17 
(0.30, 4.58) 
10/82 0.90 
(0.47, 1.72) 
1.25 
(0.32, 4.95) 
rs4263623       
 AA 97/811 1.00 1.00 91/670 1.00 1.00 
 AG+GG 28/235 1.00  
(0.66, 1.52) 
1.54 
(0.65, 3.68) 
27/192 1.04 
(0.68, 1.60) 
1.20 
(0.46, 3.10) 
rs4253699       
 TT 75/624 1.00 1.00 68/503 1.00 1.00 
 CT+CC 52/416 1.05  
(0.74, 1.50) 
1.16 
(0.45, 2.96) 
52/356 1.10 
(0.76, 1.57) 
1.09 
(0.49, 2.44) 
rs4253755       
 GG 97/803 1.00 1.00 92/662 1.00 1.00 
 AG+AA 32/247 1.08  
(0.72, 1.61) 
1.18 
(0.54, 2.60) 
30/207 1.05 
(0.70, 1.58) 
1.42 
(0.58, 3.47) 
rs4253760       
 TT 80/675 1.00 1.00 75/559 1.00 1.00 
 GT+GG 44/345 1.10  
(0.76, 1.59) 
2.25 
(1.00, 5.08) 
42/283 1.14 
(0.78, 1.67) 
2.17 
(0.95, 4.96) 
*Adjusted for a continuous time interaction term; interaction term necessary only for rs4253760 based on 
likelihood ratio test 
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